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ABSTRACT 
 
 
The formation of three-dimensional (3D) models for tissue engineering purpose 
provides a more conducive environment to enable complex biological interactions 
and processes between cells, biomaterials and bioactive molecules. Microparticles 
(MP) can be used as supporting matrix for 3D construct in cells and a carrier to 
deliver bioactive agents for cell development and differentiation, particularly for 
bone tissue engineering. Poly(glycerol adipate) (PGA) is a potential polymer for tissue 
engineering purposes as it is biodegradable and has biocompatibility with several 
cells. The aim of this study is to modify PGA polymer for MP with well-defined 
properties for drug encapsulation and release, promote cell-MP interaction and 
evaluate the osteogenic differentiation with MP incorporation in mouse embryonic 
stem (mES) and osteoblast cells.  The PGA polymer has been modified by substituting 
40% pendant hydroxyl groups onto the polymer backbone with stearoyl (C18) groups 
to increase encapsulation efficiency of drug within MP. Further modification was 
tethering one carboxyl terminus in PGA polymer with maleimide-poly(ethylene 
glycol) (MIHA-PEG-NH2) linker for ligand attachment on the surface of MP. Collagen, 
as a ligand, was modified by attaching iminothiolane to give a functional thiol group 
for interaction with maleimide group on the surface of 40%C18-PGA-PEG-MIHA MP. 
The microparticles were prepared using an emulsification method. Dexamethasone 
phosphate (DXMP) and simvastatin (SIM) were encapsulated within the MP. The MP-
cell aggregate formation was evaluated as well as cell metabolism activity. The effect 
  
 
ii 
 
of polymer modification on drug release from MP was evaluated in the cells by 
analyzing osteogenic differentiation in cells. The MP prepared from modified PGA 
polymer exhibited high encapsulation efficiency of SIM in MP.  By adjusting the 
formulation parameters, the release of SIM from MP could be extended to 21 days. 
The collagen attachment on the surface of 40%C18-PGA-PEG-MIHA MP promoted cell 
metabolic activity and produced more extensive markers related to osteogenic 
differentiation.  
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CHAPTER 1 
1. INTRODUCTION 
 
1.1. Tissue Engineering 
1.1.1. Background 
Tissue engineering arose out of the demands by surgeons in regenerating 
functionally active tissues to replace those lost due to trauma, congenital 
malformations or various diseases. The term tissue engineering relates to the use of 
living cells for replacement, repair and regeneration of various tissues and organs 
and  also be used to describe approaches for tissue replacement by creating tissue 
outside the body and then implanting it in the body [1]. Current methods for tissue 
replacement are mainly the use of autografts, allografts or metallic devices. 
However, these methods are associated with several limitations including donor site 
morbidity, shortages in supply, poor integration with target and potential induction 
of immunological reactions. These limitations highlight the need for development of 
therapies based on tissue engineering principles [2].  
Tissue engineering in the area of cell technology has to meet a number of challenges 
including the source of cell, the use of technology and the manipulation of cell 
function. Other issues include how to design and engineer tissue constructs 
with/without delivery vehicles and developing the technology to make these 
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constructs available to clinicians. The last issue relates to the integration of cells into 
the living system where the engineering of immune acceptance is the most critical 
issue. The success in tissue engineering will only be accomplished if these issues 
could be addressed [3].  
The initial issue for engineering a tissue or organ substitute is a source of the cells to 
be employed. The cells need to be available in sufficient quantity and guaranteed to 
be free of pathogens and contamination. The source of the cells could be autologous, 
allogenic, or xenogenic and each of these sources has both advantages and 
disadvantages as indicated in Table 1.1. 
Table 1.1. Cell Source for Tissue or Organ Substitution[3] 
Type Source Condition 
Autologous WĂƚŝĞŶƚ ?ƐŽǁŶĐĞůůƐ Acceptable by immune system, but does 
not lend itself to off-the-shelf availability.  
Allogenic  Cell from other 
human sources 
May require arrangement for immune 
acceptance and be able to lend itself for 
off-the-shelf availability.  
Xenogenic Cell from different 
species 
Requires arrangement for immune 
acceptance and must also deal with 
animal virus transmission. 
 
Once a particular cell type has been selected, the next issue is the manipulation of 
functional characteristics of the cell to accomplish the desired behaviour. This could 
be achieved by controlling a cell microenvironment including its matrix, the 
mechanical stresses to which it is exposed, or its biochemical environment. 
Alternatively, the cell could be genetically reprogrammed which may include the 
modification of matrix synthesis, inhibition of immune response, diminishing of 
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thrombogenicity, expression of specific biologically active molecules, and the 
controlling of cell proliferation [3]. 
The next challenge in tissue or organ substitution is to develop into a well-organized 
three-dimensional (3D) architecture with mimicking functional characteristics of the 
specific tissue. A delivery vehicle for the cells also has a role in tissue or organ 
substitution therefore several approaches have been used to engineer a tissue-like 
substitute. Cells can be seeded on a polymeric scaffold to allow them to produce 
their own matrix. Alternatively, a layer of cells can produce their own matrix to 
become a sheet of tissue [3]. Once a cell product has been manufactured, it can be 
delivered to the clinician using particular conditions such as at room temperature or 
cryopreserved [3]. 
Integration of an engineered tissue into the living system is the final challenge to 
mimicking the nature. Various animal models have been established to the study of 
different diseases. Regrettably, these models are somewhat unproven in their 
capacity to evaluate the success of the tissue engineering concept.  This is also found 
in human clinical trials. Immune response also has an important role in the success of 
any tissue engineering approach. Therefore, it would be desirable to have periodic 
assessment for a tissue substitute viability and functionality as well as a post-
implantation strategy for the patient [3].  
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1.1.2. Three Dimensional (3D) cell culture 
Most research in cell culture has been established on 2-dimensional (2D) surfaces. In 
2D culture, cells are grown in micro-well plates, tissue culture flasks and petri dishes 
which provide convenience and high cell viability in 2D culture  [4]. The conventional 
2D cell culture systems are sufficient to improve the understanding of basic cell 
biology but the system is insufficient to describe three-dimensional (3D) complexities 
in living tissue. In vivo, cells are supported by a complex 3D extracellular matrix 
(ECM) which allows cells to communicate via direct contact and through the 
secretion of a plethora of cytokines and trophic factors. In contrast, flattened 
morphology in 2D culture system  forces cells to adopt unnatural characteristics and 
require an adaptation to survive due to the lack of specific ECM environment [4, 5]. 
Therefore, 2D cultures fail to represent the complex and dynamic environment of the 
body [4].  
In pharmaceutical development, mimicking the behaviour of cells in vivo is the 
essential step for improving accuracy of prediction.  It can be achieved by creating a 
cell microenvironment that can support cell growth, organization, and differentiation 
[4, 5]. There are several methods to engineer and model 3D interactions in vitro, 
including natural aggregation using stirred or rotary cell culture, physically 
encouraging cell to cell interaction, hanging drop culture, or growth with 3D matrices 
[6].  
Aggregation of cellular spheres can be done by constant rotation of regular culture 
dishes, or use of a spinner flask or in a conical tube within a roller drum. The critical 
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factors for these methods are the size of dishes, flasks, or tubes for cell culture and 
the speed of the rotation [7].  The size of the dishes, flasks, or tubes will affect the 
diffusion of nutrient. Effective nutrient delivery and waste removal from cell culture 
could be achieved by increasing speed of rotation. However, higher speed will create 
turbulent flow and higher shear stress that can induce cell necrosis in the periphery 
of the 3D cell constructs.  Therefore, this issue should be addressed to develop 
reproducible 3D engineered constructs  [8]. It was reported that spheroid formation 
by agitation for porcine hepatocytes gave a simple and reproducible result. 
Hepatocyte culture in spheroids exhibited higher metabolic activity compared to 
those in monolayer cultures [9].   
Three-dimensional (3D) formation of cells could also be achieved by encouraging 
aggregation. The principle of this method is manipulation of cell surface chemistry. 
Surface of the cell can be functionalized with biotin via a covalent hydrazine bond. 
Addition of avidin into suspension of biotinylated cells rapidly cross-links cells into 
aggregates as avidin and biotin have a high binding affinity [6]. The other method to 
induce multicellular 3D formation is hanging drop method. In this method, cells in 
suspension have been hung as a drop from the lid of a petri dish. Gravity assures the 
cells collect at the bottom of the drop and to assemble as 3D multicellular aggregates 
[10, 11]. The hanging drop method is compatible with various cell types and has been 
used in tissue engineering to form tissue-like cancer models, for gene-function 
analysis, and in the design of functional microlivers, microhearts and microcartilage 
[10]. The advantage of the hanging drop method is the number of the cells in 3D 
aggregate could be controlled by adjusting the number of cells in the initial 
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suspension. However, the liquid volume of a drop should be less than 50 microliter in 
order to maintain the surface tension of a hanging drop on the lid.  Furthermore, 
changing the medium during cultivation is also not possible on hanging drop [11].  
Providing 3D cell constructs can also be achieved by seeding the cells on matrices. 
The matrices, also known as scaffolds, are engineered to promote the standard 2D 
cell culture system to a 3D platform and act as a temporary substrate for supporting 
and guiding tissue formation in various in vitro and in vivo settings [2, 12]. Scaffolds 
could also be implanted directly in vivo to guide the function of regeneration in a 
defective tissue or organ. Designing a scaffold could be possible through 
understanding the cell-ECM interaction in native tissue. Therefore, the main theme 
of designing matrices or scaffolds for tissue engineering is to understand the 
correlation between matrices or scaffold properties and biological function [2, 12, 
13].  
1.1.3. Tissue Engineering Scaffold 
The main components of engineered tissue for developing biological substitutes of 
tissues or organs are cells, scaffolds and signals for stimulating cell growth. A scaffold 
has a function as a matrix for cells to attach and support subsequent tissue 
development including deposition of extracellular matrix (ECM) [2, 14]. The ECM is a 
solid matrix in normal tissues which is an important component of all organs to 
provide structural scaffolding and contextual information. When cells are placed in 
contact with a suitable matrix, the cells start to multiply, proliferate, differentiate, 
secrete factors like ECM molecules and remodel their environment [2, 13]. 
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The finest scaffold for an engineered tissue should be able to act as ECM of the target 
tissue. However, it is difficult to precisely mimicking the dynamic nature of ECM in 
native tissue. Therefore, a basic concept of scaffold in tissue engineering is, at least 
partially, to mimic the architectural, biological and mechanical features of ƚŝƐƐƵĞ ?Ɛ
ECM as shown in Table 1.2 [14].  
Table 1.2. Comparison between Extracellular Matrix (ECM) in Native Tissue and 
Scaffold [14] 
 Function of ECM Function of Scaffold 
1. Support the cells to stay live. Support exogenous cells to attach, 
grow, migrate and differentiate in 
vitro and in vivo.  
2. Support the mechanical properties 
of the tissues. 
Gives the required shape and 
mechanical stability to the tissue 
defect as well as rigidity and stiffness 
to the engineered tissue. 
3. Delivers bioactive signals for cells to 
respond to their microenvironment. 
Facilitates the cells to proliferate and 
differentiate by active interaction with 
the cells. 
4. Provide a reservoir of growth factors 
and activates their effects.  
Provide a delivery vehicle and 
reservoir for exogenous growth 
factors. 
5. Gives a flexible physical environment 
to allow remodelling of tissue. 
Gives an empty space volume for 
vascularization and formation of new 
tissue during remodelling. 
 
The material for a scaffold should meet several criteria including [15, 16]: 
1. It should be biocompatible and biodegradable to support the formation of a 
new tissue with no inflammation involved. 
2. It should retain an adequate structure composition and be responsible for an 
appropriate 3D architecture of the tissue renewal. 
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3. It should be tailored to supply the particular cell types with nutrition and 
others biological needs for cell proliferation.  
4. It should interact with cells, support cell adhesion and promote ECM 
deposition [17]. 
Initial interaction between cell and scaffold plays an important role in 3D culture. 
Several factors have determined the initial interaction of scaffold with the cell, such 
as chemical composition, surface energy, roughness and topography of the top 
surface layers [15]. 
Materials for scaffolds can be synthetic or biological, biodegradable or non-bio 
degradable, depending on the purpose.  There are some main types of material used 
as biomaterial for scaffold including natural polymer, synthetic biodegradable and 
synthetic non-biodegradable polymer (Table 1.3) [17]. 
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Table 1.3. Type of materials for scaffold and its properties [17] 
Materials Properties Examples 
Natural polymers  Most of them are 
biodegradable. 
 Better interactions with 
cells to support cells 
performance. 
Protein (silk, collagen, 
gelatin), 
polysaccharides 
(cellulose, amylose, 
dextran), 
polynucleotides (DNA, 
RNA). 
Synthetic biodegradable 
polymers 
 Biodegradable. 
 Could be tailored based 
on specific purpose 
(biodegradability, 
porosity and mechanical 
characteristics). 
 Stable for long time 
storage. 
 The cost is cheaper 
compared to natural 
polymers. 
Polylactide, 
polyglycolide, poly(l-
lactide-co-glycolide), 
polyhydroxyalkanoates. 
Synthetic non-
biodegradable polymer 
 Forms a tight bond with 
tissue in physiological 
fluid. Insufficient 
biocompatibility and 
biodegradability. 
 Could be combined with 
natural polymer to 
achieve desired 
properties to meet 
biological and mechanical 
properties. 
Hydroxyapatite, 
tricalcium phosphate, 
silicate and phosphate 
glasses, glass-ceramics. 
 
Several types of scaffold are available for clinical use including porous scaffold, 
fibrous scaffold, polymeric-bioceramic composite scaffold, acellular scaffold and 
microsphere scaffold. 
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1.1.3.1. Porous Scaffold 
Porous scaffolds have a high porosity and interconnected pore network to mimic the 
ECM construction and allow cells to interact with their environment. Moreover, the 
porosity also supports cells to adhere and proliferate on the scaffold [17, 18]. The key 
parameter for initial cell impregnation within scaffold is the pore size of the scaffold 
as it will subsequently affect cell proliferation, differentiation and tissue formation. 
The optimal sizes of pores in scaffold have been suggested for regenerating various 
cell types in vivo. The larger pore volume of fibrous scaffold made from poly(ethylene 
terephthalate) lead to larger size of cells aggregate [12].  
Transport of bioactive material and nutrient to cells within the scaffold is also 
affected by the pore size of scaffold. Cells seeded in scaffold often exhibit hypoxia 
which induces cell death as a result of insufficient diffusion of nutrient within the 3D 
structure [12, 19]. The bone formation using bone morphogenetic protein was more 
rapid in scaffold with large pore diameter (350 µm) compared to bone formation in 
small pore diameter (90-120 µm). It showed that different pore size could affect the 
onset time of vascularization and differentiation of the cell [12]. 
The size of pores within the scaffold could be controlled during fabrication. However, 
it is hard to achieve controlled structure and pore size using conventional method of 
scaffold fabrication such as solvent casting, particulate leaching, gas foaming, freeze 
drying, electro spinning and laser sintering. In order to solve this problem, several 
techniques to produce highly controlled scaffold structure have been introduced, 
such as solid free-form fabrication (SFF), microfluidic patterning, laminar flow 
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patterning and projection stereo lithography (PSL) based on computer-aided design 
(CAD) [19, 20]. These methods could produce narrow variations in structure and 
pore-size of scaffold. It has been reported that controlled fabrication scaffolds 
produced significantly higher glycosaminoglycan (GAG) compare to those fabricated 
by conventional methods. That concludes that controlled method of scaffold 
fabrication gave promising in reproducible formation of functional engineered tissue 
[12, 19]. 
1.1.3.2. Fibrous Scaffold 
Fibrous scaffolds have high surface-area to volume ratio which gives excellent 
property to enhance cell attachment, proliferation, migration and differentiation [17, 
21]. Fibrous structure can be considered as a potential tissue engineering scaffold as 
it adopts the structure of natural ECM. The structure of fibrous scaffold plays an 
important role in cell behaviour as well as in the maturation process for tissue 
regeneration.  In order to act as ECM, the diameter of fibres should be in a 
nanometer scale. It has been found that collagen type I, which is the base 
attachment structure for cells in many tissues, has a nano-fibrous structure [22-24]. 
There are three common techniques available for nano fibrous fabrication: 
electrospinning, self-assembly, and phase separation.  
Fabrication using electrospinning technique is a most widely used for tissue 
engineering application due to simplicity and ability to produce nano-fibres from 
various materials [17, 24] In this technique, an electric field draws a polymer solution 
from an orifice and brings it to a collector to produce a polymer fibre with a certain 
diameter. The diameter of fibre can be controlled by varying the concentration of the 
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polymer solution. The higher concentration of polymer solution produces larger 
diameter of fibre [24].   
The second technique for fibrous scaffold fabrication is a self-assembly technique. 
This technique is applied to produce supramolecular architectures by putting 
together molecules which spontaneously form a large assembly. The structure is 
well-ordered with stable arrangement through a non-covalent interaction such as 
hydrogen bonds, Van der Waals interaction, electrostatic interaction and 
hydrophobic interaction. Biomolecules such as peptides and proteins have been 
produced using this technique and showed capability to support cell growth. Peptide-
based self-assembling structures can be assembled in the presence of cells and allow 
encapsulation of cells within the structure. In addition, the problem of stimulating 
cell growth into a preformed scaffold can be avoided [17, 24, 25]. The formation of a 
fibrous scaffold using self-assembly usually produces a smaller fibre diameter 
compared to those produced by electrospinning. However, it has not been 
demonstrated with this technique how to control pore size and pore structure which 
are important for cell incorporation, migration and proliferation [24]. 
The last technique that has been used for fabrication of fibrous scaffold is phase 
separation. The principle of this method is thermally induced phase separation to 
produce a nanofibrous scaffold. During the process, polymer is dissolved in a solvent, 
and then by controlling the temperature of polymer solution, it separates into two 
phases, a polymer-rich phase and a polymer-lean phase. Afterwards, the solvent in 
the polymer-lean phase is removed by extraction, evaporation or sublimation to 
produce a porous polymeric scaffold. In contrast, when the temperature is lowed 
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enough to freeze the solvent in the polymer-rich phase, it forms frozen solvent and a 
concentrated polymer phase. The pores would be formed later after removal of the 
frozen solvent. Different pore morphologies and structures can be produced by 
varying the polymer concentration, solvent and temperature to induce phase 
separation [24, 26].  
1.1.3.3. Polymeric-bioceramic composite scaffold 
Ceramics and their composites are attractive as scaffold material since they meet the 
requirement for the mechanical and physiological necessities of the host tissue, 
particularly for bone tissue engineering [17, 27, 28]. A ceramic scaffold could be used 
as a delivery vehicle for drug, however the release pattern of drug from ceramic 
scaffold is difficult to control [28].  Ceramics in tissue engineering, can be categorized 
into three classes [17]: 
1) Non absorbable (inert), for examples alumina, zirconia, silicone nitrides and 
carbons. 
2) Bioactive or surface reactive (semi inert), for examples glass ceramics and dense 
hydroxyapatite. 
3) Biodegradable or resorb-able (non-inert), for example aluminium calcium 
phosphate, coralline, and tricalcium phosphate. 
The main purpose of materials for bone tissue engineering is to fill bone defects. 
Thus, these materials should be able to maintain appropriate mechanical strength, be 
osteoconductive and biodegradable to provide a space for the formation of the new 
bone. Materials such as hydroxyapatite and tricalcium phosphate have been used for 
this purpose since they have similarity to chemical and structural properties of bone 
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mineral. However, the clinical application for these materials is limited due to their 
stiffness and brittleness. To overcome this problem, these materials have been 
combined with polymer into a composite to give materials with improved mechanical 
properties. The addition of polymer to the materials can alter the biodegradation 
rate of the scaffold [17, 29] and also control release drug from scaffold [28]. The 
inorganic components in natural bones such as calcium phosphate, hydroxyapatite 
and tricalcium phosphate can be combined into a composites with several materials 
like poly (l-lactide-co-glycolide), poly(l-lactic-acid), chitosan, collagen, and gelatin [17, 
28] . 
1.1.3.4. Acellular Scaffold 
As an alternative to a biodegradable scaffold, the use of matrix from a biological 
source is a favourable option. This concept has been used in acellular tissue matrices. 
Acellular matrices are the matrices produced by excluding cellular components from 
tissue by mechanical or chemical manipulation to produce collagen-rich matrices. 
They can be used alone or seeded with cells. The degradation rate for these matrices 
is slow and generally replaced by ECM of transplanted cells [17, 30-32]. The 
advantages of using acellular scaffold are they retain suitable anatomical structure 
after the decellularisation process, maintain original ECM architecture and encourage 
cell adhesion, reduce immunological response and facilitate the development of 
similar biomechanical properties [17, 30].  
Preparation of acellular matrices can be achieved by several methods including 
repetitive freezing/thawing, high pressure treatment, enzymatic and chemical 
processes [30, 33]. However, repetitive freeze/thawing and the high pressure 
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method could deposit undesired cells detritus. Consequently, this method would 
result in an acellular scaffold with potential immunogenic issues.  The immunogenic 
problem could be avoided by enzymatic process, but it would disrupt and digest part 
of the ECM. Sandmann et al [33] demonstrated a chemical process using the 
detergent sodium dodecyl sulphate to decellullarize ovine meniscus. The processed 
menisci produced cell-free scaffolds and did not alter collagen fibre arrangement 
within the scaffold [33]. A combination of enzymatic and chemical process has been 
demonstrated to yield acellular scaffold. Collaboration between hyper-hypotonic 
washes, enzymatic digestion and detergent treatment was used to produce acellular 
scaffolds from porcine cardiac tissue. The acellularized porcine cardiac extracellular 
matrix presented a fibre myocardial architecture and the myocytes seeded in the 
scaffolĚĞǆƉƌĞƐƐĞĚƚǇƉŝĐĂůĨƵŶĐƚŝŽŶĂůĐĂƌĚŝĂĐŵĂƌŬĞƌƐƐƵĐŚĂƐɲ-actinin, troponin I and 
connexin 43 [34]. 
1.1.3.5. Microsphere Scaffold 
Drug delivery method based on microsphere could be applied in tissue engineering 
for encapsulation of bioactive signal or living cells within the microsphere. 
Microspheres also can be tailored as carriers to modulate spatial and time-specific 
release profile. Moreover, microspheres can be used as matrices to encourage cell 
attachment and proliferation [16, 17, 35]. Generally, a polymer is used as a matrix to 
encapsulate the drugs or bioactive agents and then release the drug at a moderately 
slow rate for a prolonged period of time [17, 36]. Microspheres in tissue engineering 
system can be injected with a syringe or combined with the scaffold used for 
implantation. Additionally, it can be used for aggregating cells to form a 3D construct 
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and then implanting the construct at the later stage, particularly for bone and 
cartilage tissue engineering [16]. Polymers from synthetic or biologically-derived 
materials can be used to build a microsphere scaffold for tissue regeneration and 
replacement.  
Synthetic polymers are good candidates for tissue engineering application as their 
physical and chemical properties can be readily controlled and manipulated for 
certain purposes. Some of the synthetic polymers available for regenerative 
medicines and drug delivery are poly(hydroxy acid), poly(lactic acid), poly(glycolic 
acid), and poly(lactide-co-glycolide). They are biocompatible and approved by US 
Food and Drug Administration. Moreover, these polymers will degrade gradually into 
water soluble and nontoxic by-product, and then be eliminated from implant site by 
the normal metabolic pathways [36]. 
Regarding biocompatibility, biologically-derived polymers are naturally compatible 
molecules and produce the required responses in cells, tissues, or organ [36]. These 
types of polymers can be obtained by enzymatic processes or extraction from plant, 
animal or algae. Some biologically-derived polymers, such as collagen, fibronectin, 
fibrin and glycosaminoglycans, are inspired by extracellular matrix. These materials 
can be useful to guide morphogenesis in tissue development. Silk as a protein-
derived biomaterial could be used as well as polysaccharide from plant (cellulose, 
galactans, alginate), animal (chitin, chitosan, hyaluronic acid) and microbial (dextran, 
xanthan gum) sources [16]. 
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Physical characteristics of microspheres such as particle size, shape, and porosity 
take important roles in the release of encapsulated compounds from microspheres. 
[35, 36]. The size of microspheres can be controlled by passing polymer solution 
through a nozzle to create a specific size of droplet [35, 37]. Pore size also plays an 
important role for releasing drugs from microspheres as the presence of pores in the 
microspheres increase the motion of the active diffusing species such as drug 
molecules or bioactive agents. Therefore, the high porosity provides a high release of 
molecules from microspheres [38]. Increase in molecular weight and polymer 
concentration resulted in a significant decrease of molecule release from 
microspheres [39].  
1.1.4. Injectable Scaffold in Tissue Engineering  
The aim in tissue engineering is to obtain functional substitutes for damaged tissue 
using 3D construct of scaffold, living cells and bioactive molecules. The 3D structure 
can be pre-formed outside the body and implanted or injected as a mixture of 
bioactive molecules and scaffold precursors which form a 3D structure in situ.  
The advantage of using an injectable scaffold for tissue regeneration is to minimize 
patient discomfort due to surgical intervention, reduce risk of infection, scar 
formation and the cost of treatment. Additionally, an injectable scaffold would be 
able to take the shape of the tissue defect and fill it without prior knowledge of size 
and shape cavity. As a carrier for bioactive molecules, an injectable scaffold could be 
used as a controlled release device [40, 41]. However, the injectable scaffold system 
should be able to support a suspended cell population during the solidification 
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process [41]. After injection, an injectable scaffold will generate a 3D matrix where 
cells can adhere, proliferate and differentiate. In tissue engineering, an injectable 
scaffold is a promising system for tissue regeneration particularly for bone and soft 
tissue regeneration [40].  
An injectable system for tissue regeneration should meet criteria for both tissue 
engineering and drug delivery. Most importantly, the rate of degradation for 
injectable scaffold materials should ideally match the formation of the new tissues. 
Moreover, porosity in the scaffold should be enough to support cell growth and 
diffusion of nutrients as well as transport of waste products from the cells. Bioactive 
agents should be presented in the scaffold in order to promote cell growth and 
differentiation. It can be provided by combining scaffold with growth factor or 
adhesion-specific peptide which can mimic the extracellular matrix to produce 
suitable signals for cells [41]. Adhesion-specific peptides, like arginine-glycine-
aspartic acid (RGD) sequences could be incorporated in the injectable scaffold to 
promote specific functions of the cells. However, the selection of suitable peptide 
sequences and optimization of the density and distribution of the peptide sequences 
are important issues. The injectable scaffold acts as a reservoir e.g. for growth factors 
that releases the bioactive molecules at target site for a certain length of time.  Since 
most growth factors have short half-lives, the important consideration is how to 
retain their bioactivity and effectively release them to site of action with optimal 
dosage, timing and correct order [40].  
An injectable scaffold should undergo a mild solidification process close to 
physiological condition in order to keep cells viable and retain biomolecule activity. 
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There are several types of solidification for injectable scaffold including chemical 
polymerization and crosslinking, thermo gelation, ionic crosslinking and self-
assembly. 
1) Chemical polymerization and crosslinking 
Solidification of an injectable scaffold can be achieved in situ by using chemical 
activated polymerization or crosslinking. A monomer or macromer with 
unsaturated bond or photosensitive functional group will react in the presence 
of an initiator to form cross links which is activated by temperature or light. The 
properties of crosslinkable polymers depend on types and concentration of 
initiators as well as the ratio and density of crosslinking agent. Additionally, the 
period of reaction, temperature and intensity of visible light also play major 
roles for thermal and photochemical cross linking. The most common used 
crosslinkable polymers in tissue engineering are (meth)acryloyl, styryl, coumarin, 
phenylazide, and fumaryl monomers [40, 41]. An initiator like ammonium 
persulfate/E ?E ?E഻ ?E഻-tetramethylethylenediamine can be used with 
oligo(poly(ethylene glycol) fumarate) to produce a hydrogel construct at 37°C 
[41].  
The crosslinkable polymer could be combined with microparticles to give porous 
injectable composites with an ability to incorporate drugs and growth factors. 
Common microparticles loaded into injectable scaffolds were made from 
poly(lactic-co-glycolic acid), poly(propylene fumarate) and gelatin. Gelatin 
microparticles loaded with growth factor have been used to encapsulate cells 
within the composite and provide shielding for cells during the crosslinking 
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process. This microparticle was then incorporated with poly(propylene 
fumarate). The composite showed the ability to induce proliferation and 
glycosaminoglycan production in chondrocytes [41].  
2) Thermo gelation 
Some aqueous polymer solutions can be activated to produce a gel by an 
alteration in temperature. These kinds of hydrogels do not require a chemical 
agent to solidify as a gel and the gelation point can be arranged close to normal 
body temperature. Hence, they can be injected in a liquid form and become 
solid inside the body. Natural polymers like cellulose derivatives, chitosan and 
gelatin have been reported for use as injectable scaffolds based on thermo 
gelation. On the other hand, synthetic polymer like poloxamer (Pluronics®), 
poly(ethylene glycol), and poly(N-isopropylacrylamide) are most widely use due 
to their thermal behaviour [40, 41]. 
3) Ionic crosslinking 
Gel formation could be induced by ionic crosslinking. A naturally derived 
polysaccharide, alginate, in aqueous solution can perform a reversible gel in the 
presence of di- or trivalent cations, for example Ca2+. Alginate is a biomaterial 
which consists of 1,4-ůŝŶŬĞĚɴ-D-mĂŶŶƵƌŽŶŝĐĂĐŝĚ ?D ?ĂŶĚɲ-L-guluronic acid (G) 
in varying proportions and sequential arrangement. The ionic inter chain bridges 
are formed as the cations bind the guluronic acid blocks in alginate chains. As an 
injectable extracellular matrix analogue, alginate has an advantage from its 
biocompatibility for in vitro cell culture [40, 41] .  
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The gelation rate in alginate depends on concentration of cation, alginate 
composition, and gelation temperature. Increasing concentration of cation gives 
a high gelation rate and alginate with higher G content or longer G segment 
achieved faster gelation process. However, a higher alginate concentration 
tends to decrease gelation rate. Mechanical properties and uniformity of 
hydrogels are influenced by gelation rate. Homogenous structure of the gel with 
greater mechanical strength can be achieved at a lower gelation rate. 
Additionally, the desired mechanical strength is achieved with increasing 
alginate concentration, ionic content, molecular weight and G content in 
alginate. A lipid vesicle, like liposome, can be used to release calcium based on 
temperature, to induce rapid formation of alginate hydrogels [40, 41].  
4) Self-assembling systems 
In a self-assembling system, neither chemical cross linking agents nor initiators 
are involved. Polymer spheres, often referred to as nano- or microparticle, were 
mixed with a cells suspension in suitable cell culture medium then injected to 
the site of defect. Avidin could be added to support crosslinking formation of 
particles with the cells if biotin ligands are incorporated. The advantage for this 
self-assembly process is to avoid chemical exposure to the cells which 
potentially induces cytotoxicity. However, the mechanical strengths of self-
assembly systems are often lower than chemically crosslinked systems. 
Therefore, self-assembled systems are inappropriate for use in load or tension 
bearing connective tissue [40, 41]. 
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Incorporation of particles as a matrix for injectable scaffold could induce 
macrophage response. Fortunately, this immune response can be controlled by 
modifying the surface properties of particles. It has been found that particles 
coated with hydrophilic polymer chain, such as PEG, could exhibit less immune 
response and decrease clearance from the blood. The important factors for 
injectable particles are ratio of particle to cells and the type of injection system 
used. Ratio of particle to cells is not only important for dosing purpose but also 
to control the ability for injection in a clinical setting. Moreover, the effect of 
injection time should be considered. Injectability of the system is also affected 
by needle gauge. The appropriate needle gauge should be considered to be able 
to deliver the composite with a reasonable amount of force needed for 
injection, but which is acceptable for the patient [41].  
1.2. Stem Cells 
1.2.1. Background 
The cell source becomes an important parameter for replacement therapy.  Fully 
differentiated adult cells have limited ability to proliferate and tend to lose their 
phenotype during in vitro expansion. Hence, these limitations make stem cells useful 
as a potential source of cells for tissue engineering [2]. Stem cells have self-renewal 
properties, capacity to produce more undifferentiated stem cells and differentiate 
into one or more functional mature cells. The self-renewal capability of stem cells can 
be encouraged and retained for certain periods of time, even years, to produce a 
large number of cells [42, 43]. However, inside the body, stem cells do not divide 
frequently and remain dormant until they receive signals to start or stop dividing. 
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Hence, stem cells are usually quite rare and only limited amount being found in 
particular region of human body. The tight control of self-renewal in stem cells is 
necessary to control these cells to not divide indeterminately as it will induce over 
population of the cells and potentially become a cancer [43]. 
The principle rule of cell therapy is to explore the natural capacity of the human body 
to rebuild tissues through the regeneration process. Since stem cells have ability to 
differentiate to various cell lineages, it has the potential for use in tissue engineering 
and replacement therapy for various tissue such as for heart disease, bone or 
connective tissue disorders, neural defects, and haematological disorders [42]. The 
capacity of stem cells to differentiate into other types of cells can be classified into 3 
types [42, 43]: 
1) Totipotent: The cell has ability to differentiate into all types of cells that 
contribute to the formation of fertilised egg or zygote 
2) Pluripotent: the cell has capacity to differentiate into almost all cell types 
including germ cells but not the placental tissue. Example for this type is 
embryonic stem cells. 
3) Multipotent: The cell has ability to differentiate into most mature cells and 
featured tissue. Example for this type is hematopoietic stem cells. 
The cells potency state depends on the genetics of the cells. Moreover, the 
ĞŶǀŝƌŽŶŵĞŶƚŽĨƚŚĞĐĞůů ?ƐůŽĐation also plays an important role. The process of cells to 
differentiate into a particular characteristic usually involves the formation of 
intermediate progenitor cells. Progenitor cells, or transit amplifying cells, 
differentiate into more specific cells than stem cells and have the ability to divide but 
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with very limited capacity for self-renewal [43]. The isolation of stem cells from 
different sources may provide adequate number of cells for various diseases as well 
as enhance application or autologous transplantation [42]. 
1.2.2. Types of Stem Cells 
Based on the source, stem cells can be classified into adult stem cells, embryonic 
stem cells and induced pluripotent stem cells. 
1) Adult stem cells 
Adult stem cells (ASC) are undifferentiated cells in tissue with limited self-renewal 
and differentiation capacity. They are supposed to play important roles in the repair  
mechanism intrinsic  to many tissues and organs [1, 3]. ASC usually differentiated into 
the cell types of tissue where they originally located, thus ASC are categorized to be 
multipotent cells [42, 43]. 
The ASC derived from embryonic germ layers consists of endodermal, mesodermal 
and ectodermal (Figure 1.1) [42, 44]. The most common of ASC is isolated from bone 
marrow, a mesoderm derived tissue. Bone marrow consist of 2 types of stem cells: 
hematopoietic and stromal mesenchymal stem cells [1, 42]. The bone marrow stem 
cells can be maintained without adding specific growth factors but they need specific 
growth factors for in vitro differentiation into several cell types such as osteoblast, 
chondrocytes, adipocytes, stromal cells, tendon cells and muscle cells [43]. 
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Figure 1.1. Schematic diagram showing the differentiation of human tissues from 
germ layers. Image is taken from Chandross, K.J. and É. Mezey (2002) without any 
modification [44]. 
 
In addition, several tissues like skin, gut and liver, also contain a population of stem 
cells to replace or heal cells that are missing due to normal wear or injury as these 
particular tissues have a high cell attrition rate. Cartilage, brain, heart and teeth also 
have been shown to contain a population of stem cells but with limited capacity for 
normal repair. The capacity of ASC to self-renew and differentiate is controlled by 
tissue-specific environmental factors. This environmental factor, referred as  “ƐƚĞŵ
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cell nichĞ ? ŝƐ ŝŵƉŽƌƚĂŶƚ ƚŽ ŵĂŝŶƚĂŝŶ ŚŽŵĞŽƐƚĂƐŝƐ ŽĨ ƚŚĞ ĐĞůůƐ ĂŶĚ ƚŽ ůŝŵŝƚ ĐĞůůƐ ƚŽ
differentiate, become apoptotic or produce other signalling that would reduce stem 
ĐĞůůƌĞƐĞƌǀĞƐ ?dŚĞ “ŶŝĐŚĞ ?ĐŽŶƚƌŽůs the cells not to become overpopulated in a tissue 
which would potentially lead to cancer. Therefore, it is important to understand the 
relationship between stem cells and their niche to utilise cells effectively for 
therapeutic application [3, 43].  
Cells obtained from less-mature sources like umbilical cord blood and foetal tissues 
also categorized as adult stem cells. Characteristic of stem cells from umbilical cord 
blood and foetal tissue are similar to hematopoietic stem cells (HSC) and bone 
marrow stromal stem cells (BMSC) [43]. Umbilical cord blood stem cells contain an 
original sub population of CD34, CD38 HSC [42]. Accordingly, the characteristics and 
ability to differentiate into   multiple linages, umbilical cord blood stem cells and 
foetal stem cells are potentially useful for allogenic transplants.  
2) Embryonic stem  cells 
Embryonic stem cells (ESC) are isolated from the inner cell mass of pre-implantation 
embryo during blastocyst stage [3, 43]. ESCs are usually isolated before day 5 when 
the entire embryo consists of a few hundreds of cells. In human embryo, 
manipulation is restricted to 14 days from its creation as this period is a specific stage 
in embryonic development. ESC have ability to differentiate into all specialized cell 
types but they unable to form tissue like placenta. For this reason, ESC is categorized 
as pluripotent, not totipotent [43].  
 Chapter 1  Introduction 
 
27 
 
The first lines of ESC were produced from mouse blastocyst in 1981, then from 
human ESC lines 17 years later. Currently, at least 225 human ESC lines have been 
produced in different laboratories by isolation of cells on mouse feeder layers of 
undifferentiated fibroblast [42, 43, 45]. As human ESC are derived from different 
embryos, they express different gene characteristics [3]. Besides culturing ESC on 
mouse feeder layer fibroblasts, ESC also can be cultured on human fibroblast derived 
from tissue like neonatal foreskin. Human ESC was recently cultured on human foetal 
fibroblast and animal-free product cell media in order to minimize transfer of 
potential harmful agents like animal pathogens. Co-culture of ESC cells with another 
type of cell is possible to be achieved on the surface coated with ECM preparation 
like gelatin or purified ECM protein, laminin [43]. 
The pluripotency of ESC can be maintained in culture by adding Leukemia-Inhibitory 
Factor (LIF), however, LIF alone is not sufficient for human ESC. Human ESC cultures 
require supplementation of basic fibroblast growth factor (bFGF) or the presence of a 
feeder layer. Both mouse ESC and human ESC express common transcription factors 
like NANOG, OCT4 and alkaline phosphatase but they slightly vary in expression in 
stage specific embryonic antigen (SSEA) [43, 45]. 
ESC will differentiate immediately after removal from the feeder layer and LIF or 
bFGF. The ES cells are usually maintained in suspension culture to form embryoid 
bodies, which contain endodermal, mesodermal and ectodermal cell lineage. ESC 
cells differentiate and proliferate in embryoid bodies as they mimic the process of 
gastrulation in early development of an embryo. However, not all ES cells have 
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capability to form embryoid bodies. Some of human ESC showed inability to form this 
structure [43].  
3) Induced pluripotent stem (iPS) cells 
Induced pluripotent stem cells (iPSC) are adult cells reprogrammed through retroviral 
transfection to resemble the pluripotency of embryonic stem cells [3, 46]. The use of 
viruses to introduce genes of pluripotency may cause mutation by viral insertion into 
the genome and result in abnormal proliferation. However, recent development of 
inducing pluripotency under protein-controlled conditions may eliminate the risks 
[46].  
Identification and evaluation of iPSC begin with identifying compact colonies that 
have a distinct border and well-defined edge as well as large nucleus and scant 
cytoplasm. Although many colonies appear similar to ESC morphology, only a subset 
of these has comparable molecular and functional features. Furthermore, fully 
reprogrammed cells showed pluripotency markers including OCT4, SOX2 and 
NANOG, reactivate telomerase gene expression, down-regulate THY1 and up-
regulate SSEA. Functional characterisation of iPSC can be assessed by in vitro 
differentiation as embryoid bodies or through two-dimensional (2D) differentiation in 
a culture dish. The current method to evaluate the function of iPSC involves teratoma 
formation. The potency of iPSC to differentiate in vivo is assessed by injecting the 
cells subcutaneously or intramuscularly to immune-deficient mice. If they formed 
well-defined tumours containing elements of each of the three germ layers, it can be 
conclude that the cells are truly pluripotent [47]. 
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Although both iPSC and ESC show pluripotency, they are not identical in 
differentiation ability. Some mouse iPSC showed lower teratoma formation 
compared to mouse ESC. In addition, some human iPSC showed lower tendency to 
differentiate along hematopoietic and neuroephithelial lineage than human ESC. 
These findings elicit that iPSC has lower differentiation capability than ESC. 
Moreover,  differentiation capacities of iPSC depend on the origin of the cells [47]. 
Generating patient-specific stem cells through reprogramming is a long-standing goal 
in field of regenerative medicines. The differences between iPSC and ESC do not 
diminish potential use of iPSC in medical application. Some research showed the 
utilisation of iPSC to use for disease modelling, drug screening, gene therapy and 
tissue engineering [46, 47].  
1.2.3. Stem Cells for Bone Regeneration 
Bone can be used as a prototype model for tissue regeneration, thus stem cells could 
be used to engineer functional tissue for implantation or preserve physiological 
function of bone [48]. Some basic considerations have been used to decide the 
source of cells for bone regeneration. These include [49]: 
1. dŚĞ ƐŽƵƌĐĞ ŽĨ ƚŚĞ ĐĞůůƐ P ĨƌŽŵ ƉĂƚŝĞŶƚ ?Ɛ ŽǁŶ ĐĞůůƐ  ?ĂƵƚŽůŽŐŽƵƐ ? Žƌ ĂŶŽƚŚĞƌ
person cells (allogeneic) 
2. The availability and efficiency of cells for isolation 
3. The use of primary osteogenic cells or self-renewal stem cell 
4. The homogeneity and ability to control osteogenic induction 
5. The possibility of automation and control the generation of cells 
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For bone construct preparation, cells are isolated and expanded in vitro. 
Approximately, 70 million of bone cells are required to form 1 cm3 new bone. The 
critical step in expansion process is to maintain a stable expression of osteogenic 
phenotype and to avoid non-specific tissue development[49].  
Source of stem cells for bone regeneration can be divided into two main categories. 
They are adult stem cells and embryonic stem (ES) cells. 
1. Adult stem cells 
Bone marrow contains adult mesenchymal stem cells which have the ability to 
differentiate into several cells lineage including adipocyte, osteoblast, 
chondrocyte, cardiac myocyte, skeletal myocyte, neural cell, hepatic cell and 
renal tubular cell [50-52]. The proportion of mesenchymal stem cell (MSC) in 
bone marrow is around 0.001% to 0.01% of the total of adult bone marrow [49, 
50]. Adult MSC contain positive marker for CD29, CD44, CD105 and CD166 and 
has ability to be doubling within 2 days [51]. 
The use of MSC for bone regeneration is simple. Cells are isolated and expanded 
ex vivo. Then, cells are loaded into an appropriate carrier and transplanted in 
vivo [53]. All MSC can be maintained in undifferentiated state, yet sometimes 
difficult to maintain cell plasticity in vitro. Decrease in cells plasticity is indicated 
by decrease in proliferation rate and reduced capacity to differentiate into 
multiple cells lineage. In addition, cells differentiation potency is affected by the 
cell culture condition [50]. The potency of cells to differentiate can be 
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maintained by adjusting the appropriate condition in vitro, for example using 
collagen as substrate for cell culture, and using supplements in cell media [49].  
Evaluation of differentiation potential in adult stem cells isolated from several 
tissues can be identified through the expression of surface antigen using flow 
cytometry, molecular, biochemical and histology assay. The bone marker gene 
expression related to functional osteogenesis have been used recently to design 
a mathematical model for bone formation capacity in synovial periosteal stem 
cell [49]. 
2. Embryonic stem cells 
Embryonic stem (ES) cells have the capacity to continuously self-renew and 
differentiate into all cell types in the body to be established for replacement 
therapy [50, 54]. However, culture conditions for ES cells are more complex than 
adult stem cells. They are cultured in mitotically inactivated feeder layer in 
media supplemented with basic fibroblast growth factor [49]. The ES cells are 
characterised by specific surface antigens such as stage-specific embryonic 
antigen -4 (SSEA-4), tumor rejection agent-1-60 (TRA-1-60), TRA-1-81, alkaline 
phosphatase, telomerase activity,  and expression of transcription factors OCT4, 
NANOG and SOX2 [49, 54].  
Differentiation of ES cells commonly initiated by growing ES cells as aggregates 
in suspension culture, which are called embryoid bodies (EB). The EB leads to 
the formation of multi-differentiated structures. The capability for osteogenesis 
in EB appeared after 4 or 5 days of culture [49, 50]. Nevertheless, this method 
has limitations as the differentiated cells become heterogeneous. Individual cells 
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may receive different signals depending on their location in EBs. As a 
consequence, the several methods have been developed to select the required 
cells based on specific cell surface markers [50]. Co-culture ES cells with stromal 
cells can be used to induce differentiation, then followed by immunoselection of 
mesenchymal stem cell-like population [49]. Differentiation in ES cell could be 
induced by culturing ES cells in serum and media containing growth factors, for 
example, the osteoblast lineage can be developed in murine ES cells by culturing 
in media supplemented with ascorbic 2-ƉŚŽƐƉŚĂƚĞ ? ɴ-glycero phosphate and 
dexamethasone [49, 54]. 
Bone tissue contains 4 types of cells and their composition are varied throughout the 
body [55] : 
1. Osteoblasts, as bone matrix producing cells 
2. Osteoclasts, as bone matrix degrading cells 
3. Osteocytes, the mature osteoblasts in mineralisation matrix 
4. Osteoprogenitor, immature cells which have capability to differentiate into 
osteoblasts. 
Differentiation of osteoblast as a bone-forming cell can be subdivided as in Figure 
1.2. The phases are related with sequential expression of the genes involved in 
biosynthesis, organization and mineralisation of bone cellular matrix. The initial 
phase for osteoblast differentiation is proliferation which involves genes for 
proliferation (e.g., c-fos), progress of cells cycle (e.g., cyclins, histons) and 
biosynthesis of ECM (e.g., collagen type I). The next stage of osteoblast 
differentiation is maturation which involves genes for maturation and organisation of 
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bone extracellular matrix, for example alkaline phosphatase. Eventually, after 
proliferation and differentiation of osteoid, they become mineralized. In this phase, 
expression of genes related to deposition of hydroxyapatite occurred including 
osteopontin and osteocalcin [56, 57]. 
 
Figure 1.2. The stages of osteoblast development. The major transcription factors 
and growth factor in each stages of osteoblast differentiation are illustrated. The 
diagram taken from Strohbach, C.A., D.D. Strong, and C.H. Rundle (2011) [57]. 
 
There are three factors required to differentiate stem cell to bone cell for 
regenerative application, including morphogenetic signal, responding stem cells and 
extracellular matrix scaffolding [48]. The signals should be capable to modulate 
cellular activity and induce osteogenic process for bone formation. Growth factors or 
drugs could be used as the signals to either stimulate or inhibit cell proliferation, 
differentiation, migration and genes expression [58] ?dĞƌŵ “ŐƌŽǁƚŚĨĂĐƚŽƌ ?ŚĂƐbeen 
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used for natural protein that encourages cell proliferation and differentiation, usually 
refers to cytokines or hormones that bind into specific cell membrane receptor. In 
addition, some drugs such as statin, bisphosphonate, corticosteroids and antibiotics 
can be used to stimulate growth factor activity [55]. The list of growth factors and 
drugs that can be used as signals for bone formation are laid out in Table 1.4.  
Growth factors usually bind to the specific receptor on the surface membrane of the 
cell target. In order to activate, they may need proteolytic activation and binding to 
matrix molecules for stabilisation. Their short half-life, relatively large molecular-size 
and slow penetration into cells or tissues make it difficult to deliver them through the 
conventional route such as adding them to culture media. This problem can be solved 
by incorporating them into a polymeric carrier which can facilitate the release of the 
bioactive molecules over extended periods [58].  
 
 
 
 
 
 
 
 
 
 Chapter 1  Introduction 
 
35 
 
Table 1.4. Several Growth Factors and Drugs for Morphogenetic Signals to Induce 
Bone Formation in Stem Cells.  
Growth Factor or Drug Function 
Basic Fibroblast Growth Factor (bFGF) Stimulate cell proliferation and increase 
production of mineralized matrix by enhance 
intrinsic osteogenic potential [55, 59, 60]. 
Vascular Endothelial Growth Factor 
(VEGF) 
 
Stimulate proliferation, cells migration and 
osteoblast formation and control survival of stem 
cell by prevent inhibitor to penetrate the plasma 
membrane [61]. 
Platelet Derived Growth Factor (PDGF) Increase population of bone forming cells by 
involved in cell division, migration and growth [55, 
62]. Stimulates osteochondral progenitor and 
modulate response to BMP[63].  
Nerve Growth Factor Beta (NGF-ɴ) Accelerated maturation in bone formation [64] and 
reducing apoptosis in osteoblast [55]. 
Transforming Growth Factor (TGF) 
family (TGF-ɴ ? ?d'&-ɴ2 and TGF-ɴ3) 
Induce cell growth, proliferation, differentiation 
and apoptosis [55, 65], regulating extracellular 
matrix formation [55], increase osteocytes density 
and bone formation [65, 66]. 
Bone Morphogenetic Protein (BMP-2 
and BMP-4) 
Initiate and promote stem cell osteogenesis [48, 
55, 58, 67]. 
tŶƚ ?ɴ-catenin Controlling homeostasis of bone-forming 
osteoblast and bone-resorbing osteoclast [62, 68] 
Insulin-like Growth Factor (IGF-I and 
IGF-II) 
Local regulator in osteoblastic function and 
formation [62, 69, 70]. 
Corticosteroid Stimulate expression of genes involved in bone 
formation and mineralization [71-73]. 
Statin Involve in  BMP2 up regulation and bone matrix 
mineralization production [55], increase anabolic 
effect and genes expression involving in osteogenic 
differentiation [74-76]. 
Ascorbic acid Act as antioxidant [55], initiate extracellular matrix 
formation [77], stimulated ALP and osteocalcin for 
osteoblast formation [78, 79]. 
Biphosphonate Inhibit bone-resorbing osteoclast activity [55, 80], 
enhance proliferation and initiate osteogenic 
differentiation [80-82]. 
Dihydropyridine  Increase collagen type I and osteoid calcification by 
stimulation calcium channel [55, 83, 84] 
Antibiotic  Reduce or inhibit microorganism such as bacteria 
to prevent bone cells infection [55, 85] 
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1.3. Microparticles 
Microparticles are small particles ranging in size from 1 to 1000 µm, with one or 
multiple core substances (solid or liquid) that are surrounded by polymer matrices 
[36, 86]. Microparticles offer several benefits such as controlling delivery and release 
of the drugs, they are easy to produce and biochemically stable. The incorporation of 
drugs can be achieved by encapsulation. The drug encapsulation into microparticles 
could be useful to deliver drugs with a sustained release profile over a period of time 
[87].  
1.3.1. Microparticle Production 
The method of microparticle production plays an important role in microparticle 
characteristics and drug loading. There are several techniques to create 
microparticles, such as emulsification, polymer phase separation (coacervation), 
spray drying and the use of supercritical fluid (SF). 
1) Emulsification 
An emulsion of two or more immiscible liquids can be used to produce 
microparticles. Usually, a volatile organic solvent with low water miscibility such as 
dichloromethane (DCM) or chloroform are used. In the initial step, polymer and drug 
are dissolved in organic solvent. Then, it is emulsified into a bulky aqueous phase 
containing tensioactive molecules, for example poly(vinyl alcohol) (PVA) [86, 88]. 
Microparticles are generated by solvent removal through an evaporation or 
extraction process and become free-flowing injectable microspheres after drying or 
lyophilization [88]. The emulsion type can be varied depend on the solubility of drug 
in water and encapsulating polymer [86].  
 Chapter 1  Introduction 
 
37 
 
Hydrophobic drugs can be encapsulated into microparticles by an oil-in-water (O/W) 
emulsification process. The amount of drug loading in the non-polar polymer matrix 
can be increased by adding sodium chloride (1 M NaCl solution) into the aqueous 
phase. Sodium chloride increases the polarity of aqueous phase and reduces the 
solubility of the drug in aqueous phase and improves encapsulation of the drug in 
non-polar polymer matrix [89]. However, the oil-in-water (O/W) emulsification 
process is not suitable for encapsulating a hydrophilic drug as it leads to poor 
encapsulation efficiency. Hydrophilic drug also can be deposited on the surface of 
microsphere and lead to rapid release of drug at the beginning or burst release[88]. 
Moreover, hydrophilic substances are drained during the intense solvent elimination 
and concentrate on the surface of microparticles then contribute to the initial burst 
release [90].  
Modifications have been made to encapsulate hydrophilic drugs using water-oil-
water (W/O/W) emulsion. In this particular method, a volatile organic solvent has 
been used to dissolve the polymer. Then, an aqueous solution containing the drugs is 
added to the organic phase under high shear to form water-in-oil (W/O) emulsion. 
Subsequently, the mixture is added into a large volume of water containing tensio-
active molecules (e.g., PVA) to form a W/O/W emulsion under rapid stirring. Solvent 
removal is completed using evaporation or extraction with the formation of solid 
microparticles [88].  
In this multiple emulsion method, the stability of the primary emulsion is an essential 
requirement to stabilize the multiple emulsions and it also influences the loading of 
the drug in solid microparticles. A high loading of hydrophilic drug can be obtained 
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from a stable primary emulsion. Stable primary emulsion can be reached by 
increasing the concentration of the emulsifier. Consequently, the average size of 
microparticles is also reduced in a higher concentration of emulsifier [91].  
2) Polymer phase separation (coacervation) 
The phase separation technique is based on solubility of the encapsulating polymers 
in an organic solvent by varying the temperature, or by adding the third component 
that interacts with the organic solvent but not with the polymer, it is called a 
coacervating agent (CA) [88]. Depending on the number of polymers that are 
involved in the formation of microparticles, coacervation can be categorized into 
simple and complex coacervation. Simple coacervation involves only one polymer 
and phase separation can be stimulated by desolvation (or dehydration) of the 
polymer phase. In contrast, complex coacervation involves two hydrophilic polymers 
of reverse charges. Separation of the polymers is obtained by neutralization of the 
overall positive charges on one of the polymers using the negative charge on the 
other polymer [86].  
The coacervation process is suitable for encapsulation of both hydrophilic and 
hydrophobic drugs. Phase separation and the solidification stages in coacervation 
process are affected by CA. The CA should not dissolve the polymer and the drug, but 
should be soluble in the solvent. Coacervation is induced  gradually when CA agent is 
added to the stirred polymer-drug-solvent system [86].  
Thote et al (2005) demonstrated fabrication of dexamethasone phosphate 
microparticles, a hydrophilic drug, by using coacervation technique with silicon oil to 
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generate microparticles of PLGA polymer. Dry microparticles have been obtained by 
extracting silicone oil with hexane [89]. In contrast, microparticles of lipophilic drugs 
can be prepared by adding an aqueous hydroxypropyl methylcellulose (HPMC) 
solution into an organic polymer solution to separate the polymer and induce the 
formation of microparticle as established by Dong and Bodmeier (2006). The aqueous 
HPMC solution acted as a stabilizer for the coacervate droplets by preventing 
coalescence [92].   
3) Spray drying 
Spray drying is a single step microparticle production based on the atomization of 
drug and carrier solutions, using compressed air or nitrogen. This process includes 
three consecutive steps: formation of the aerosol, contact the aerosol with the warm 
air to dry the aerosol and separation of dried product. The spray drying method is a 
continuous process, easy to scale up and inexpensive [86, 88]. In the spray drying 
process, a high viscosity solution will create the formation of fibres instead of 
microspheres as the sprayed solution is not completely broken up into droplets.  In 
addition, it also occurs when using inappropriate geometry of nozzle or at lower flow 
rates. Moreover, it will denature thermally labile drugs such as proteins due to the 
high temperatures (over 100°C) used to dry particles [88].  
Chaw et al (2003) successfully entrapped physostigmine into microparticles using a 
spray drying method due to the absence of the water during the process [93]. Other 
research showed the highest encapsulation amount from poly(lactic acid) (PLA) 
polymer was obtained by spray drying PLA in dimethyl carbonate solution. The use of 
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dimethyl carbonate solution and carbon dioxide for the microencapsulation 
preparation would reduce concerns over excess solvent in the product [94].  
4) Supercritical fluid 
Supercritical fluid (SF) results in microparticles with no or very low amounts of 
residual organic solvent and provides a feasible and clean way to process thermo 
labile or unstable biological compounds [88]. In a supercritical process, the active 
compound and polymer are dissolved in an organic solvent and then sprayed into the 
column containing the supercritical gas phase. The organic solvent will be dissolved 
in the supercritical gas phase and subsequently extracted directing the formation of 
solid microparticles. The condition of gases such as pressure and temperature will 
produce a difference in gas density. The difference in gas density, in some case, can 
influence the size and shape of microparticles [95].  
Supercritical anti-solvent precipitation was shown to be an effective process for 
manufacture of a water-insoluble drug since it produces smaller particles to improve 
the dissolution rate of poorly soluble drugs [96]. In this method, the organic solution 
containing drug and polymer were sprayed into supercritical fluid. The miscibility of 
organic solvent and supercritical fluid gas allow the drug particles to precipitate [97]. 
Supercritical anti-solvent precipitation produces spherical microparticles over 
pressures from 75 to 250 bar and temperatures between 35 and 60°C. Decrease in 
pressure would increase particle size distribution, while increase of solute 
concentration produces bigger particle [98].  
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1.3.2. Release of Active Drugs from Microparticle 
dŚĞ ƚĞƌŵ  “ƌĞůĞĂƐĞ ? ĚĞƐĐƌŝďĞƐ ŚŽǁ ƚŚĞ ĚƌƵŐ ŵŽůĞĐƵůĞƐ ĂƌĞ ƚƌĂŶƐƉŽƌƚĞĚ Žƌ ƌĞůĞĂƐĞĚ
from microparticles, including mechanism and rate. The release of drug from 
microparticles is influenced by physico-chemical properties of polymer, physico-
chemical properties of encapsulated molecules, properties of the microparticle itself 
and the surrounding environment e.g., in vitro or in vivo [87, 99]. Several release 
mechanisms of microparticles have been proposed, which include diffusion, osmotic 
pressure and erosion of the polymer matrix or combination of these [99, 100]. 
Most of drug release from microparticles is by a diffusion process. The release rate 
also can be regulated depending on microparticle properties like pore size, polymer 
molecular weight, crystallinity and copolymer composition [101]. High porosity 
microparticles provided high release of lidocaine from PLGA microparticles due to  
rapid  mobility of the diffusing molecules (drug molecules, acids and bases) [38]. The 
effect of molecular weight of polymer on drug release from microparticle was shown 
in felodipine release from chitosan-tripolyphosphate cross-linked polymer. High 
molecular weight and high concentration of chitosan give a significant decrease of 
felodipine release from microparticles [39]. Crystalline microstructure also influenced 
ƚŚĞ ƌĞůĞĂƐĞ ŽĨ ƉĂƉĂǀĞƌŝŶĞ ĨƌŽŵ ƉŽůǇ ?ɸ-caprolactone) (PCL) microparticles. As 
molecular weight increases in PCL, the crystallinity of polymer is considerably 
reduced to form amorphous regions which allow the drug to diffuse rapidly [102]. 
The effect of copolymer composition on drug released showed on release kinetics of 
levonorgestrel and estradiol from copolymers of caprolactone and DL-lactide. 
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Permeation rates and release fluxes of levonorgestrel and estradiol increased as the 
ratio of caprolactone in copolymer was increased [103]. 
Drug molecules could be released by convection, which is driven by osmotic pressure 
or by an osmotic pump. This is the mechanism usually given for release of drug from 
ethyl cellulose polymer [99]. The molecules of drug can be released from the 
microparticle upon contact with water. Water diffuses through microparticle pores 
and polymer swelling generates an internal pressure to drive the release of drug from 
the polymer [104]. The release rate of drug using this system depends on the 
permeability of the polymer and osmotic pressure of the core formulation, but it is 
pH independent [104, 105].  
The release of drug molecules from microparticles may also occur by dissolution of 
the microparticle i.e., erosion. The mechanism of erosion involves weight loss from 
the microparticle mass. The erosion process begin with solvent penetration into the 
matrix of microparticle then the matrix starts to degrade by hydrolysis [106]. Pores 
are also created in the erosion process, therefore, the rate of drug release with 
erosion mechanism is not only influenced by rate of hydrolysis but also rate of pore 
formation [99]. In addition, drug properties and drug-polymer interaction highly 
affect the rate of release of proteins with different isoelectric points [107] .  
1.3.3. Determination of Drug Release from Microparticles 
The effectiveness of microparticle formulations is dependent on drug release and it is 
useful to gain information on the amount of release, the rate and mechanism of 
release to understand the behaviour of formulation at the molecular level. Release of 
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drug from microparticles can be evaluated either in vivo or in vitro. However, in vitro 
techniques are more promising due to lower cost than in vivo. The important points 
for in vitro release studies are selection of media and temperature. Selection of 
media is related to drug solubility and stability, whereas, selection of temperature is 
related to physiological conditions. In addition, an appropriate drug release study 
should be conducted in a sufficient volume of medium to dissolve the expected 
amount of drug. This condition is known as sink conditions and it can be maintained 
by apply media replacement to ensure solubility of drug and avoid accumulation of 
polymer degradation products in the system [108]. Adding surfactant into media can 
be used to increase solubility of drug to achieve sink conditions during drug release 
evaluation [109]. The common methods for in vitro drug release are the sample and 
separate (SS) method, the continuous flow (CF) method and dialysis [108, 110]. 
In the sample and separate (SS) method, microparticles are placed into a vessel 
containing medium and assessed at certain intervals. Medium for release study is 
selected based on drug solubility and stability during the period of evaluation. 
Medium is taken at certain intervals, separated from disperse microparticles (usually 
by centrifugation or filtration) and then the release of drug is assayed in the 
supernatant or filtrate [108, 110]. Replacement of medium is needed to maintain sink 
conditions in the system. Size of vessel or container depends on the volume of 
medium used to maintain sink conditions. During the period of study, continuous or 
intermittent agitation may be applied to the system to prevent aggregation of 
microparticles [38, 108, 111]. This technique gives satisfactory results for in vitro 
release. However, separation of medium from disperse microparticles is the major 
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issue, particularly if the size of microparticle is very small as it will be difficult to filter 
or to precipitate by centrifugation [108, 110].  
The continuous flow (CF) method is adopted from USP apparatus 4. In this method 
microparticles are loaded into the base of cells containing media and a filter is placed 
on the base of cell. Medium is continuously pumped into the cell during the period of 
study and samples are taken by filtration from the base of the cells. Fresh medium is 
added to the system to keep the volume constant after sampling [108, 110]. 
Continuous medium flow mimics in vivo conditions in which microparticles are 
exposed to a continuous flow of biological fluid. Hence, this method demonstrates a 
good in vitro  Win vivo correlation [112].    
In the dialysis method, a dialysis membrane or bag is used to separate a suspension 
of microparticles from the bulk medium in a vessel. The drug diffuses out of sample 
and through the dialysis membrane to the outer bulk medium. Release of drug is 
assessed by sampling the bulk medium at intervals. Agitation may be applied to 
increase diffusion of drug to the bulk medium and prevent accumulation of drug at 
certain locations in bulk medium [108, 110]. The volume of outer bulk medium used 
should be approximately 6-10 fold higher than the volume of medium inside dialysis 
bag, to provide a driving force for drug molecules to move into the outside media. 
This method is not appropriate for protein release since a large pore size is needed 
for the protein to diffuse through the membrane and the protein can also adsorb to 
the membrane. In addition, detection of protein released may be a problem due to 
dilution in the bulk medium [108, 112]. This method offers advantage in sampling 
and medium replacement because the sample is separated by dialysis membrane. 
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However, this technique can be ambiguous as the partition of drug molecules to 
outer medium is controlled by concentration of drug in inner medium and the rate of 
diffusion of molecules through the dialysis membrane, not by the microparticle itself 
[110].  
1.3.4. Microparticles in Tissue Engineering 
A delivery approach using microparticles can be applied in the tissue engineering 
field including the encapsulation of growth factors or living cells within the scaffold. 
Microparticles can be used as a carrier to control a site-specific and time-specific 
release profile. Microparticles may act as supporting matrices for cell attachment 
and/or as a carrier for bioactive agents and provide controlled release kinetics [35]. 
In addition, microparticles are small enough to be used as an injectable scaffold and 
deliver through a syringe [36, 113].  
A 3D construct for tissue replacement can be achieved using microparticles as a 
carrier. The schematic diagram for 3D construct using microparticles for tissue 
replacement is presented in Figure 1.3. In this figure, cellular aggregates are formed 
using microparticles and differentiated by culturing the cells aggregates in vitro and 
then injected at the later stage for tissue reconstruction in vivo. Tan et al., 
demonstrated the use of poly (L-lactide) (PLLA) microparticles as a micro-carrier to 
promote formation of cell aggregates. The 3D shape of cell aggregates would be able 
to be injected into the defect site for cartilage repair [114]. Mixing microparticles 
with chondrocytes as a mouldable scaffold has been used for cartilage tissue 
engineering. The presence of microparticles increased total tissue-mass and 
glycosaminoglycan production [115]. 
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Figure 1.3. A schematic diagram of the formation of cell aggregates using 
microparticle for injectable tissue replacement 
 
Microparticle matrices prepared from PLGA  have been used in intra-cerebral 
transplantation to enhance cell attachment and provide structural support to form 
new tissue [116]. Sahoo et al (2005) also reported use of a PLGA microparticle 
scaffold to support 3D growth of breast cancer cells. The 3D system of breast cancer 
cell can then be potentially used as a model for preclinical evaluation of anticancer 
agents [117]. 
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Most reports on the use of microparticles in tissue engineering focus on the 
encapsulation of bioactive molecules to support cell development. In this case, 
microparticles have been used as a reservoir that releases bioactive molecules at a 
repair site for particular length of time. Additionally, the structure of microparticles is 
advantageous in protecting encapsulated bioactive molecules from degradation [36, 
40]. Microparticles can be used as injectable scaffold by incorporating microparticles 
with other materials or living cells. Incorporation of PLGA microparticles with 
calcium-phosphate cement in an injectable scaffold was used to control release of 
rhBMP-2 up to 28 days [118]. A mixture of microparticle and fibroblast cells showed 
promising results as an injectable scaffold for muscular tissue [119]. 
1.4. Functionalized Polymer for Tissue Engineering Scaffold 
1.4.1. Introduction 
Polymeric biomaterials have been used in tissue engineering for matrices and carriers 
for drugs. Surface interactions between biomaterials and cells play an important role 
for cell growth and development. Changing the biomaterial surface may improve cell 
behavior with respect to individual processes of cell like proliferation, differentiation 
and motility, hence, modification of polymer properties are needed to achieve 
biocompatibility, biodegradability and interconnectivity in the formation of the new 
tissue [120-122]. 
Understanding the influence of polymeric material on cell behavior is needed to 
select suitable polymers for tissue engineering. In this evaluation, cell and polymer 
should be in contact. Some different techniques have been used to evaluate cell 
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interaction with polymer in vitro such as adhesion and spreading, cell migration, cell 
aggregation and evaluation of cell phenotype. In addition, in vivo techniques also can 
be used to evaluate the interactions of cells with polymers, such as the wound 
chamber model which is adopted from intra-peritoneal or subcutaneous 
implantation technique in rodent and large animals.  Most polymers implanted in 
vivo induce an inflammatory response or a foreign-body response (FBR). Response of 
cells to polymer are assessed by short-term studies (0-72 hours) of protein 
adsorption, inflammatory cell recruitment and adhesion, and macrophage fusion 
[123]. 
A potential polymer for tissue engineering scaffold is poly(glycerol adipate) (PGA). 
This novel polymer prepared from non-toxic monomers, divinyl adipate and glycerol, 
and synthesized by an enzymatic reaction. Biocompatibility of the polymer to several 
cells is promising for the scaffold to mimic the structure and properties of human 
tissue [124, 125].  Nanoparticles from poly(glycerol-adipate) has capability to 
degrade within the lysosomal compartment of  cell.  The ester bonds in the polymer 
backbone are expected to be unstable in the lysosomal environment [126] due to the 
presence of enzymes capable of reversing the synthetic reaction. Pendant hydroxyl 
groups in polymer backbone are potentially used for modification. The highest drug 
loading have been achieved in modified PGA nanoparticles with 40% acylation of C18. 
High levels of drug interaction will be useful for encapsulation of growth factors into 
microparticles. PGA can be modified by tethering a functional group for ligand 
attachment such as poly(ethylene glycol). Addition of PEG molecules in the end 
group of polymer could reduce immunological interactions and increase in vivo 
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stability. Microparticles prepared from functionalized PGA polymer with diamino 
PEG-maleimide linker for attachment of RGD ligand demonstrated cellular 
aggregation in C6 and 3T3 cells [127].  
1.4.2. Modified Polymer for Tissue Engineering Scaffold 
Surface characteristics of polymers, for instance hydrophilicity, density of surface 
charge, micro-morphology of surface, free energy and specific chemical groups 
influence cell adhesion, spreading and signaling and thus regulate a broad variation 
in biological functions. Surface chemistry and surface topography of polymers play 
significant role for the biocompatibility of biomedical devices. Consequently, surface 
modification is needed to eliminate undesired effects and produce specific biological 
responses in vivo [15]. 
Specific interactions between polymers and their corresponding cell surface 
receptors could be obtained using ligands [121]. Ligands integrate into the material 
to produce chemically defined bioactive surfaces (Figure 1.4). This model involves the 
immobilization of biologically active ligands from extracellular matrix proteins such as 
fibronectin, laminin, vitronectin and collagen. In addition, the tripeptide adhesion 
sequence Arg-Gly-Asp (RGD) also contributes as cell adhesion proteins because it 
interacts with the integrin family of cell surface adhesion receptor [128].  
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Figure 1.4. General chemical scheme for immobilized ligand onto a surface [128]. 
 
Hydroxyls, amines, carboxylic acid and thiols are typical chemical groups in protein as 
ligands for cell surfaces studies [128]. Polymer bioconjugates were prepared by 
modifying polymers with protein-reactive end-groups. The amine-bearing side-chains 
of lysine residues have been targeted for conjugation with polymer as it has excellent 
reactivity towards a wide range of electrophiles [129]. Modification of polymers using 
thiol-reactive end-groups has also been used. Thiol-reactive end groups create well-
defined protein-polymer conjugates with the sulfhydryl group of cysteine, an amino 
acid in many proteins.  The functional groups that have been demonstrated to be 
effective for conjugation with sulfhydryl group are vinyl sulfone, maleimide and 
activated disulfide end-groups. The recent progress of protein-polymer conjugates is 
the use of protein-reactive initiators to synthesis polymers. These polymers are 
reactive towards proteins directly after polymerization [129].  
Nevertheless, several factors must be considered to retain maximum bioactivity. The 
ligand may not have optimum cell-receptor interactions due to physical constraints 
imposed by the surface. Thus, ligand surface immobilization may proceed in low yield 
due to sterically inaccessible reactive sites on the ligand molecule. The density of 
ligands immobilized upon a surface can be measured using radiolabelling, surface 
analysis or gravimetry [128] 
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1.4.3. Functionalized Polymer with Poly(ethylene glycol) 
Polymer as a drug carrier can be modified to improve delivery of drug to target of 
site. One strategy of polymer modification is conjugating the polymer with 
poly(ethylene glycol) (PEG). PEG is a FDA approved-non-toxic polymer, hydrophilic, 
soluble in water and many organic solvents [130, 131]. The important characteristics 
of PEG conjugating are increasing solubility in water and circulation time in vivo, 
decrease of enzymatic degradation and immunogenicity. Moreover, PEG conjugation 
could be used to prevent unwanted adsorption of serum proteins and cellular 
recognition [130, 132]. Due to its benefits, PEG is highly suitable for functionalized 
polymer in targeted delivery.  
PEG attachment on the surface of hydrophobic carriers increases their solubility in 
aqueous media and inhibits aggregation of drugs in vivo as well as in vitro. It occurs 
due to steric hindrance of PEG chains through formation of a  “ĐŽŶĨŽƌŵĂƚŝŽŶĂůĐůŽƵĚ ? ?
dŚĞ  “ĐŽŶĨŽƌŵĂƚŝŽŶĂů ĐůŽƵĚ ? ŽĨ W' ĂůƐŽprotects from interaction with blood 
component and enzymatic degradation as well as uptake by the reticuloendothelial 
system (RES). Consequently, conjugation of PEG demonstrates prolonged half-life in 
the body and enhanced bioavailability of the active molecules. The other advantage 
of the  “ĐŽŶĨŽƌŵĂƚŝŽŶĂůĐůŽƵĚ ?ŝŶW'ǇůĂƚĞĚƉƌŽĚƵĐƚƐŝƐƚŚĞǇƉĞƌĨŽƌŵƐƚĞƌŝĐŚŝŶĚƌĂŶĐĞ
to interact with charge-induced components within the body, so immune recognize 
systems can be diminished [133].  
Conformation of attached PEG to the surface is influenced by relation between the 
distance of two adjacent chains (D) and the radius of gyration (Rg). Attached PEG to 
the surface ďĞĐŽŵĞƐ  “ŵƵƐŚƌŽŽŵ ? ĐŽŶĨŽƌŵĂƚŝŽŶ ŝĨ AN ?Zg  ǁŚŝůĞ Ă  “ďƌƵƐŚ ?
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conformation appears at D<<Rg. (Figure 1.5). Radius of gyration (Rg) is related to the 
chain length of PEG [130]. Repellence capacity of PEG towards unwanted protein 
depends on chain length, chain density and the conformation of attached PEG to the 
surface. The efficiency of protein repellence becomes increased if more PEG chains 
overlap. Theoretically, protein can adsorb onto the surface by two mechanisms. 
Primary adsorption is at interface between PEG and substrate, while secondary 
adsorption is at the top of PEG brush. Increasing chain density of PEG would decrease 
the primary adsorption. However, for larger proteins, they may go through secondary 
adsorption. Therefore, they require a sufficient thickness of PEG to shield 
electrostatic forces interaction between protein and substrates [130, 133].  
 
 
Figure 1.5. A schematic diagram represent different conformation of PEG grafted to 
the surface. Image is taken from Wattendorf and Merkle (2008) without any 
modification [130].  
 
Microparticle can be conjugated with PEG polymer to gain several advantages of 
PEGylated products. In this case, PEG moieties may be presented in the bulk and on 
the surface of microparticles to ensure the availability of PEG moieties during 
biodegradation and erosion process. Preparation of microparticles typically involve 
aqueous media where PEG moieties are preferably oriented towards water phase 
and leading to microparticle with PEG enriched surfaces. For the purpose of cell or 
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tissue targeting, PEG moieties can be equipped with targeting ligands for specific cell 
surface receptor [130]. PEG conjugation using thiol-PEGylating agents are reported as 
the most specific method for conjugation with proteins and peptide as cysteine are 
rarely present in proteins or peptides. PEG-pyridylsulphide, PEG-maleimide, PEG-
vinylsulfone and PEG-iodo-acetamide have been use as thiol-PEGylating agents [130, 
131].  
1.4.4. Role of proteins for cell attachment 
In order to bind with other cells or ECM, cells are equipped with several types of 
proteins as cell adhesion molecules which are an integral part of membrane proteins. 
The adhesion molecules have ability to bind with cells or matrices via other adhesion 
molecules in the same type (homophilic binding), other adhesion molecules in a 
different type (heterophilic binding) or with an intermediary linker which binds itself 
to other adhesion molecules. Adhesion molecules can be divided as four major 
classes. They are cadherin, immunoglobulin-like adhesion molecules, selectin and 
integrin [134]. 
Cadherin are involved in cells adhesion by homophilic binding to other cadherin in 
calcium dependent manner, therefore removal of calcium from extracellular 
components disrupts binding. While, immunoglobulin-like adhesion molecules 
perform both homophilic and heterophilic binding and they have been found in 
nervous tissue and intracellular cell adhesion molecules. Another cells adhesion 
molecule is selectin, which binds to carbohydrate ligands on cells. It expresses mainly 
on the surface of endothelial cells, leukocytes and platelets.  Interaction between 
selectin and carbohydrate allows leukocytes to roll along vascular endothelium in the 
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direction of blood flow as an introduction to integrin-mediated adhesion. Lastly, 
integrins as adhesion molecules play important roles for interaction between actin in 
cytoskeleton and  extracellular matrix to regulate cell migration and activate a 
number of intracellular signaling pathways [134, 135].  
Most adhesive interactions between cell and extracellular matrix are directed 
primarily by integrins ? /ŶƚĞŐƌŝŶĐŽŶƐŝƐƚŽĨɲ  ?ĂůƉŚĂ ?ĐŚĂŝŶƚŽƉƌŽǀŝĚĞ ŝŶĨŽƌŵĂƚŝŽŶ ĨŽƌ
ůŝŐĂŶĚďŝŶĚŝŶŐĂŶĚɴ ?ďĞƚĂ ?ĐŚĂŝŶƚŽƉƌŽǀŝĚĞůŝŶŬƚŽĐǇƚŽƐŬĞůĞƚŽŶ ?dŚĞĂďŝůŝƚǇŽĨĐĞůůƐƚŽ
identify adhesive substrate is determined by integrin expression profiles. Most of 
cells ĞǆƉƌĞƐƐɲ1ɴ1 ?ɲ2ɴ1 ?ɲ3ɴ1 ?ĂŶĚɲ6ɴ1 which are involved for adhesion to collagen 
and laminin [135]. The role of integrin is to facilitate a signaling cascade to allow 
efficient interaction between signaling components. Proper integration of these 
signals provides appropriate cellular growth, differentiation and tissue 
morphogenesis [136].  
Adequate interaction between cells and matrices is needed to assemble cells in 3D 
structure. The interaction can be mediated using proteins or peptides as cell 
adhesion molecules.  Therefore, several techniques have been used to improve 
biomaterials for cell attachment by adsorption of specific protein or immobilization 
of cell recognition motives.  Introduction of protein as a cell adhesion molecules to 
matrices could be achieved by chemical modification, i.e. co-polymerization, and 
physical modification, i.e. plasma treatment [16, 137, 138]. Chemical modifications 
are more preferable than physical attachments as they lead to more stable and 
strong anchoring to the surface of materials [137].   
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1.4.5. Methods of Polymer Modification  
Polymer surface modification can be achieved by several methods including chemical 
methods, photo induced grafting methods, and plasma treatment methods.  
1) Chemical methods  
For biodegradable aliphatic polyesters such as poly(glycolic acid) and poly (lactic 
acid), the cleavage of the ester bonds of the polymers result in the generation of 
carboxylic acid and hydroxyl groups at the ends of chain. Exposure of polymers to an 
alkaline solution can be used to modify the surface of biodegradable polymer to 
produce a hydrophilic and rough surface for cell attachment [122]. Thissen et al. 
(2006) reported that surface modification of PLGA by partial hydrolysis using sodium 
hydroxide could improve the proliferation rate of articular cartilage chondrocytes. 
Partial hydrolysis and covalent immobilization of amine-terminated dendrimer 
exhibited the maximum proliferation rate of chondrocytes [139].  
Modification of poly(methyl methacrylate) (PMMA) with diamino poly(ethylene 
glycol) (PEG) by hydrolysis and aminolysis lead to amide formation has been used to 
produce a specific region for cell adhesion. The functionalization of PMMA-diamino-
PEG with RGD peptide restored cell adhesion and enhanced cell attachment 
compared to unmodified PMMA [140]. 
2) Photo induced grafting  
Photo-induced grafting polymerization is surface modification using irradiation in the 
presence of monomer in the vapor solution state. Ultraviolet (UV) light is typically 
use for source of irradiation [141]. The UV irradiation technique offers several 
 Chapter 1  Introduction 
 
56 
 
advantages like economic operation, mild reaction condition, rapid reaction, 
selective absorption without altering the bulk polymer and permanent modification 
on surface chemistry [15, 141].  
Photo-induced grafting followed with polymerization have been used to increase 
hydrophilicity of the surface of poly(L-lactide) (PLLA) polymer using several 
combination of hydrophilic polymers.  A single monomer of vinyl acetate, acrylic acid 
and acrylamide or a combination of those monomer, were grafted onto PLLA film 
surfaces by polymerization process using UV-light. As the result, the  hydrophilicity of 
the film surface of PLLA increased when copolymerized with vinyl acetate or acrylic 
acid [15]. 
Several hydrophilic groups such as hydroxyl (-OH), carboxyl (-COOH) or amide (-
CONH2) could be presented onto PLLA surfaces via photo-induced grafting 
copolymerization. The modified PLLA membranes with hydroxyl or amide groups 
enhanced chondrocyte compatibility compared to the unmodified PLLA membrane. 
In contrast, the PLLA membrane modified with carboxyl groups had even worse 
cytocompatibility though it possessed a similar hydrophilicity [15]. 
3) Plasma grafting and plasma treatment methods  
Plasma treatment has been extensively used to modify the surface of biomaterials.  
Polymer surfaces can be modified by physical and chemical techniques since they 
have good interaction with plasma containing electrons, ions, radicals and neutral 
molecules. Various cell culture devices such as petri dishes, microcarriers and 
membranes can be treated with plasma to improve cell adhesion. A hydrophobic 
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surface can be modified to a hydrophilic surface by treatment with oxygen plasma. 
On the other hand, modification of hydrophilic surface to hydrophobic surface can be 
achieved by treating with tetrafluoromethane (CF4) plasma [15].  
Cationized gelatin (CG) could be used to improve compatibility of PLLA nanofibres 
with chondrocytes.  The  WCOOH groups on the surface were introduced to the PLLA 
fibers with oxygen plasma, then CG molecules were covalently grafted onto the fiber 
surface. Chondrocytes formed a tight attachment to CG-PLLA nanofibers. The 
research indicated that CG grafting onto the PLLA nanofibers could enhance viability, 
proliferation and differentiation of rabbit articular chondrocytes in vitro. The cell 
differentiation on CG-PLLA nanofiber was proven by an increased glycoaminoglycan 
and collagen secretion [142].   
1.5. Project Overview 
Poly(glycerol-adipate) (PGA) (Figure 1.6) is a potential polymer for use as a tissue 
engineering scaffold. The ester bonds in the polymer backbone would be expected to 
be unstable in the lysosomal environment due to the presence of acid hydrolase 
enzymes that capable to break down materials including polyesters such as 
polyurethane, poly(lactic acid) and poly(glycolic acid). Nanoparticles from 
poly(glycerol-adipate) showed a rapid breakdown within the lysosomal compartment 
of  cells [143].  
PGA polymer backbone has pendant hydroxyl group that could be substituted to 
provide maximum drug interaction in the polymer [125]. High level of drug 
interaction will be useful for encapsulation of growth factors into microparticle based 
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scaffolds. The PGA polymers showed good results for incorporation of drugs such as 
dexamethasone phosphate. PGA nanoparticles had the highest dexamethasone 
phosphate loading when acylated with 40% stearoyl (C18) in the backbone of 
polymer. Although dexamethasone phosphate is water soluble, it has a hydrophobic 
steroid ring which interacts very strongly with the polymers [125]. Wahab et al 
(2012) found that the 100% acylated polymer with C18 also increased encapsulation 
efficiency of ibuprofen sodium within a PGA nanoparticle [144]. 
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Figure 1.6. Poly(glycerol-adipate) backbone was formed from polycondensation of 
glycerol and divinyl adipate [125]. 
 
In order to allow specific region of cell adhesion, PGA microparticle is functionalized 
using cell adhesion peptides. A maleimide-poly(ethylene glycol) (MIHA-PEG-NH2) 
linker then tethered into 40%C18-PGA polymer to provide hybrid formation with a 
peptide onto polymer surface. PEG is considered non-toxic and non-adhesive 
polymer towards protein. Attachment of PEG onto the PGA polymer provides PEG 
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moieties on the surface of MP to prevent particle aggregation. In addition, PEG can 
be equipped with the maleimide group,  a thiol-reactive-group, which has specific 
interaction with sulfhydryl group in ligand [130, 131].  
Microparticles (MPs) for 3D assembly of cells are then prepared from modified PGA 
polymers, 40%C18-PGA and 40%C18PGA-PEG-MIHA. A MIHA-PEG-NH2 chain onto 
microparticles hypothesizes to prevent the MP from aggregating each other by 
providing the spacer between the microparticles and ligand. Thus, it can allow 
optimum aggregation between cells (Figure 1.7). Moreover, the PEG hydrophilic layer 
reduces the immune response on parenteral delivery of MP [41]. Cell adhesion on 
the microparticle can be mediated using extracellular matrix protein such as collagen 
[128].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. A schematic of ligand-functionalized PGA microparticles for cellular 
agregation 
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Collagen has been used as a ligand in this system to encourage cell attachment. 
Collagen, particularly type IV collagen, is a major constituent of mammalian 
basement membranes. Collagen type IV forms a spider web-like suprastructure that 
interacts with other components of molecules such as laminins, perlecans, and 
nidogen (entactin) to form a highly cross-linked and insoluble basement membrane 
on the basolateral of various cells. The interaction occurs via adhesion molecules and 
important for creating a productive cell-matrix interaction and subsequent 
intracellular signaling [145]. 
Bioactive molecules for osteogenic formation have been encapsulated within 
modified PGA microparticle. The microparticle would act as reservoir to release drug 
molecules in controlled manner. The ability of the microparticle to deliver bioactive 
molecules to targeted cells will be evaluated through evaluation of osteogenic 
development on mouse embryonic stem (mES) cell and osteoblast cell.  
1.6. Aims of the Project 
The overall aim of the project is to modify the poly(glycerol-adipate) (PGA) polymer 
for MP to create a 3D construct in tissue engineering and evaluate the use of MP to 
deliver bioactive molecules  for osteogenic differentiation in mouse embryonic stem 
cells (mES) and osteoblast cells. It can be divided into four objectives.  
The first objective is to modify poly(glycerol adipate) (PGA) polymer for high 
efficiency of encapsulated drug by 40% stearoylation (C18) of the polymer backbone. 
The highest drug loading has been achieved in modified poly(glycerol adipate) 
nanoparticles with 40% acylation of C18. Furthermore, acyl-substituted poly(glycerol 
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adipate) was further functionalized using  maleimide-poly(ethylene glycol linker 
(MIHA-PEG-NH2) for ligand attachment. Addition of PEG molecule in the end group of 
polymer reduces immunological interactions and encourages polymer scaffold 
attachment in situ. Maleimide group was added to facilitate conjugation of the 
polymer with peptide and react selectively with the sulfidryl group on the ligand. 
The second objective is to develop a method for production of MP and ligand 
attachment into the surface of MP. The emulsification method will be the main 
method used to create MP due to its adaptability to different polymer matrix.  
Control of the emulsification processes will be investigated together with specific 
conditions needed to attach ligand into microparticle surface. Density of ligand 
attachment onto MP will be considered to maximise bioactivity with cells.  
The third objective is the development of a microenvironment for stem cells using 
functionalized PGA MP as matrices to encourage cell aggregation. The specific 
conditions for cell aggregation, incorporation of MPs within cell aggregates, effect on 
cell proliferation in the presence of microparticles will also be investigated.   
The last objective is to evaluate the drug release profile of MP prepared from 
modified PGA and ability of MP to deliver bioactive molecule for osteogenic 
differentiation. The extent and length of drug release from MPs will be tailored to 
meet the requirement for inducing bone formation. Osteogenic development in mES 
and osteoblast cells will be evaluated by determining alkaline phosphatase level, 
bone-protein formation and mineralization. 
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CHAPTER 2 
2. EXPERIMENTAL METHODS 
 
 
2.1. Introduction 
The first step in this study was PGA polymer modification by substituting 40% 
pendant hydroxyl group in PGA polymer with stearoyl (40%C18-PGA). The next step of 
polymer modification is attaching MIHA-PEG-NH2 linker onto one of the the carboxyl 
group on the end of PGA polymer backbone. The MIHA-PGA-NH2 linker is synthesized 
from N-maleimidohexanoic acid (MIHA) and diamine poly(ethylene glycol) (diamine 
PEG).. Besides the PGA polymer modification, collagen was also modified by 
providing iminothiolane functional group on the molecule of collagen for attachment 
with maleimide functional group. The iminothiolane-modified collagen was attached 
on the surface of 40%C18-PGA-PEG-MIHA MP as a ligand to improve interaction 
between the microparticle and cells. 
Second step of this study was using the modified PGA polymer, 40%C18-PGA and 
40%C18-PGA-PEG-MIHA, for microparticles (MP). The particle size, zeta potential and 
shape of microparticles prepared from 40%C18-PGA and 40%C18-PGA-PEG-MIHA were 
characterized. In addition, the interaction between polymers and drugs was 
evaluated by determining encapsulation efficiency of dexamethasone phosphate 
(DXMP) and simvastatin (SIM) within the MP. The release of drug from MP in vitro is 
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also evaluated in phosphate buffer saline (PBS) medium. The ability of 40%C18-PGA-
PEG-MIHA MP to attach with iminothiolane-modified collagen was evaluated. 
The next step of this study was evaluation of aggregate formation using modified 
PGA microparticle in mouse embryonic stem (mES) and osteoblast cells. The process 
of aggregate formation in various ratios of empty MP to cells was evaluated. 
Moreover, ability of modified PGA MP to act as matrix for cell proliferation was 
assessed by evaluating cell metabolic activity. 
The last part of this study was incorporation of MP containing active drug within mES 
and osteoblast cells. The ability of modified PGA polymer to deliver drug for 
osteogenic differentiation was evaluated by determining alkaline phosphatase level, 
staining of osteocalcin expression and staining of mineralisation in cell using von 
Kossa staining. The schematic diagram for this study is laid on Figure 2.1. 
All chemicals were purchased from Sigma Aldrich, UK while all solvents were 
obtained from Fisher Scientific, UK, unless otherwise stated.  
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Figure 2.1. A schematic diagram of experimental methods from PGA polymer 
modification to application of microparticle for osteogenic differentiation. 
Chemistry  Modifications: 
x Substitution of 40% pendant hydroxyl group of PGA polymer 
using stearoyl (40%C18-PGA) 
x Synthesis of  MIHA-PEG-NH2 linker 
x Attachment of MIHA-PEG-NH2 linker to the end of carboxyl 
group of PGA polymer (40%C18-PGA-PEG-MIHA) 
x Modification of collagen by attaching iminothiolane  
 
Microparticle (MP) preparation: 
x Emulsification method 
x Solvent Displacement method 
  
Microparticle Characterisation: 
x Particle size 
x Zeta potential 
x Scanning Electron Microscope (SEM) 
x Encapsulation Efficiency 
Cells aggregates formation with 
microparticles 
x Microparticle for cell aggregation 
x Cell metabolic activity 
Drug Release Study 
  
Incorporation MP Containing Active Drug 
in Cells Aggregate: 
¾ Evaluation of osteogenesis : 
x Alkaline phosphatase activity 
x Osteocalcin immunostaining 
x Von Kossa staining 
Attachment of modified 
collagen to microparticles 
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2.2. Modification of Poly(glycerol adipate) Polymer 
2.2.1. Materials and Equipments 
The materials used for polymer modification were poly(glycerol- adipate) (PGA) 8 and 
12 kDa, which was provided by Dr.G.Hutcheon, Liverpool John  Moores University, 
UK; stearoyl chloride (C18); dried tetrahydrofuran (THF); dichloromethane (DCM); 
dried pyridine; hydrochloric acid (HCl); chloroform; diamine poly(ethylene glycol) 
(diamine PEG, MW 2000); N-maleimidohexanoic acid (MIHA); 
dicyclohexylcarbodiimide (DCC); N-hydroxysuccinimide (NHS);  2-iminothiolane 
hydrochloride  ?dƌĂƵƚ ?Ɛ ? ? collagen type IV (type VI Sigma); Trizma® hydrochloride 
buffer solution pH 8; Fluorescein-5-isothiocyanate (FITC) from Molecular Probe; 5- ? ?-
dithiobis-2-nitrobenzoic acid (DNTB); Bradford Reagent; paraformaldehyde (PFA) for 
cells fixation and Bovine Serum Albumin (BSA). The buffer used in the experiment 
was Phosphate Buffered Saline (PBS) tablets (Fisher Scientific, UK).  The water used in 
the experiments was ultrapure deionized water (ELGA water). 
The equipments used for polymer characterisation were Bruker Avance 400MHz 
Spectrometer and Nicolet FTIR spectrometer. The UV spectrophotometer DU800 
from Beckman Coulter was used for qualitative and quantitative characterisation of 
modified collagen. Purification of the collagen was carried out by size exclusion 
chromatography using PD-10 column from GE Healthcare. The ability of modified 
collagen to attach to cells was assessed using a Beckman Coulter EPICS Altra flow 
cytometer. 
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2.2.2. General Methods for Polymer Modification 
The synthesis of functionalized polymer was characterized using thin layer 
chromatography (TLC), proton nuclear magnetic resonance (1H-NMR) spectroscopy, 
and fourier transformed infrared (FTIR) spectroscopy.  
2.2.2.1. Thin Layer Chromatography (TLC) 
Thin layer chromatography (TLC) was carried out on Merck 60 F254 silica gel plates 
and visualised using UV irradiation 254 nm or by staining the samples using 
potaasium permanganate (KMnO4).  
2.2.2.2. Proton Nuclear Magnetic Resonance (
1
H-NMR) Spectroscopy 
The 1H-NMR spectra were recorded on a Bruker Avance 400MHz Spectrometer. The 
sample was dissolved in deuterated solvent in a 5-mm tube.  Deuterated acetone 
((CD3)2K ?ɷH = 2.05 ppm) was used as solvent for PGA polymer backbone, stearoyl 
chloride (C18) and 40% C18 substituted PGA. While, deuterated chloroform (CDCl3, ɷH = 
7.28 ppm) was used as solvent for MIHA-PEG-NH2 and 40%C18-PGA-PEG-MIHA 
polymer.  
2.2.2.3. Fourier Transformed Infrared (FTIR) Spectroscopy  
Fourier transformed infrared (FTIR) spectrum was obtained using a Nicolet FTIR 
Spectrometer. The samples were dissolved in chloroform (2 mg samples in 100 µl 
chloroform) and prepared on sodium chloride (NaCl) disks. The scanning range was 
400 W4000 cm-1.  Sample analysis was carried out by the OMNIC software. 
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2.2.2.4. Analytical Data of Poly(glycerol adipate) 
Poly(glycerol adipate) (PGA) is a copolymer of divinyl adipate and glycerol which is 
synthesized by a lipase catalysed  polycondensation reaction. PGA polymer backbone 
was synthesized and characterized using 1H-NMR and FTIR by Dr. G. Hutcheon as 
followed: 
1H-NMR (300 MHz, (CD3)2CO): ɷ  ?ƉƉŵ ?1.66 (bs, 4H, -C(O)CH2CH2 from diacid), 2.36 
(bs, 4H, -C(O)CH2 from diacid), 2.85 (br, 1H, -OH), 4.38-3.54 (m, 5H, -O-CH2CHCH2-O 
from glycerol). IR: v (cm-1): 3443, 2948, 2873, 1727, 1455, 1416, 1382, 1165, 1133, 
1078, 1061, 940, 755.  
2.2.3. 40% of acylation on poly(glycerol adipate) (40%C18-PGA) 
 
 
Figure 2.2. Acylation of poly(glycerol adipate) using stearoyl chloride 
 
Poly(glycerol adipate) was substituted by 40% stearoyl acid (C18) to increase the 
amount of drug loading into the microparticles (Figure 2.2). The percentage of acyl 
substitution was calculated using the repeat unit size of the backbone polyester 
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(202.21 g mol-1). Poly(glycerol adipate) (PGA) (10.38 mmol, i.e. 2.10 g for 12 KDa) was 
dissolved in dried THF (10 ml). The mixture was warmed to reflux to dissolve the 
polymer and then stearoyl chloride (4.11 mmol, 1.4 ml,) was added. After those 
steps, pyridine (2 ml) was added to the mixture, producing acid fumes and white 
precipitate. The mixture was refluxed for 2 hour and then poured into 2 M HCl (100 
ml). The aqueous solution was extracted with DCM (3 x 50 ml).  The organic phase 
was then collected and extracted with water (100 ml). It was then dried over 
magnesium sulfate and the solvent was evaporated to dryness in vacuo to form a 
white waxy solid. The material was then washed with petroleum ether (10 ml) to 
remove the excess of stearic acid. The excess of petroleum ether was removed by 
evaporation under nitrogen gas for 2 hours followed by drying it in a vacuum 
desiccator until dried (2.48 g, 79% yield). Rf  0.40 (DCM/MeOH, 97.5: 2.5, KMnO4 
staining). 1H-NMR (400 MHz, (CD3)2K ? Pɷ(ppm):  0.86 (t, J 6.83 Hz, 72H, CH3), 1.37 (s, 
677H, CH2), 1.65 (s, 252H, CH2CH2), 2.36 (bs, 240H, CH2C(O)), 2.85 (br, 36H, OH), 4.21 
(m, J 5 Hz, 250H, OCH2CHCH2O). IR : v  (cm
-1)3472, 2917, 2849, 1739, 1170, 1080, 757. 
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2.2.4. N-maleimide hexanoyl- diamine poly(ethylene glycol) (MIHA-PEG-NH2) 
 
Figure 2.3. Synthesis of N-maleimidohexanoyl diamine poly(ethylene glycol) (MIHA-
PEG-NH2) 
MIHA-PEG-NH2 linker for the attachment of ligand on the microparticle was 
synthesized from maleimidohexanoic acid (MIHA) and diamine PEG (PEG) (Figure 
2.3). The N-maleimidohexanoic acid (MIHA) (0.20 mmol, 43.4 mg) was dissolved into 
chloroform (10 ml). Dicyclohexylcarbodiimide (DCC) (0.24 mmol, 49.8 mg) and N-
hydroxysuccinimide (NHS) (0.25 mmol, 28.9 mg) were then added to the solution. 
The mixture was stirred overnight at room temperature. The insoluble dicyclohexyl 
urea was removed by filtration. After that, the organic solvent was removed under 
vacuum evaporator in vacuo. 
The residual material was dissolved in chloroform (10 ml), the solution was then 
added to diamine PEG (0.20 mmol, 403 mg) in dropwise. The solution was stirred 
overnight at room temperature. The reaction was monitored using TLC. The mixture 
was then filtered and evaporated in vacuo. The resultant solid was triturated using 
diethyl ether followed by a filtration. The collected solid was dissolved into 
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chloroform (10 ml) and extracted using distilled water (10 ml) and saturated NaCl 
solution (10 ml). The organic phase was collected and evaporated in vacuo to afford a 
waxy, brownish-yellow solid (302.6 mg, 69% yield); Rf = 0.60 (DCM/MeOH, 90:10, 
KMnO4 staining). 
1H-NMR (400 MHz, (CDCl3 ? P ɷ (ppm) :  1.30 (m, J=5 Hz, 2H, CH2), 
1.60 (m, J=7.6 Hz, 4H, CH2CH2), 3.50 (m, J=5 Hz 4H, CH2-N), 3.55 (m, J=5 Hz, 2H, 
CH2N), 3.6 (bs, 196 H, CH2CH2O), 6.7 (s, 2H, CH=CH).  IR: v (cm
-1): 3325, 2884, 1626, 
1467, 1105. 
2.2.5. Attaching N-maleimidohexanoyl diamine poly(ethylene glycol) (MIHA-PEG) 
to 40%C18-PGA (40%C18-PGA-PEG-MIHA) 
 
 
Figure 2.4. Synthesis of N-maleimidohexanoyl acid diamino PEG (MIHA-PEG-NH2) 
coupled to 40% C18-PGA (40%C18-PGA-PEG-MIHA). 
 
MIHA-PEG-NH2 linker was tethered to 40%C18-PGA for ligand attachment (Figure 2.4). 
A 40%C18-PGA (0.05 mmol, 0.93 g,) was dissolved in 10 ml chloroform. After that, 
DCC (15.7 mg, 0.06 mmol) and NHS (6.9 mg, 0.06 mmol) were added to the PGA 
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solution. The mixture was stirred overnight at room temperature. MIHA-PEG-NH2 
(109.66 mg, 0.05 mmol) was added to the mixture and stirred continuously for 3 days 
at room temperature. Reaction was monitored using TLC. Following 3 days, the 
insoluble dicyclohexyl urea was then removed using filtration and the organic solvent 
was evaporated in vacuo. The solid compound was dissolved with chloroform (10 ml) 
and extracted using distilled water (10 ml) and saturated NaCl (10 ml). Organic 
solvent was evaporated in vacuo to obtain a brownish-yellow semisolid (579.6 mg, 
56% yield);  Rf = 0.40 (DCM/MeOH, 97.5:2.5, UV 254 nm). 
1H-NMR (400 MHz, (CDCl3): 
ɷ(ppm): 0.90 (t, J=8.1 Hz, 72H, CH3), 1.37 (bs, 675H, CH2), 1.67 (bs, 260H, CH2CH2), 
2.37 (m, 240H, CH2CO), 3.45 (m, J=5.6 Hz, 10H, CH2-N), 3.56 (m, J=5.6 Hz, 4H, CH2N), 
3.6 (bs, 135 H, CH2CH2O), 4.15 (m, J=7 Hz, 250H, OCH2CHCH2O), 6.7 (s, 2H, CH=CH). 
IR: v (cm-1): 3473, 3323, 2924, 2849, 1739, 1621, 1465, 1169, 948. 
2.2.6. Modification of Collagen for Ligand 
2.2.6.1. Preliminary study for determination amount of thiol group  
 
Figure 2.5. Attachment of 2-iminothiolane hydrochloride (dƌĂƵƚ ?Ɛ ƌĞĂŐĞŶƚ ? ƚŽ
collagen.  
 
Collagen was modified to provide a thiol group on its molecule (Figure 2.5). Due to 
the small amount of iminothiolane needed for conjugation with collagen, the amount 
 Chapter 2  Experimental Methods 
 
72 
 
of thiol group cannot be analysed using spectrophotometer. Therefore, it was 
estimated by preliminary studies (Table 2.1).  
Table 2.1. Preliminary study estimate the amount of thiol group attached to 
collagen 
Batch Amount of 
Collagen 
(nmol) 
Amount of 
Trauts added 
(nmol) 
AS008DD 1 100 
AS009DD 1 500 
 
Collagen (5 mg/ml) was dissolved in phosphate buffered saline (PBS) by continuous 
stirring for a minimum of 4 hours. Collagen solution (100µl, 1 nmol,) was added to 
tris buffer pH 8 (1.5 ml). The 2-iminothiolane hydrochloride (dƌĂƵƚ ?Ɛ ƌĞĂŐĞŶƚ ? ŝŶ
solution was added to the mixture as amount stated in Table 2.1. The mixture was 
ƐƚŝƌƌĞĚ Ăƚ ƌŽŽŵ ƚĞŵƉĞƌĂƚƵƌĞ ĨŽƌ  ? ŚŽƵƌ ? ǆĐĞƐƐ dƌĂƵƚ ?Ɛ ƌĞĂŐĞŶƚ ǁĂs removed by 
passage through a PD-10 column (GE Healthcare). The collagen-SH fraction (fraction 
3-5) was collected after detection using UV-spectrophotometer (Beckman Coulter 
DU800). The amount of thiol group was determined using 5- ? ?-dithiobis-2-
nitrobenzŽŝĐĂĐŝĚ ?dE ? ?ůůŵĂŶ ?ƐƌĞĂŐĞŶƚ ? ? 
ůůŵĂŶ ?ƐƌĞĂŐĞŶƚ ? ? ?A?ů ?ǁĂƐĂĚĚĞĚƚŽƚŚĞƐĂŵƉůĞŽĨĐŽůůĂŐĞŶ-dƌĂƵƚ ?ƐĨƌĂĐƚŝŽŶ ? ? ?A?ů ? ?
Tris buffer (1M) pH 8 (100 µl) and water (820 µl) were added to the mixture. The 
mixture was mixed and measured using UV-spectrophotometer (Beckman Coulter 
h ? ? ? ? Ăƚ ʄ  ? ? ? Ŷŵ ? dŚĞ ĐŽŶĐĞŶƚƌĂƚŝŽŶ ŽĨ ƚŚŝŽů ŐƌŽƵƉ ǁĂƐ ĐĂůĐƵůĂƚĞĚ ďǇ two 
methods: 1). calculated using Equation 2-1 and 2). plotted the absorbance onto an 
acetyl cysteine calibration curve. 
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Equation 2-1: -SH (thiol) concentration. 
ɸ
nmʄatabsorbance
x
lʅvolumesample
lʅvolumetotal
MionconcentratthiolSH
412
)(
)()()(  
  
tŚĞƌĞ࠱ŝƐƚŚĞĞǆƚŝŶĐƚŝŽŶĐŽĞĨĨŝĐŝĞŶƚŽĨdE ? ? ? ? ?ǆ ?4 M-1. cm-1) 
The acetyl cysteine calibration curve was produced using samples with known 
concentration of acetyl cysteine ranging from 10 to 50 µM ĂŶĚŵŝǆĞĚǁŝƚŚůůŵĂŶ ?Ɛ
reagent (50 µl) and Tris buffer (1M) pH 8 (100 µl). The volume of each concentration 
then adjusted with water to 1 ml. The mixture then scanned using UV-
spectrophotometer at 412 nm.  
2.2.6.2. Attach collagen to FITC and 2-iminothiolane ;dƌĂƵƚ͛ƐͿ 
FITC was dissolved in DMSO to a concentration of 1 mg/ml. FITC (50 nmol, 20 µl) was 
taken from the stock solution and the solvent was dried to give solid FITC in glass vial. 
The collagen was dissolved in PBS to a concentration of 5 mg/ml. The collagen (10 
nmol, 1 ml,) and sodium carbonate buffer 0.1 M, pH 9.5 (970 µl) was added to the 
glass vial. The mixture was incubated at room temperature for 4 hours in darkness. 
After 4 hours, the pH of the solution was adjusted to 8 using monobasic sodium 
ƉŚŽƐƉŚĂƚĞ ? ? ? ?D ? ?dŚĞŶ ?dƌĂƵƚ ?ƐƌĞĂŐĞŶƚ ?200 nmol, 20 µl) was added and stirred for 
 ? ŚŽƵƌ Ăƚ ƌŽŽŵ ƚĞŵƉĞƌĂƚƵƌĞ ? ŵŽƵŶƚ ŽĨ ƚŚĞ dƌĂƵƚ ?Ɛ ƌĞĂŐĞŶƚ ƚŽ ďĞ ĂĚĚĞĚ ǁĂƐ
estimated from the amount of thiol group provided in the previous step (section 
2.2.6.1). The reaction steps of collagen modification can be found in Figure 2.6  
The mixture was purified by desalting through PD-10 column using phosphate buffer 
ƐĂůŝŶĞ  ?W^ ? ĂƐ ĞůƵĞŶƚ ƚŽ ƌĞŵŽǀĞ ƚŚĞ ĞǆĐĞƐƐ ĐŽůůĂŐĞŶ ? dƌĂƵƚ ?Ɛ ƌĞĂŐĞŶƚ ĂŶĚ &/d ?
Fraction number 3-5 was collected to get 3 ml of product.  Amount of FITC was 
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ĚĞƚĞƌŵŝŶĞĚƵƐŝŶŐƐƉĞĐƚƌŽƉŚŽƚŽŵĞƚĞƌĂƚʄ  ? ? ?ŶŵĂŶĚƚŚĞĂŵŽƵŶƚŽĨĐŽůůĂŐĞŶǁĂƐ
ĚĞƚĞƌŵŝŶĞĚƵƐŝŶŐƌĂĚĨŽƌĚŵĞƚŚŽĚĂƚʄ ? ? ?Ŷŵ ? 
FITC concentration on the sample was calculated using Equation 2-2: 
Equation 2-2: Concentration of FITC 
ɸ
A
FITCionConcentrat 495  
Whereas A495 ŝƐƚŚĞĂďƐŽƌďĂŶĐĞĂƚʄ ? ? ?ŶŵĂŶĚɸŝƐƚŚĞĞǆƚŝŶĐƚŝŽŶĐŽĞĨĨŝĐ ĞŶƚŽĨ&/d
(7.97 x 104 M-1. cm-1).  
 
 
 
Figure 2.6. Collagen was modified with FITC and iminothiolane. FITC was attached 
for fluorescence (1) and iminothiolane was tethered to collagen to provide a thiol 
group in the collagen molecule (2). 
 
The concentration of collagen in the solution was determined using the Bradford 
method. The method is based on the proportional binding of the Brilliant Blue G dye 
to proteins. The protein-dye complex causes a shift in the absorption maximum of 
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the dyes from 465 nm to 595 nm. Sample (100 µl) and water (400 µl) were added to 
Bradford reagent (500 µl) then incubated at room temperature for 10 minutes. The 
ĂďƐŽƌďĂŶĐĞ ŽĨ ƚŚĞ ƐĂŵƉůĞ ǁĂƐ ŵĞĂƐƵƌĞĚ ƵƐŝŶŐ Ă ƐƉĞĐƚƌŽƉŚŽƚŽŵĞƚĞƌ Ăƚ ʄ  ? ? ? Ŷŵ ?
Collagen concentration was calculated by plotting the absorbance of the sample into 
a collagen calibration curve. 
2.2.6.3. Cells attachment on modified collagen 
The ability of iminothiolane-modified collagen to attach to cells was evaluated using 
a flow cytometry assay. Briefly, mouse embryonic stem (mES) cells (passage 23-30) 
were trypsinized, harvested and fixed with 4% paraformaldehyde solution (2 ml, 10 
minutes)  continued by rinsing with PBS+0.1% BSA (3 x 2 ml). The cells were then 
adjusted to concentration of 105/ml in PBS. For flow cytometry assay, the cells (0.5 
ml) were added to flow cytometry tubes. Various concentrations of modified collagen 
were then added to each tube and allowed to bind on the cells for half an hour in the 
dark. The mixture was then centrifuged (180 x g, 5 minutes) and the supernatant was 
discarded to remove unbound collagen. The pellet of cells was dispersed in PBS+0.1% 
BSA (0.5 ml) by gently pipetting. The number of cells tagged with modified collagen 
was evaluated using flow cytometry by determining the fluorescence intensity 
(ʄemission 495 nm,  ʄexcitation 521 nm) . 
2.3. Microparticles production and characterization 
2.3.1. Materials and equipment 
The materials used for MP preparation and release studies were 40%C18-PGA 
polymer and 40%C18-PGA-PEG-MIHA polymer, which was modified from PGA 
polymer backbone, poly(vinyl alcohol) (PVA) (87-89% hydrolyzed, MW 85,000-
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146,000),  DCM, acetone, dexamethasone 21-disodium phosphate (DXMP), 
dexamethasone (DXM), simvastatin (SIM) from Merck Biosciences UK, phosphate 
buffer saline  (PBS) tablet for PBS buffer, HEPES buffer, rhodamin B, tween 20.  
The equipments used for MP preparation were Ultra-Turrax T25 Basic (IKA®), 
Magnetic Multi Stirrer RT 10 (IKA®) and centrifuge (Centaur 2). The characteristics of 
the microparticles were determined using Particle Size Analyser (Beckman Coulter 
LS230), Zetasizer (Malvern Zetasizer Nanoseries ZS90) and Scanning Electron 
Microscope (JEOL JSM 6060). The drug loading determination was carried out using 
HPLC Hewlett Packard (HP) Agilent 1050 equipped with an auto sampler. The 
fluorescence intensity measurement was obtained using a Fluorescence 
Spectrophotometer (Hitachi F-4500).  
The equipment for the drug release study are included shaking water-bath DMS 360 
(Fisher Scientific UK), centrifuge (Centaur 2), microcentrifuge (Eppendorf type 5430), 
and 15 ml Greiner centrifuge tubes. Quantitative analyses of drugs were carried out 
using HPLC Hewlett Packard (HP) Agilent 1050.   
2.3.2. Manufacture of the Microparticles 
Three different methods were applied to prepare MP from modified PGA polymer. 
The method was selected based on the properties of the encapsulated drugs and the 
modified PGA polymer.  
2.3.2.1. Single emulsion method 
The single emulsion method was used to prepare the MP from 40%C18-PGA and 
40%C18-PGA-PEG-MIHA containing SIM as a drug. The polymer (100 mg) was 
 Chapter 2  Experimental Methods 
 
77 
 
dissolved in 2 ml or 20 ml of DCM to give 0.5% and 5% polymer concentrations, 
respectively. SIM (200 µl, containing 1 mg of simvastatin in methanol) was added to 
the polymer solution and homogenised for 3 minutes at 22,000 rpm using the Ultra-
Turrax. A small amount of rhodamine B (50 µl of 10mg/ml stock solution) was added 
to label the MP for cell work.  The mixture was then added to PVA solution (5 ml) and 
mixed for 3 minutes at 22,000 rpm. PVA solution was provided by dissolving PVA in 
water and stirred for a minimum of 4 hours. The concentration of PVA used in the 
experiment varied from 0.005% to 2.5%. Organic solvent was evaporated by slowly 
stirring in a fume hood overnight. The MP was collected using centrifugation at 1818 
x g for 5 minutes followed by rinsing with ultrapure water (3 x 10 ml). Supernatants 
were collected to determine the amount of free drug.  The microparticles were 
freeze dried and kept in a fridge.  
2.3.2.2. Double emulsion method  
DXMP was incorporated in 40%C18-PGA and 40%C18-PGA-PEG-MIHA polymers using 
the double emulsion method. The polymer (100 mg) was dissolved in DCM (20 ml) to 
give 0.5% polymer concentration. A small amount of rhodamine B (50 µl of 10mg/ml 
stock solution) was added to label the MP for cell work. DXMP (1 mg in water) was 
added to the polymer solution and homogenized for 3 minutes using the Ultra-Turrax 
to form a primary emulsion. Volume of DXMP as a solution was varied towards 
organic phase to perform the primary emulsion as described in Table 2.2. Two 
variations of mixer speeds were used to prepare the microparticles. Those speeds 
were 11,000 rpm and 13,000 rpm. The mixture was then added with 2.5 % PVA 
solution (20 ml) and continued to homogenise for 3 minutes at 13,000 rpm to 
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complete the secondary emulsification process. PVA solution was prepared by 
stirring PVA in water for a minimum of 4 hours. The organic solvent was evaporated 
by stirring the mixture slowly in a fume hood overnight. The MP was collected by 
centrifugation at 1818 x g for 5 minutes followed by rinsing with ultrapure water (3 x 
10 ml) to remove free DXMP from the microparticles. Supernatants were collected to 
determine the amount of free drug.  The microparticle was freeze dried and kept in a 
fridge.  
Table 2.2. Volume ratio of primary emulsion for DXMP encapsulation within 
modified PGA microparticle using double emulsion method. 
Volume ratio of aqueous 
to organic phase 
Volume of aqueous phase 
(ml) 
Volume of organic phase 
(ml) 
1 : 200 0.1 20 
1 : 20 1 20 
 
2.3.2.3. Solvent displacement method 
The solvent displacement method was used to produce MP from 40%C18-PGA 
without PVA. SIM was used as encapsulated drug. Briefly, a 40%C18-PGA (100 mg) 
was dissolved in acetone (2 ml). A small amount of rhodamin B (50 µl of 10mg/ml 
stock solution) was added to label the MP for cell work. SIM (200 µl, containing 1 mg 
of simvastatin in methanol) was added to the polymer solution and homogenised for 
3 minutes at 22,000 rpm. The mixture was then added dropwise to 5 ml water under 
homogenisation at speed setting 5.  The organic solvent was evaporated by 
continuous stirring in a fume hood for overnight. The microparticles were obtained 
by centrifugation at 1818 x g for 5 minutes followed by rinsing with ultrapure water 
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(3 x 10 ml). Supernatants were retained to analyses drug loading using the indirect 
method. The microparticles were then freeze dried and kept in a fridge.  
2.3.3. Characterisation of Microparticles 
2.3.3.1. Particle size 
The particles size was determined using a Beckman Coulter LS230 instrument. A 
microparticle suspension (100 µl) was placed in the fluid module and circulated 
through a sample cell at a constant speed. A beam of laser light passed through the 
cell was diffracted by particles within the sample cell, and the forward scattered (or 
diffracted) light was collected by a series of detectors. The distribution of light falling 
on the sensors enables the size distribution of the sample to be calculated. The 
measurement of particle size was taken at 8-12% obscuration. 
2.3.3.2. Zeta potential 
The zeta potentials of the MP were determined using Malvern Zetasizer Nanoseries 
ZS90. The sample of the MP was suspended in 1 mM HEPES buffer pH 7 to give a 
concentration of 1 mg/ml. The sample was then filtered through a 5µm filter to get 
particle size below 5 µm. The suspension of MP (1 ml) was then placed into a 
disposable folded capillary cell and inserted into the instrument. An electric field was 
applied to the suspension of the MP to move the microparticles with a certain 
velocity related to the zeta potential of the particle. The electrophoretic mobility was 
measured using Phase Analysis Light Scattering to determine the zeta potential of the 
MP. 
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2.3.3.3. Scanning Electron Microscope  Images 
A small amount of dried MP was placed on a carbon disk and positioned into a low 
vacuum sputter machine for gold coating. The sample was coated with gold for 5 
minutes under vacuum then was placed into the vacuum-sample chamber. Images 
were taken from 15 mm working distance using a voltage of 40 KV. A high energy of 
electrons beam applied through the sample and interacted with the electron within 
the samples to produce back-scattered electrons that can be detected to give a high-
resolution image.  
2.3.4. Determination of Drug loading in Microparticle 
2.3.4.1. Indirect method 
Determination of drug loading using the indirect method was based on the amount 
of free drug in the supernatant. The supernatant was diluted in ultrapure water or 
methanol. The diluted sample then centrifuged at 19,466 x g for 5 minutes in a 
microcentaur microcentrifuge to precipitate the excess of polymer before injected to 
High Performance Liquid Chromatography (HPLC) HP 1050 for analysis.  
For DXMP determination, supernatant was diluted in ultrapure water then 
centrifuged at 19,466 x g for 5 minutes to precipitate the excess of polymer in the 
supernatant. The supernatant was taken and injected into HPLC system as described 
in section 2.3.4.3. The DXMP concentration was calculated by plotting the peak area 
obtained on DXMP calibration curve. 
For determination of SIM, supernatant was diluted five times using methanol then 
spun down using a centrifuge at 19,466 x g for 15 minutes. The clear supernatant was 
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then analysed using HPLC as described in section 2.3.4.4. The SIM concentration was 
calculated by plotting the peak area obtained on SIM calibration curve.  
2.3.4.2.  Direct method 
Preliminary studies for validation of drug extraction method from MP were done by 
using various ratio of DCM: water and DCM: MeOH for DXMP and SIM, respectively. 
A known amount of drug was mixed homogenously with 40%C18-PGA polymer and 
then extracted with the solvents. For DXMP extraction, DCM and water was used in 
ratio 1:1, 1:2 and 1:4, while in SIM extraction the combination DCM and MeOH was 
used in the same ratio as used for DXMP extraction.  
According preliminary study for extraction method, the ratio 1:4 of DCM: water was 
used to extract DXMP from modified PGA MP. The MP containing DXMP (10 mg) was 
dissolved in DCM (2 ml). Then, DXMP was extracted from MP with distilled water (8 
ml). The solution was kept to equilibrate overnight. The water phase was then taken 
for determination of DXMP using HPLC. The organic phase was diluted in methanol 
then injected into HPLC system as described in section 2.3.4.3 to determine the 
amount of dexamethasone (DXM) as degradation product of DXMP in organic phase. 
The DXMP and DXM concentration was calculated by plotting the peak area obtained 
on their calibration curve. 
The 1:4 ratio of DCM: MeOH was used to extract SIM from modified PGA MP 
containing SIM. The MP (10 mg) was dissolved in DCM (2 ml) followed by adding 
methanol (8 ml) to precipitate the polymer. The mixture was centrifuged at 19,466 x 
g for 5 minutes to get a clear supernatant. The supernatant was taken for HPLC 
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analysis as described in section 2.2.4.4.  The SIM concentration was calculated by 
plotting the peak area obtained on SIM calibration curve. 
2.3.4.3. Method for DXMP determination using HPLC 
The determination of DXMP was carried on using eluent 0.01 M KH2PO4 : Methanol 
(35:65) in isocratic mode (1 ml/minute) at ambient temperature. The Lichrosphere 
100 RP-18 (25 cm × 4.6 µm;  ?ʅŵ ?ĐŽůƵŵŶ was fitted into the HPLC HP 1050 system. 
The DXMP standard solution or sample containing DXMP was injected to the system 
using auto sampler. The volume of the injection was 20 µl. The peak of DXMP was 
eluted at 3.1 minutes and detected using UsĂƚʄ ? ? ?Ŷŵ. The HPLC analysis for DMP 
was carried out using the same method with DXMP and the peak of DXM is eluted at 
6.6 minutes.  
The calibration curve of DXMP was obtained by prepared series concentration of 
DXMP in water ranging from 0.39 -100 µg/ml and analysed by HPLC using the method 
described above. The calibration curve of DXM was obtained with the same method 
for DXMP but DXM was dissolved in MeOH.  
2.3.4.4. Method for SIM determination using HPLC 
The analysis was conducted using 1 mM ammonium acetate pH 4.4: methanol 
(10:90) as eluent in isoctratic mode (1 ml/minute). The Lichrosphere 100 RP-18 (25 
ĐŵA? ? ? ?A?ŵ ? ?ʅŵ ?ĐŽůƵŵŶ was fitted into HPLC HP 1050 system. Volume of sample 
injection is 5 µl and the temperature of the system was maintained at 40°C. The SIM 
ƉĞĂŬǁĂƐĚĞƚĞĐƚĞĚƵƐŝŶŐhsĂƚʄ238 nm and eluted at 4.4 minutes.   
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The calibration curve of SIM was obtained by prepared series concentration of SIM in 
MeOH ranging from 0.20 -200 µg/ml and analyzed by HPLC using the method 
described above.  
2.3.5. Manufacture of Solid Dispersion  
2.3.5.1. Materials and equipments 
The materials used for solid dispersions preparation were 40%C18-PGA polymer and 
40%C18-PGA-PEG-MIHA polymer, which was modified from PGA polymer backbone, 
DCM, simvastatin (SIM) from Merck Biosciences UK.  
The equipments used for solid dispersions preparation were Ultra-Turrax T25 Basic 
(IKA®). The drug loading in solid dispersion was determined using HPLC Hewlett 
Packard (HP) Agilent 1050 equipped with an auto sampler.  
2.3.5.2. Preparation of Solid Dispersions  
A polymer (100 mg) was dissolved in DCM (2 ml) and then SIM (200 µl, containing 1 
mg of drug) was added to the solution. This solution was homogenized at 13,000 rpm 
for 3 minutes. The organic solvent was evaporated overnight in a fume hood to 
obtain a waxy solid. This solid material was then rinsed with methanol to remove 
unbound SIM. The solid dispersions were then freeze dried for 2 x 24 hours to obtain 
a brittle waxy solid.  
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2.3.5.3. Determination SIM loading in solid dispersions 
The solid dispersions (10 mg) was dissolved in DCM (2 ml) followed by adding 
methanol (8 ml) to precipitate the polymer. The mixture was centrifuged at 19,466 x 
g for 5 minutes to get a clear supernatant. The supernatant was taken for HPLC 
analysis as described in section 2.3.4.4.  
2.3.6. Drug Release Study 
Drug release studies were applied to 40%C18-PGA microparticle (MP),  40%C18-PGA-
PEG-MIHA MP and 40%C18-PGA-PEG-MIHA MP coated with collagen as well as solid 
dispersion of SIM in 40%C18-PGA and 40%C18-PGA-PEG-MIHA. PBS tablet (Fisher 
Scientific UK) dissolved in distilled water was used as drug release medium. Tween 20 
was added into the medium for simvastatin (SIM) release to increase the solubility of 
the active drug in the system and ensure sink conditions were obtained.  
The drug release from the MP was evaluated using the Sample and Separate (SS) 
method. In a 15 ml centrifuge tube, 10 mg of MP or solid dispersions was placed 
within 1 ml PBS as a medium for drug release. For MP containing SIM, 0.1% tween 20 
was added to PBS to improve the solubility of released SIM in PBS. The tubes were 
placed in shaking water-bath at 37°C. Gentle agitation (100 rpm) was applied to 
prevent MP precipitation. At a predetermined time point, the tubes were centrifuged 
at 1818 x g for 5 minutes to precipitate MP.  A 1 ml sample was taken and fresh 
media was added for replacement at each time point. The sample for the drug 
release study was examined using HPLC HP 1050 using the methods described at 
section 2.3.4.3 and 2.3.4.4.  
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2.3.7. Collagen attachment onto microparticle 
2.3.7.1. Preliminary study to evaluate collagen attachment onto microparticle 
Preliminary study had been carried out to evaluate ability of iminothiolane-modifified 
collagen to attach on 40%C18-PGA-PEG-MIHA MP. Various amount of iminothiolane-
modified collagen (Table 2.3) were added to the microparticle (5 mg) in PBS (1 ml). 
The mixture was stirred in darkness for 24 hours. The microparticles were isolated by 
centrifugation at 20,187 x g for 10 minutes followed by rinsing with ultrapure water 
(3 x 1 ml). Amount of iminothilane-modified collagen was determined by measuring 
fluorescence intensity of FITC attached to collagen.  
Table 2.3.  Amount of collagen added to evaluate collagen attachment onto 40%C18-
PGA-PEG-MIHA microparticle. 
Sample Microparticle 
(mg) 
Amount of collagen added 
(nmol) 
A 5 0.1 
B 5 0.2 
C 5 0.4 
D 5 0.8 
E 5 1.6 
 
2.3.7.2. Attach iminothiolane-modified collagen onto microparticle 
Iminothiolane-modified collagen (500 µl) was added to MP (10 mg) in PBS (1 ml).  The 
mixture was stirred in darkness by wrapping the container with aluminium foil for a 
minimum 24 hours. MP coated with collagen were isolated by centrifugation at 
20,187 x g for 10 minutes followed by rinsing with ultrapure water (3 x 1 ml). 
Microparticles coated with collagen were then freeze dried for 2 days to get dried 
microparticle and were kept in a freezer.  
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2.3.7.3. Determination of collagen attachment onto microparticle 
The amount of collagen attached onto MP was determined by both an indirect 
method and direct method. 
2.3.7.3.1. Indirect method 
The amount of modified collagen attached to the MP was determined using the 
fluorescence intensity of the unbound collagen in the solutions obtained from the 
supernatant and the washing steps.  The fluorescence intensity of unbound collagen 
ŝŶƚŚĞůŝƋƵŝĚƉŚĂƐĞǁĂƐĚĞƚĞƌŵŝŶĞĚƵƐŝŶŐĨůƵŽƌĞƐĐĞŶĐĞƐƉĞĐƚƌŽƉŚŽƚŽŵĞƚĞƌĂƚʄexcitation 
ŽĨ ? ? ?ŶŵĂŶĚʄemission of 521 nm. The concentration of FITC in the unbound collagen 
was determined using the fluorescence intensity which was plotted to the FITC 
calibration curve. Since the amount of collagen added and the ratio of FITC to 
collagen had been known, the amount collagen attached to the MP can be calculated 
2.3.7.3.2. Direct method 
A MP coated with collagen (5mg) was suspended in water. The amount of collagen 
attached to the MP was determined by measuring the fluorescence intensity of FITC 
in collagen using fluorescenĐĞƐƉĞĐƚƌŽƉŚŽƚŽŵĞƚĞƌĂƚʄexcitation ŽĨ ? ? ?ŶŵĂŶĚʄemission of 
521 nm. Since the ratio FITC to collagen had been known, the amount of collagen 
attached to the MP can be determined. 
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2.4. Cells Aggregate Formation using Microparticles 
2.4.1. Materials and Equipment 
2.4.1.1. Cell Culture Media 
STO Neo-Leukemic (SNL) fibroblast was proliferated standard culture medium (SCM) 
containing ƵůďĞĐĐŽ ?ƐDŽĚŝĨŝĞĚĂŐůĞDĞĚŝƵŵ ?DD ?ĨƌŽŵInvitrogen, Paisley UK, 
supplemented with 10% Fetal Bovine Serum (FBS) from Biosera (Catalogue No. FB-
1001); penicillin-streptomycin (50 units/ml) from Invitrogen, Paisley UK; L-Glutamine 
(1 mM) ĂŶĚɴ-mercaptoethanol (100 µM). 
The medium for mouse embryonic stem (mES) cells was SCM supplemented with 
Leukemia Inhibitory Factor (LIF) (500 unit/ml) from Chemicon, Hampshire UK from 
Chemicon, Hampshire UK. 
The medium for primary osteoblast cells was Alpha Modified Eagles Medium (Alpha 
MEM) from BioWhittaker, Belgium supplemented with 10% FBS from Sigma 
(Catalogue No. F9665), penicillin-streptomycin (50 units/ml), L-Glutamin (1 mM) and 
sodium pyruvate (1 mM) from Invitrogen, Paisley UK. 
2.4.1.2. Other Materials 
The other materials for cells culture preparation and maintenance were PBS; gelatin; 
trypsin 0.25% containing 0.02% EDTA (Trypsin/EDTA); mitomcyn C, S. caespitosus 
from Merck Biosiences Ltd. Resazurin in Hanks Balanced Salt Solution (HBSS) was 
used to determine the cells proliferation.  
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2.4.1.3. Equipments 
The equipments used for performing and maintaining the cell culture experiments 
were Class II cabinet fitted with high efficiency particulate air (HEPA) filter; cell 
incubator (Sanyo, 37°C, 5% CO2); multifunction rotator (Grant PS-M3D); microscope 
Nikon Eclipse TS100; plate reader (Tecan); disposable lab-ware for tissue culture 
included cell culture flasks T75 and T25, non-tissue culture treated 96-well plates, 7 
ml bijoux, pipette tips, 1.5 ml microcentrifuge tubes from Scientific Laboratory 
Supplies (SLS); 20 ml universals tube from Starsted; 0.25µm filter from Sartorius, 
Epsom UK for sterilisation of cell medium; UV lamp for steriliation of microparticles.  
2.4.2. Culture of SNL fibroblast 
SNL fibroblasts were obtained from Miss Magdalen Self, Wolfson Centre for Stem 
Cell, Tissue Engineering and Modelling (STEM), University of Nottingham, UK. They 
are of unknown passages, however it is well established in Tissue Engineering Group 
for embryonic stem cell proliferation and pluripotency maintenance and used 
between passages 1-50 post receipt. SNL were maintained in SCM described in 
section 2.4.1.1 and cultured in T75 cell culture flask and incubated in humidified 
static condition at 37°C with 5% CO2 until confluence was reached. Once at 
confluence, the cells were passaged. The medium was carefully aspirated from the 
flask and the cells were washed using 10 ml PBS. Trypsin/EDTA (2 ml) was added to 
the flask to detach cells from the flask for no longer than 5 minutes to minimize 
damage to cells.  Medium (3 ml) was then added to inactivate the trypsin. The cell 
suspension was transferred to a 20 ml universal tube and was centrifuged at 180 x g 
for 5 minutes. The supernatant was then aspirated, leaving the pellet of cells. The 
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cells pellet was then diluted with 5 ml cells medium with typical ratio of 1:5 by gently 
pipetting to avoid cell clumps. The cell suspension (1 ml) was then cultured in T75 cell 
culture flask containing 9 ml cell media and was incubated for 4-5 days until reaching 
confluence and ready for subsequent passaging.  
2.4.3. Preparation of Feeder Layer for mES cell culture 
Confluent SNL cells were used for feeder layer preparation. The feeder layer was 
prepared in a T25 cell culture flask treated with 0.1% gelatin for 2 hours. The medium 
was aspirated from confluent SNL cell culture then treated with 10 ml mitomycin C 
solution (0.01 mg/ml). The cells treated with mitomycin were incubated at 37 °C with 
5% CO2 for 2 hours. The mitomycin C solution was then removed and the cells were 
washed twice with 10 ml PBS. Trypsin/EDTA (2 ml) was then added to detach the 
cells from the flask for no longer than 5 minutes. The flask was gently agitated to 
dissociate the cells and SNL medium (3 ml) was added. The cell suspension was then 
transferred to a 20 ml universal and centrifuged for 5 minutes at 180 x g. The 
supernatant was aspirated and the cells were diluted with SNL medium (2 ml) prior 
to cell counting using a haemocytometer. The cells were then seeded in a T25 cell 
culture flask-gelatin treated at density of 8x104/ml in SCM medium (5 ml). The feeder 
layers were incubated in static condition at 37°C and 5% CO2 in humidified 
atmosphere. The feeder layer was ready for mES cells culture by the next day and 
could be used as feeder layer until 14 days. The medium was replaced when the 
colour of the media became slightly yellow. 
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2.4.4. Culture of mouse embryonic stem (mES) cell 
The mouse embryonic stem (mES) cells were cell line originally derived from mouse 
columnar epiblast epithelium (CEE) and maintained as stock in the Tissue Engineering 
Group.  The mES cells were cultured in a T25 fibroblast feeder layer and proliferated 
in mES cell medium as described in section 2.4.1.1. The confluent mES cells were 
passaged to maintain pluripotency of the stem cells. The media was aspirated from 
the confluence mES culture flask followed by rinsing with PBS (5 ml). The cells were 
detached from the culture flask by adding trypsin/EDTA (2 ml) for no more than 5 
minutes. The flask was gently agitated to completely dissociate the mES cells. The 
medium (3ml) was then added to deactivate trypsin/EDTA. The mES suspension was 
then transferred to a 20 ml universal tube and was pelleted using centrifugation at 
180 x g for 5 minutes. The supernatant was aspirated to remove trypsin/EDTA.  The 
pellet of mES cells was then suspended in 4 ml medium for splitting at ratio 1:4 and 
gently pipetted to break cell clumps. The cells suspension (1 ml) was then cultured in 
a T25 fibroblast feeder layer containing 4 ml mES cells media. The cells were 
incubated in static condition at 37°C and 5% CO2 in humidified atmosphere until 
reaching confluence and ready to use for cells experiment or for passaging. The mES 
cells typically reached confluence after 2-3 days. Mouse ES cells could be kept 
undifferentiated until passage 30.  
2.4.5. Culture of primary osteoblast cells 
The primary osteoblast cells were isolated from neonatal (1-5 day old) CD1 mouse 
calvariae. The primary osteoblast cells were proliferated in aT75 flask supplemented 
with primary osteoblast medium described in section 2.4.1.1. The primary osteoblast 
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cells from frozen stock (1 ml) was thawed and diluted in osteoblast medium (4 ml). 
The cells were then centrifuged at 300 x g for 5 minutes. The supernatant was 
removed and the cells were suspended in osteoblast medium (2 ml). The osteoblast 
suspension was seeded in T75 cell culture flask containing osteoblast medium (8 ml). 
The cells were incubated at 37°C with 5% CO2 in humidified atmosphere for 2-3 days 
to reach confluence and ready for experiments.  
2.4.6. Aggregate formation with microparticle 
The confluent cells were harvested using trypsinization, centrifuged and resuspended 
in appropriate cell culture media described in section 2.4.1.1. Passage 23-29 was 
used for an experiment with mES cells while the primary osteoblast cells were used 
without passaging. MP was sterilized under a UV light for 45 minutes prior to use. 
Microparticles (MP) suspension in phosphate buffer saline (PBS) was seeded in non-
tissue culture treated 96-well plate then cells (1x104 cells per well) were seeded in 
ratio 1:1 cells to MP. The volume of media was adjusted to 200 µl per well. The plate 
was placed in a 15 rpm multifunction rotator in an incubator at 37°C and 5% CO2 for 6 
hours (for mES cells) or 3 hours (for primary osteoblast) then transferred to a static 
condition incubator. The cultures were maintained in a static incubator for 14 days. 
The cell culture medium was replaced every 2 days (for mES cells culture) and 5 days 
(for osteoblast cells culture) or when the colour of the cell medium turned to yellow.  
2.4.7. Determination of the Diameter of Cell Aggregates 
Aggregate formation images were taken using Nikon Eclipse TS100 microscope at day 
3, 5 and 7. The cell aggregate images were taken at three random areas in each well. 
The images were labelled and the aggregate diameter was analysed using ImageJ 
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Software. Two perpendicular diameters diameter were measured across the centre 
of the aggregate and the average of these two measurements was calculated.  
2.4.8. Determination of the amount of microparticle inside cell aggregates 
The incorporation of MP inside the cell aggregates were evaluated by dissociating the 
cell aggregates at day 3. The cell aggregates were taken out from the well-plate and 
rinsed with PBS (3 x 1 ml) to remove unincorporated MP before dissociating using 
trypsin/EDTA. The number of microparticles inside the cell aggregates was counted 
by taking image of microparticle and cells at three random selected areas using 
fluorescence and bright field microscope, respectively. The number of particle and 
cell were counted by image analysis using ImageJ software. The incorporation of the 
microparticles inside cell aggregates was calculated using Equation 2-3. 
Equation 2-3. Incorporation of microparticle inside cells aggregate (%) 
 
۷ܖ܋ܗܚܘܗܚ܉ܜܑܗܖܗ܎ܕܑ܋ܚܗܘ܉ܚܜܑ܋ܔ܍ܑܖܛܑ܌܍܋܍ܔܔܛ܉܏܏ܚ܍܏܉ܜ܍ሺ ?ሻൌ ܖܝܕ܊܍ܚܗ܎ܕܑ܋ܚܗܘ܉ܚܜܑ܋ܔ܍ܛܑܖܚ܉ܖ܌ܗܕܛ܍ܔ܍܋ܜ܍܌܉ܚ܍܉ܖܝܕ܊܍ܚܗ܎܋܍ܔܔܛܑܖܚ܉ܖ܌ܗܕܛ܍ܔ܍܋ܜ܍܌܉ܚ܍܉ ܠ૚૙૙ 
 
2.4.9. Determination number of single cells 
The number of single cells was counted by image analysis using ImageJ software. The 
images was taken at three random selected areas each well under bright field 
microscope.  
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2.4.10. Alamar Blue assay for cell proliferation and metabolism activity 
Cells proliferation and metabolism activity were evaluated using the Alamar Blue 
assay on 7-day and 14-day old cell cultures. The cell aggregates were washed using 
PBS then transferred to a 96-well plate.  Resazurin (Alamar Blue) was dissolved in 
HBSS buffer to get 20µg/ml solution. The solution was filtered through 0.25 µm filter 
and was kept in the dark. Alamar Blue solution (200 µl) was added to the washed cell 
aggregates. The plate was incubated for 15 minutes at 37°C in the dark. The 
fluorescence intensity of the reduced form of resazurin was measured using a plate 
ƌĞĂĚĞƌĂƚʄexcitation ŽĨ ? ? ?ŶŵĂŶĚʄemmision of 590 nm. 
2.5. Microparticles for cell differentiation 
2.5.1. Materials and Equipment 
Microparticle (MP) containing simvastatin prepared from 40%C18-PGA and 40%C18-
PGA-PEG-MIHA were used to induce osteogenesis in mES and primary osteoblast 
cells. Cells culture is maintained in an appropriate media as described in section 
2.4.1.1. 
The alkaline phosphatase was identified using p-nitrophenyl phosphate (pNPP) in 0.2 
M Trizma® base pH 9.8.   
Osteocalcin imunostaining was identified using anti osteocalcin polyclonal antibody 
from Millipore (Catalogue No. AB 10911, raised in Rabbit), Biotinylated Anti-Rabbit 
IgG H+L from Vector Laboratories (Catalogue No. BA-1000, raised in goat), and 
diaminobenzidine (DAB) histochemistry kit from Molecular Probes (Catalogue No. 
D22187). PBS with 1% Triton X-100 was used to permeabilize aggregates; PBS with 
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0.1% bovine serum albumin (BSA) was used as general solvent during staining 
process with antibody. 
The mineralisation in cells was identified using the von Kossa staining method using 
silver nitrate and sodium thiosulfate.  
The other materials for cells culture maintenance were deionized tissue culture 
water, phosphate buffer saline (PBS); trypsin 0.25% containing 0.02% EDTA 
(Trypsin/EDTA).  
The equipments used for performing and maintaining cell culture experiments are 
described in section 2.4.1.3.  
2.5.2. Incorporation of microparticles within cells for osteogenic differentiation 
The osteogenic differentiation of mES cells was maintained in SCM supplemented 
with ɴ-Glycerophosphate (50 mM) and L-ascorbic acid (50 µg/ml).   
The osteogenic differentiation of primary osteoblasts was maintained in primary 
osteoblast medium supplemented with ɴ-Glycerophosphate (50 mM) and L-ascorbic 
acid (50 µg/ml).   
The microparticles (MP) were dispersed in phosphate buffer saline and sterilized 
under UV light for 45 minutes prior to use. The calculated amount of MP suspension 
was seeded into non-tissue culture treated 96-well plate, given the ratio 1:10 of MPs 
to cells. Then, cells were seeded to the plate at 104 cells per well and the volume of 
medium was adjusted to 200 µl per well. The plate was placed on 15 rpm 
multifunction rotator in 37°C incubator for 6 hour (for mES cell) or 3 hour (for 
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osteoblast cell)  to induce aggregate formation then moved to a static incubator. The 
cells were maintained in the culture for 28 days. The media was changed every 2 
days for mES cell and every 5 days for osteoblast cell. 
2.5.3. Alkaline phosphatase assay 
The samples of cells from day 7th, 14th and 21st were collected and washed using PBS 
to remove the media. Alkaline phosphatase was lysed in 0.2 M Trizma® buffer by 
freezing down the cell aggregate in -80°C for 2 hours continued by sonication for 2 
minute. The samples were centrifuged for 10 minutes at 14,420 x g to remove 
cellular debris. The supernatant was collected for alkaline phosphatase assay. The 
alkaline phosphatases in the samples were determined using pNPP as substrate. One 
tablet of pNPP substrate was dissolved in 0.2 M Trizma® buffer (20 ml). The 
supernatant (100 µl) was placed in 96-well assay plate and p-NPP (200 µl) solution 
was added to the sample. The alkaline phosphatase hydrolysed pNPP to the yellow 
end product, p-nitrophenol, which was soluble in buffer.  The absorbance of the 
supernaƚĂŶƚǁĂƐŵĞĂƐƵƌĞĚĂƚʄ ? ? ?Ŷŵ ?dŚĞĂůŬĂůŝŶĞƉŚŽƐƉŚĂƚĂƐĞŝŶƚŚĞƐĂŵƉůĞƐǁĂƐ
quantified using alkaline phosphatase enzyme as a standard.  
2.5.4. Imunostaining of osteocalcin 
Osteocalcin in the cell aggregates was detected using horseradish peroxidase-
streptavidin (HRP-streptavidin) immunodetection. Diaminobenzidine (DAB) was used 
as substrate for HRP to give brown-coloured oxidation product.  
A sample of 28-day cell aggregate was fixed with 4% paraformaldehyde for 1 hour 
and kept in fridge to preserve active proteins until ready for immunostaining. The 
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aggregates were permeabilized in PBS containing 1% Triton X-100 for 30 minutes at 
room temperature followed by rinsing with PBS (200 µl, 3 x 5 minutes). Endogenous 
peroxidase in the cell aggregates was blocked by incubating the aggregates in 3% 
H2O2 for 1 hour in room temperature followed by rinsing with PBS (200 µl, 3 x 5 
minutes). After blocking the endogenous peroxidase, the aggregates were incubated 
in 0.5% goat serum (200 µl) for 1 hour at room temperature to prevent non-specific 
binding of secondary antibody. The blocking serum was rinsed away three times with 
PBS+0.1% BSA (200 µl, 3 x 5 minutes).  
Primary antibody (anti osteocalcin polyclonal antibody, raised in rabbit) was diluted 1 
to 200 using PBS+0.1% BSA. The diluted primary antibody was then added to cell 
aggregates and incubated at 4°C overnight. The washing out using PBS+0.1% BSA 
(200 µl, 3 x 5 minutes) was carried out to rinse out primary antibody from the 
aggregates. Secondary antibody (biotinylated anti-rabbit IgG (H+L), raised in goat, 
1:500 dilution in PBS+0.1% BSA, 200 µl) was added to the cells aggregates. The cell 
aggregates were incubated in secondary antibody at room temperature for one hour. 
Subsequently, the secondary antibody was rinsed with PBS+0.1% BSA (200 µl, 3 x 5 
minutes).  
The osteocalcin labelling was then detected using HRP-streptavidin conjugate. The 
cell aggregate was incubated with HRP-streptavidin conjugate (1:500 dilution in 
PBS+0.1% BSA, 200 µl) for 1 hour at room temperature, then HRP-streptavidin 
conjugate was rinsed out three times with PBS+0.1% BSA (200 µl, 3 x 5 minutes). DAB 
solution (1 mg/ml) was mixed with the cell aggregates using gentle agitation for 15 
minutes. Afterward, 0.03% H2O2 (200 µl) was added to the cells aggregates and 
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allowed to remain for 5 minutes.  DAB solution was rinsed out with PBS (200 µl, 3 x 5 
minutes). Staining in the cells aggregates was viewed under bright field microscope.  
2.5.5. Von Kossa staining for mineralisation 
The von Kossa staining was used to detect mineralisation in 28 day old cells 
aggregates. This technique was used to detect the calcium deposition in the cell 
aggregates using silver nitrate solution. The calcium in the sample was reduced using 
strong light and replaced with silver deposit. The sample of 28-day cells aggregates 
was fixed with 4% paraformaldehyde for 1 hour and kept in a fridge for the 
experiments.  
The fixed cell aggregates were rinsed and dehydrated by placing the aggregates in 
deionized water (200 µl) for 2 hours. The aggregate was then exposed to 1% silver 
nitrate solution under strong light for 1 hour. Mineralised aggregates turned to 
brown or black colour to indicate a complete reaction. Subsequently, the aggregates 
were rinsed three times with deionized water (200 µl, 3 x 5 minutes). The unreacted 
silver nitrate was removed by mixing with 2.5% sodium thiosulfate for 5 minutes. The 
aggregates were then washed three times with deionized water. Mineralisation in 
the cell aggregates was indicated by brown colour visualized under a light 
microscope. 
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CHAPTER 3 
3. MODIFICATION OF POLY(GLYCEROL ADIPATE) 
 
 
3.1. Introduction 
Microparticles (MP) can be applied as matrices in tissue engineering to facilitate 3D 
assembly of cells and act as a drug reservoir to release drug in controlled manner [16, 
17, 35].  Poly(glycerol-adipate) (PGA)  is a potential material for preparation of 
microparticles for 3D tissue engineering as it is biodegradable and biocompatible 
with several cells [124, 125, 146]. However, modifications of the polymer are useful 
to meet the requirement for delivering bioactive molecules to cell for tissue 
engineering.  
Many bioactive molecules have hydrophobic properties and tend to interact with 
lipid environment in biological membrane [147, 148]. Consequently, it is anticipated 
that material could be efficiently encapsulated within PGA polymer by creating 
lipophilic environment on the polymer backbone [149]. A lipophilic environment can 
be created by conjugation of lipophilic acyl chloride to the pendant hydroxyl group of 
PGA polymer. Previous studies showed that PGA with a 40% substitution of stearoyl 
groups (C18H35O-) to the hydroxyl group of PGA polymer exhibited the highest 
encapsulation efficiency for dexamethasone phosphate. The steroidal moiety on 
dexamethasone phosphate is expected to interact very well with the alkyl moieties of 
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stearic acid [125]. This result could be applied to encapsulate other hydrophobic 
bioactive molecules for modulating cell growth.  
Further modification is needed for the microparticle to support cell aggregation for 
generating a 3D structure. The adhesiveness of the microparticle can be achieved by 
attaching ligand or extracellular matrix (ECM) proteins, as cell adhesion molecules, 
onto the surface of microparticle. Moreover, attachment of ECM proteins can mimic 
an in vivo microenvironment to control the development of cells. The attachment of 
ECM using physical adsorption e.g. plasma coating seems not effective as desorption 
occurs after a period of time [138]. Thus, conjugation via covalent bonding offers 
stable attachment of ECM protein on the surface of MP. Therefore, a linker is needed 
to facilitate ECM protein conjugation to MP.  
Poly(ethylene glycol) is an attractive linker to enable ECM protein conjugation.  The 
W' ĐŚĂŝŶ ǁŽƵůĚ ƉƌŽĚƵĐĞ Ă  “ĐŽŶĨŽƌŵĂƚŝŽŶĂů ĐůŽƵĚ ? ĂƌŽƵŶĚƚŚĞ DW ƚŽ ƉƌĞǀĞŶƚ
aggregation. In addition, PEG configuration protects MP from immune recognition, 
thus reducing immunological reactions [130, 132, 133]. The thiol-PEGylating agent, 
N-maleimidohexanoyl diamino-poly(ethylene-glycol) (MIHA-PEG-NH2) linker, has 
been used to provide more specific conjugation with protein. MIHA-PEG-NH2 linker 
only reacts with thiol functional groups on protein molecules. The thiol groups are 
rarely present in proteins, therefore, it offers a more selective attachment of 
proteins on the surface of MP [130, 131]. The PEGylation of MP can be prepared 
before fabrication of MP or after MP was formed. MIHA-PEG-NH2 linker was attached 
to modified PGA polymer to ensure that PEGylation occurred on the bulk of MP.  
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The aims of the experiment presented in this chapter are functionalization of PGA 
polymer by substituting 40% of hydroxyl group of PGA with stearoyl moiety (C18), 
attaching N-maleimidohexanoyl diamino-poly(ethylene-glycol) (MIHA-PEG-NH2) to 
provide linker for ligand attachment to the 40% C18 substituted PGA (40%C18-PGA) 
and installation of iminothiolane-modified collagen as ligand for cell attachment.  
3.2. Stearoyl Substitution on Poly(glycerol adipate) (40%C18-PGA) 
The pendant hydroxyl group on PGA polymer backbone was substituted with C18 to 
provide a lipophilic environment for encapsulation of drug. Stearic acid (C18) was 
conjugated on 40% of hydroxyl group in PGA backbone and the synthesis involved 
addition of stearoyl chloride into the polymer backbone and refluxed for 2 hours as 
described in Chapter 2, section 2.2.3. For 40% stearoyl substitution, 4 mmol of 
steroyl chloride was added to 10 mmol (2.02 gram) of PGA polymer. The yields from 
this procedure on several batches are around 76 % which is comparable to previous 
study by Kalinteri et al (2005) with reported yield of 79% [125].  
The acylation of polymer was confirmed using 1H-NMR and FTIR. The following 
figures (Figure 3.1 and Figure 3.2) are 1H-NMR spectra of poly(glycerol adipate) 
backbone and 40% C18 substituted poly(glycerol adipate) (40%C18-PGA). The 
percentage of the o-acylation was confirmed using the CH3 ƉĞĂŬĂƚɷ0.86 which is 
assigned to terminal of the C18 and CH2KĂƚɷ ? ? ? ?ĂƐƐŝŐŶĞĚƚŽW' ?dŚĞƉĞƌĐĞŶƚĂŐĞ
of the polymer acylation from several batches showed that the percentage of the 
acylation was varied from 38% to 42%. This result was also confirmed using FTIR 
spectrum. 
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The FTIR spectrum showed the functional groups in both polymer backbone and 40% 
C18-PGA (Figure 3.3). The peak of  WOH group at 3472 cm-1 from polymer backbone 
was still present in 40% C18 substituted polymer since acylation was not intended to 
be completed.  However, the -OH group in the 40%C18-PGA appeared in lower 
intensity than unsubstituted PGA. 
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Figure 3.1. 1H-NMR spectrum of poly(glycerol adipate) (PGA) backbone 
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Figure 3.2. 1H-NMR spectrum for 40% C18 acylation of poly(glycerol-adipate) 
(40%C18-PGA) 
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(a) 
 
(b) 
 
(c) 
 
Figure 3.3. FTIR spectrum of (a) poly(glycerol adipate (PGA), (b) stearoyl chloride 
(C18) and (c) 40% C18-PGA 
 Chapter 3  Modification of PGA 
 
104 
 
3.3. Synthesis of N-maleimidohexanoyl diamino-poly(ethylene-glycol) 
(MIHA-PEG-NH2) linker  
In order to attach ligand onto the surface of microparticles, PGA polymer was 
functionalized with N-maleimidohexanoyl diamino-poly(ethylene-glycol) (MIHA-PEG-
NH2) linker. The conjugation of ligand on polymer surface can be achieved using 
maleimido functionality. The MIHA-PEG-NH2 linker was synthesized from N-
maleimidohexanoic acid (MIHA) and diamine poly(ethylene glycol) (H2N-PEG-NH2, 
MW 2000) by amide formation. Diamine PEG has a functional amine at each end of 
the PEG chain and each of the amine groups in the end of PEG chains has the ability 
to react with activated maleimidohexanoic acid. Thus, the diamine PEG was used in 
high molar excess in order to ensure mono-substitution.  
The formation of an amide bond between the terminal carboxylic acid group in 
maleimidohexanoic acid and an amine on diamine-PEG can be accomplished by 
carbodiimide-mediated coupling as mentioned in Chapter 2, section 2.2.4. Thus, N-
maleimidohexanoic acid was activated using combination of N,N-
dicyclohexylcarbodiimide (DCC) and N-hydroxysuccinimide (NHS). This combination 
was reported as an efficient way of creating active ester necessary for formation of 
amide linkage [150]. 
The activation of N-maleimidohexanoic acid took overnight. During the process, the 
mixture became cloudy as the by-product, N,N-dicyclohexylurea, was produced. 
Dicyclohexylurea was removed from the activated maleimidohexanoic acid (MIHA) by 
filtration. The activated MIHA was then added to diamine PEG dropwise to ensure 
that only one end of the amine group react with the carboxylic acid from 
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maleimidohexanoic acid. Following an overnight reaction, again, the dicyclohexylurea 
was removed from the product using filtration and the product was triturated with 
diethyl ether to remove the excess of DCC. After that step, the excess of NHS was 
removed by aqueous extraction of the organic phase using water. The yield of MIHA-
PEG-NH2 synthesis after the purification was 68% and confirmation of MIHA-PEG-NH2 
synthesis was established by 1H-NMR (Figure 3.4) and FTIR (Figure 3.5). 
 
 
Figure 3.4. 1H-NMR spectrum for N-maleimidohexanoyl diamino poly(ethylene-
glycol) (MIHA-PEG-NH2) 
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(a) 
 
(b) 
 
(c) 
 
Figure 3.5. FTIR spectrum of (a) diamine poly(ethylene glycol) (PEG), (b) N-
maleimidohexanoic acid (MIHA (c) N-maleimidohexanoyl diamino Poly (ethylene-
glycol)(MIHA-PEG-NH2) 
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The comparison of the relative peak area of  WO-CH2-CH2 group in diamine W' ?ɷ ? ?6-
3.7) and the peak area of  WCH of maleimide ring (ɷ 6.7) showed that the ratio of PEG 
to MIHA was 1:1. The NH2 stretching broad spectrum from diamine PEG at 3434 cm
-1 
was shifted to 3327 cm-1 indicated the amide bond formation in MIHA-PEG-NH2. In 
addition, a sharp peak around 1626 cm-1 in MIHA-PEG-NH2 spectrum from O=C-N- 
indicated that one of NH2 of diamine PEG substituted to carboxyl group of MIHA and 
became O=C WNH. 
3.4. Attachment of MIHA-PEG-NH2 linker to 40%C18-PGA 
The next stage of functionalizing the poly(glycerol adipate) polymer is attachment of 
MIHA-PEG-NH2 to 40%C18-PGA. The target of this reaction is coupling the amine 
group from MIHA-PEG-NH2 to the terminally located carboxylic acid group in PGA 
(Chapter 2, section 2.2.5). Since the amide formation to afford a 40%C18-PGA-PEG-
MIHA is similar to the formation of PEG-MIHA-NH2, the combination of the coupling 
agents, DCC and NHS, were again used to activate the carboxylic acid in the end chain 
of polymer.  
The 40%C18-PGA was activated overnight using DCC and NHS. The activated 40%C18-
PGA with MIHA-PEG-NH2 were left for 3 days at room temperature. The purification 
of desired product was done by extraction of organic phase using water to remove 
the excess NHS. The final product of 40%C18-PGA-PEG-MIHA is a brownish-yellow 
semisolid and the yields of several batches were varied from 65-83%. The polymer 
was analysed using 1H-NMR and FTIR to confirm the final product of 40%C18-PGA -
PEG-MIHA.  
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1H-NMR spectrum (Figure 3.6) was used to confirm 40%C18-PGA-PEG-MIHA structure. 
The spectrum was difficult to analyse due to relatively small amount of PEG-MIHA 
added to 40%C18-PGA. Consequently, the important peaks were only visible in small 
intensities. The comparison of the relative peak area of  WCH2 group near carbonyl in 
PGA polymer  ?ɷ2.3-2.4) and the peak area of  WCH on maleimide ring  ?ɷ6.7) showed 
that PGA was coupled with PEG-MIHA.  
 
Figure 3.6. 1H-NMR spectrum for 40%C18-PGA-PEG-MIHA 
 
The FTIR spectrum of 40%C18-PGA-PEG-MIHA (Figure 3.7) showed that the sharp peak 
at 3323 cm-1 came from N-H stretching. The broad -OH band of PGA polymer at 3473 
cm-1 still presented since acylation was not intended to be completed. In addition, 
there was a sharp peak around 1621 cm-1 assigned to O=C-N- in 40%C18-PGA-PEG-
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MIHA spectrum. It confirmed that NH2 from PEG-MIHA was substituted to carboxylic 
acid of PGA polymer and created the newly amide bond.  
 
Figure 3.7. FTIR spectrum of N-maleimidohexanoyl diamino PEG (MIHA-PEG) 
coupled to 40%C18-PGA (40%C18-PGA-PEG-MIHA) 
 
3.5. Preparation of Iminothiolane-modified collagen as ligand 
Collagen was proposed as a ligand on the surface of MP for cell adhesion. Collagen, 
as ECM protein, provides structural support for cell growth and proliferation. Despite 
mediation by matrix glycoprotein, cells have an ability to attach directly to collagen 
through an integrin receptor on cell membrane [151-153]. In order to attach to 
40%C18-PGA-PEG-MIHA polymer, a thiol functional group must be present on 
collagen. Since free cysteine residues are not present on collagen, a thiol group was 
installed by reacting collagen with 2-ŝŵŝŶŽƚŚŝŽůĂŶĞ  ?dƌĂƵƚ ?Ɛ reagent) [154].  In this 
experiment, two molecules of thiol were attached to collagen. 
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Due to the small amount of 2-iminothiolane needed to attach with collagen, the 
amount of thiol group cannot be analysed by spectrophotometry. Therefore, it was 
estimated by ůůŵĂŶ ?ƐĂƐƐĂǇ as described in Chapter 2, section 2.2.6.1. The amount of 
 WSH group in preliminary studies was determined by ƵƐŝŶŐ ůůŵĂŶ ?Ɛ ƌĞĂŐĞŶƚ. The 
amount of thiol group was calculated using Equation 2-1 and plotting the absorbance 
at acetyl cysteine calibration curve (Figure 3.8). The calculation using both methods 
gave the same result for thiol group concentration in sample. According to the result 
from preliminary study, 2 molecules of thiol per mole of collagen can be obtained by 
reacting 200 nmole of 2-iminothiolane to 10 nmole of collagen (Table 3.1).   
 
Figure 3.8. Acetyl cysteine calibration curve in Tris buffer. The calibration curve was 
created using standard concentration of acetyl cysteine ranging from 10 to 50 µM 
ĂŶĚ ƌĞĂĐƚĞĚ ǁŝƚŚ ůůŵĂŶ ?s reagent. The absorbance was measured using 
spectrophotometer UV. All samples are taken triplicate and averages calculate. 
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Table 3.1. Calibration to estimate the amount of thiol group attached to collagen 
Batch Amount of 
Collagen 
(nmol) 
Amount of 
Trauts added 
(nmol) 
Amount of 
thiol group 
attached 
Amount of thiol 
group per mol 
collagen 
AS008DD 1 100 10 10 
AS009DD 1 500 55 55 
AS010DD* 10 200 A?20 A?2* 
*) estimate amount of thiol group conclude from AS008DD and AS009DD. 
 
 
For the next stages of the experiments, fluorescein-5-isothiocyanate (FITC) needs to 
be reacted with collagen. The attachment of FITC is necessary in order to determine 
the amount of collagen attached to MP. Collagen was labelled by adding FITC (50 
nmole) to 10 nmole collagen. The attachment of collagen with FITC and 
iminothiolane was carried out in consecutive reactions (Figure 3.9) and the 
procedure was described in Chapter 2, section 2.2.6.2. FITC was attached to proteins 
via primary amines in sodium carbonate buffer pH 9.5. Subsequently, after FITC 
reaction, the solution was adjusted to pH 8 for attachment of 2-iminothiolane to 
collagen as described in literature [155]. The reaction for 2-imnothiolane attachment 
was for 1 hour. The 2-iminothiolane reacts with primary amine to provide thiol group 
in the peptide. The purification of iminothiolane-modified-collagen-FITC was carried 
out by size exclusion chromatography using a PD-10 (Sephadex G-25) column. The 
amount of collagen was determined using Bradford method by plotting the 
absorbĂŶĐĞĂƚʄ ? ? ?ŶŵƚŽĐĂůŝďƌĂƚŝŽŶĐƵƌǀĞŽĨĐŽůůĂŐĞŶ ?Figure 3.10). The amount of 
FITC attached to collagen was determined using equation 2-2 at ʄ  ? ? ? Ŷŵ as 
described in Chapter 2.  The FITC attached at ratio 4 to 1 collagen (Table 3.2). 
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Figure 3.9. Collagen was modified with FITC and iminothiolane. FITC was attached 
for fluorescence (1) and iminothiolane was tethered to collagen to provide thiol 
group in collagen molecule (2). 
 
 
Figure 3.10. Collagen calibration curve in PBS. The calibration curve was created 
using Bradford method with known amount of collagen ranging from 0.02 to 0.4 
nmol. The absorbance was measured using spectrophotometer UV. All samples are 
taken triplicate and averages calculate.  
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Table 3.2. The amount of FITC and collagen determined in iminothiolane-modified-
collagen-FITC. 
 Amount 
added 
(nmole) 
Amount determined*) in 
iminothiolane-modified-collagen-FITC 
(nmole)±SD 
Ratio 
Collagen 10 7.07±0.89 1 
FITC 50 27.88±0.09 4 
*) Collagen was determined by measuring collagen absorbance with Bradford 
reagent at ʄ 595 nm while FITC was determined by measuring FITC absorbance at ʄ 
495 nm and calculated using Equation 2-2. 
 
In order to ensure that iminothiolane-modified collagen-FITC have an ability to attach 
to the cells, the fluorescence intensity of collagen attached to cells was evaluated 
using flow cytometry as described in Chapter 2 section 2.2.6.3. Fixed mouse 
embryonic stem (mES) cells were used in this experiment. The cells were mixed with 
a series of concentrations of iminothiolane-modified collagen-FITC for half an hour. 
Unbound modified collagen was removed from the cells by discarding the 
supernatant after centrifugation. The suspensions of cells attached with collagen in 
PBS+0.1% BSA were passed through the flow chamber of the flow cytometry. The 
amount of collagen attached to the cells was determined by the fluorescence 
intensity attached to each cell. The result from the flow cytometry showed that the 
amount of modified collagen attached to the cells increased proportionally with the 
amount of collagen added (Figure 3.11). The figure presented that collagen retained 
its ability for cells attachment although it had been modified by attaching FITC and 
iminothiolane onto its molecule.  However, fluorescence intensity declined when 
more than 18 picomoles collagen was added. It indicated that the surface of the cells 
became saturated with collagen and was not able to interact any further.  
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Figure 3.11. The fluorescence intensity of iminithiolane-modified-collagen-FITC 
attached to mES cell. The mES was fixed with 4% paraformaldehyde solution before 
attached with collagen. The 5x104 mES cell was used to interact with the each 
amount of iminothiolane-modified-collagen-FITC. The fluorescence intensity was 
ŵĞĂƐƵƌĞĚƵƐŝŶŐĨůŽǁĐǇƚŽŵĞƚĞƌĂƚʄĞŵŵŝƐŝŽŶ ? ? ?ŶŵĂŶĚʄĞǆĐŝƚĂƚŝŽŶ ? ? ?Ŷŵ 
 
3.6. Discussion 
Acylation of PGA polymer backbone could be completed with pyridine as catalyst or 
without pyridine as described in Figure 3.12. Since the  WCl is a good leaving group, 
PGA substitution could be accomplished without pyridine. However, pyridine was 
involved in this reaction as acid scavenger [125]. In addition, pyridine was used as a 
nucleophile for stearoyl chloride (C18H35OCl). Pyridine donated a pair of electron on 
acyl chloride and provided active carboxyl group in stearoyl chloride, therefore 
became ready to attach with hydroxyl on polymer backbone. The acylation of PGA 
polymer was indicated by formation of acid fume. The reaction was carried out for 2 
hours to ensure complete substitution of hydroxyl group on PGA polymer. The 
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substitution of hydroxyl group using pyridine resulted in a basic environment for the 
polymer solution. The hydrochloric acid (2M, 100 ml) was added to neutralize 
polymer solution in order to stop the reaction. The polymer solution was then 
obtained by extraction using dichloromethane. In previous study by Kallinteri et al, 
the substituted polymer was used without further purification. In this experiment, 
the excess of stearic acid (C18) was removed by washing the substituted polymer with 
petroleum ether followed by drying the substituted polymer with nitrogen. The acyl 
substitution with stearoic acid also changed the physical characteristics of PGA 
polymer from sticky semisolid polymer to white waxy solid. 
The percentage of acylation was calculated by comparing the mĞƚŚǇůƉĞĂŬĂƚɷ0.86 
ppm assigned to the end of acid chains of C18 and the methylene peak near the 
ĐĂƌďŽŶǇůŐƌŽƵƉĂƚɷ  ? ? ? ?ƉƉŵĂƐƐŝŐŶĞĚƚŽW' ?^ince the peak intensities on those 
peaks related to the number of hydrogen presented on molecule, the percentage of 
C18 substitution could be determined. The percentage of substitution could not be 
determined using FTIR spectrum. FTIR presented the fingerprint of each molecules 
but it was not related to the amount of functional groups on molecules. However, 
the substitution of stearoyl molecule to PGA polymer could be confirmed by the 
disappearing peak of O=C-Cl at 1800 cm-1 and C-Cl from stearoyl chloride at 721 cm-1. 
As the substitution reaction was controlled under dry condition, the disappearing of 
O=C-Cl and C-Cl band can be used to confirm acyl substitution to PGA polymer. The 
hydroxyl group on PGA polymer still appeared at 3472 cm-1 since not all of hydroxyl 
group on PGA intended to be substituted by C18.  
  
 
 
 
1
16
 
 
 
Figure 3.12. Proposed reaction mechanism of stearoyl acid substitution on hydroxyl groups of PGA polymer catalyzed by pyridine (a) and without 
pyridine (b).  
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Further modification on PGA polymer is attaching PEG-maleimide (MIHA-PEG-NH2) 
linker to the polymer backbone. The amide formation on both MIHA-PEG-NH2 linker 
and 40%C18-PGA-PEG-MIHA were mediated using coupling agents, DCC and NHS. DCC 
and NHS are effective coupling agent to create amide linkage molecules [150, 156]. 
The DCC is widely used to create amide bond in peptide synthesis as reported by Han 
and Kim (2004). This carbodiimide coupling agents categorized as low cost and mild 
coupling reagents in peptide synthesis. The by-product from DCC is not dissolved in 
solvents, therefore it is easy to separate by filtration. However, since it produces 
insoluble by-product, DCC not suitable for polypeptides synthesis as it is difficult to 
separate from the product [157].  
The carboxylic acid functional group on the end of PGA chain reacted with DCC to 
produce an intermediate product O-acylisourea and then reacted with NHS to form a 
stable-amine-reactive NHS-ester. The NHS-activated species was then ready to 
couple with the amine nucleophiles leading to amide bond formation (Figure 3.13) 
[156, 158, 159].  The MIHA-PEG-NH2 attachment to the 40%C18-PGA would be useful 
to prevent aggregation of MP. Since MIHA-PEG-NH2 linker attached to the 40%C18-
PGA prior to microparticle fabrication, the PEG chain will present in the bulk of MP 
and oriented to aqueous phase leading to the formation of enriched PEG 
microparticle [130]. Thus, the maleimide functional group would be effectively 
attached with ligand on the surface of microparticle. Instead of attachment in bulk 
polymer, the PEG linker attachment could also be achieved by attaching the PEG 
linker to preformed microparticle as studied by Madani et al (2007). Madani et al 
demonstrated PEG attachment to preformed microparticle using DCC and NHS as 
coupling agents [160]. However, this technique may lead to incomplete PEG 
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attachment on the surface microparticle leaving PEG-unprotected microparticle 
surface.  
 
Figure 3.13. The carboxylic group was converted to active intermediate by DCC and 
then reacted with NHS to form stable-amine-reactive NHS-ester. The nucleophilic 
of amine group attacked to NHS-ester to form an amide bond [158, 159]. 
 
Amide formation on both on MIHA-PEG linker and 40%C18-PGA-PEG-MIHA can be 
identified using FTIR by the sharp peak in area 1620-1630 cm-1. While, the ratio of 
each component in coupling reactions could be identified using 1H-NMR spectrum. 
The single peak of  WCH2 on maleimide ring (ɷ 6.7 ppm) is a specific peak to calculate 
ratio of coupling diamine PEG to MIHA and coupling MIHA-PEG-NH2 to 40%C18-PGA.   
Collagen was modified by attaching with 2-iminothiolane and FITC for further 
experiments. The attachment of 2-iminothiolane on collagen molecule gave a thiol 
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functional group, while FITC acted as a labelling agent on collagen molecule. Both of 
the reactants were attached to collagen through primary amine of lysine on the 
collagen molecule. However, the conditions for the two consecutive reactions were 
different. The optimum pH for isothiocyanate conjugation was 9.5 while the 
optimum condition of for 2-iminothiolane conjugation was at a pH below 9 [155, 
161]. In this experiment, the 2-iminothiolane conjugation was carried out at pH 8 in 
room temperature. This condition was adopted from Jue et al (1978) who 
successfully demonstrated the conjugation of 2-iminothilane to 30S ribosome at pH 8 
in room temperature (22°C). The 2-iminothiolane could also be attached to 
macromolecule, such as human serum albumin (HSA) under the similar condition (pH 
8.5) as demonstrated by Langer et al (2000). The iminothiolane-labelled HSA 
nanoparticle had specific interaction with maleimide-activated avidin. However, 
amount of sulfhydryl group attached to HSA nanoparticle reduced after four weeks of 
preparation due to an oxidative formation of disulfide cross-links during storage  
[162]. Therefore, iminothiolane-modified collagen should be prepared freshly prior to 
use to avoid the degradation of thiol active group.  
After modification, iminothiolane-modified collagen-FITC still maintained its ability to 
interact with cells since only 4 molecules of FITC and 2 molecules of 2-iminothiolane 
attached to the collagen. However, there was a maximum amount of collagen to 
interact with cell. The surface of cell would be saturated with collagen in certain 
concentration. In this experiment, the surface of cells reached saturation on the 
concentration 18 picomole of collagen for 50,000 cells. Consequently, in a further 
addition of collagen, the molecule was not able to interact with the surface of cell.  
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3.7. Conclusion 
A 40% substitution of C18 on PGA polymer backbone was effectively catalysed with 
pyridine as a nucleophile for acyl chloride. In addition, further purification on 40%-
C18-PGA was established to remove the free stearoyc acid from substituted PGA. The 
percentage of acyl substitution was mainly identified by 1H-NMR spectrum instead of 
using FTIR spectrum. However, FTIR could be used to identify the main functional 
group prior to substitution. Although percentage of stearoyl substitution from 
several batches not exactly reached 40% substitution, but it is acceptable to provide 
lipophilic environment for encapsulation of hydrophobic drug.  
The amide linkage on MIHA-PEG-NH2 and 40%C18-PGA-PEG-MIHA was successfully 
formed using combination of DCC and NHS as coupling agent. The ratio of diamine 
PEG attached to N-maleimidohexanoic acid was determined by 1H-NMR spectrum 
while the amide bond formation was identified using FTIR spectrum. However, the 
identification using 1H-NMR spectrum was facing difficulties for analysis of 40%C18-
PGA-PEG-MIHA due to small intensities of important peaks on the spectrum. The 
amide linkage formation on 40%C18-PGA-PEG-MIHA was clearly determined based on 
FTIR spectrum.  
The immobilized thiol group on collagen molecule was provided by attaching 
iminothiolane to collagen at pH 8. The FITC molecule was also successfully attached 
to collagen for further cell experiment. Although it has been modified by attaching 2-
imiothiolane and FITC, the iminothiolane-modified collagen still maintained its ability 
to interact with the surface of cell. The interaction of iminothiolane-modified 
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collagen with cells reached saturation at a certain concentration indicated by inability 
of collagen to attach to cells.    
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CHAPTER 4 
4. MICROPARTICLE PREPARATION AND CHARACTERISATION 
 
 
4.1. Introduction 
Microparticles (MP) can be applied to tissue engineering for encapsulation of 
bioactive molecules and delivery active molecules to the cells.   In addition, MP may 
act as supporting matrices to help form three dimensional (3D) structures with cells 
[35].  Controlled release of bioactive molecules can be tailored during the MP 
formulation processes and the method of MP formulation can be selected based on 
the characteristics of polymers used to form the MP and the bioactive molecules to 
be encapsulated.  Several techniques have been introduced to generate MPs such as 
emulsification, polymer phase separation (coacervation), spray-drying and 
supercritical fluid. 
Among those methods of MP preparation, the emulsification method is commonly 
used at the laboratory scale due to relative ease of processing [36, 163]. In this 
method, the polymer is dissolved in a suitable organic solvent and added to the 
aqueous external phase. The two immiscible solvents will perform a stable emulsion 
with the presence of emulsifier in the aqueous phase. As the organic solvent is 
evaporated, the MP will precipitate. The MP can be then collected by centrifugation 
followed by washing steps in ultrapure water and freeze drying [86, 88, 163].  
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The type of emulsion method, single emulsion or double emulsion, is selected 
depending on the solubility of the bioactive compound in the aqueous phase. An oil 
in water (O/W) emulsification process can be used to encapsulate hydrophobic drugs 
within the MP, while water-oil-water (W/O/W) emulsification process can be applied 
for hydrophilic drugs [88, 90].  Simvastatin (SIM) and dexamethasone phosphate 
(DXMP), as bioactive molecules for inducing bone formation, will be encapsulated 
within functionalized poly(glycerol adipate) (PGA) MP. Simvastatin (SIM), developed 
as a cholesterol lowering drug, has also been shown to have anabolic effects on bone 
tissue stimulating osteoblastic activity and mineralisation of bone matrix [55, 74-76]. 
Simvastatin  may act as a stimulator of  BMP2 expression in murine osteoprecursor 
cells at early stage of cell culture [75].  Dexamethasone phosphate (DXMP) is a 
corticosteroid and has been shown stimulate bone formation and mineralisation by 
stimulating transcription of osteoblast-specific genes [71-73]. In vitro, DXMP delivery 
by a polymer gel increased osteogenic differentiation of mesenchymal stem cells 
(MSCs) as suggested  by increasing activity of alkaline phosphatase enzyme, 
osteopontin and core binding factor alpha expression [73].  
Due to the hydrophobicity of SIM, oil-in-water (O/W) emulsification process was used 
to prepare modified PGA MP containing SIM. However, emulsification process had 
been modified to encapsulated water soluble drug, DXMP. Double emulsion, water-
oil-water (W/O/W), is used to prepare MP containing DXMP. An emulsifier, poly(vinyl 
alcohol) (PVA)  was used to reduce surface tension of immiscible phase during 
emulsification process and increase the stability of emulsion [164]. The 
manufacturing MP without surfactant was done using solvent displacement method. 
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In this method, organic solvent containing polymer is emulsified with the aqueous 
external phase and then precipitated followed by diffusion of organic solvent to 
aqueous medium.  A water-miscible solvent normally used in this method in order to 
perform spontaneous emulsification. Fast diffusion of the organic solvent results in 
the formation of a colloidal suspension. Particles are then generated by removal of 
organic phase and aqueous phase through evaporation.  [165, 166].  
Modified PGA polymer with 40% stearoyl substitution (40%C18-PGA) and 40%C18-PGA 
with MIHA-PEG-NH2 linker (40%C18-PGA-PEG-MIHA) was used for formation of 
biodegradable MP and mixing with cells to promote 3D assembly of cells.  Kallinteri 
et al., (2005) showed that 40% stearoyl substitution on PGA polymer backbone 
increased the encapsulation efficiency of DXMP within PGA nanoparticles. The 
encapsulation efficiency of DXMP within 40%C18-PGA nanoparticles reached 35-38% 
compare to un-substituted PGA [125]. In MP preparation, physicochemical properties 
of the active compound and critical factors such as polymer concentration, ratio 
dispersed phase to continuous phase, and concentration of emulsifier during 
manufacturing process affected encapsulation efficiency, physical characteristics of 
MP and release of drug from MP [164, 167]. Moreover, attachment of MIHA-PEG-NH2 
linker to PGA polymer will significantly affect the chemical properties of PGA and 
might affect the physical characteristics and encapsulation efficiency of MP overall.  
The aim of this chapter was to evaluate the influence of critical factors during 
manufacturing process of MP prepared from modified PGA polymers in terms of MP 
size and size distribution, surface charge, encapsulation efficiency and drug release. 
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Furthermore, the ability of MP to be attached with iminothiolane-modified collagen 
was also investigated.  
4.2. Particle Size 
In order to promote the formation of 3D cells matrices, the size of MP should meet 
the requirement of matrices for cells in tissue engineering. The size should be small 
enough to be incorporated within the cell aggregate but not to be taken up by the 
cells.  These requirements are important to maintain integrity of 3D constructs of the 
cells for tissue replacement. The size of particle that would be taken up through 
endocytosis, including phagocytosis, is varying from nanoscale up to 10 µm and also 
depends on physicochemical properties of the particle [168-170]. Wang et al (2010) 
explained that the optimum diameter of gold nanoparticle for being up taken by 
HeLa cells is around 45 nm and the efficiency of endocytosis reduces related to the 
increasing size of particle [171]. The critical factors that affected the size of MP are 
chemical properties of modified PGA polymers, properties of encapsulated drug, 
homogenisation speed during manufacturing process and concentration of PVA as 
emulsifier.   
4.2.1. Effect of polymer type 
The size of modified PGA MP is influenced by chemical properties of the polymer. To 
investigate the effect of PEG attachment on particle size, MPs were prepared by 
emulsification process with 2.5% PVA as emulsifier as described in Chapter 2 section 
2.3.2.1. The sizes of MP are shown in Figure 4.1. The mean particle diameters 
prepared from 40%C18-PGA and 40%C18-PGA-PEG-MIHA were 9.0 ± 1.63 and 5.0 ± 
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0.50 µm, respectively. It showed that attachment of MIHA-PEG-NH2 linker to PGA 
polymer exhibited the smaller particle size than the one without the linker.  
 
Figure 4.1. Size of microparticles prepared from modified PGA polymer. 
Microparticles were prepared using emulsification method with 2.5% PVA as 
emulsifier. The mean diameter was taken from different batches of MP (n=3). Bars 
represent SEM.  
 
  
a) 40%C18-PGA b) 40%C18-PGA-PEG-MIHA 
 
Figure 4.2. Particle size distribution of MP prepared from 40%C18-PGA (a) and 
40%C18-PGA-PEG-MIHA (b) using emulsification method with PVA 2.5% as 
emulsifier. 
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The size distribution of particles showed bimodal poly-dispersed MP with diameter 
ranging from 0.4 µm to 60 µm (Figure 4.2). The bimodal peak on particle size 
distribution revealed that the aggregation of particle was occurring.  MP prepared 
from 40%C18-PGA showed a positively skewed population with high population of MP 
below 6 µm. In contrast, MP prepared from 40%C18-PGA-PEG-MIHA displayed normal 
distribution, with the mean diameter at the highest population of MP.  Microparticle 
prepared from 40%C18-PGA-PEG-MIHA polymer exhibited narrow size distribution 
compared with the MP prepared from 40%C18-PGA, indicating a smaller variation on 
particle size for 40%C18-PGA-PEG-MIHA MP. 
4.2.2. Effect of homogenizer speed 
Particle size is also affected by the speed of the stirrer used during the manufacturing 
process.   In this method, control of homogenisation speed was applied both during 
the formation of primary emulsion and mixing with PVA solution.  Figure 4.3 presents 
the effect of homogenizer speed on particle size. Increasing homogenizer speed 
reduced the particle size. This result was seen for both MPs prepared from 40%C18-
PGA and 40%C18-PGA-PEG-MIHA. Increasing homogenizer speed related to the 
formation of finer droplet of emulsion, so the smaller particles were formed [167, 
172].  
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Figure 4.3. Effect of homogenizer speed on size of microparticles prepared from 
40%C18-PGA and 40%C18-PGA-PEG-MIHA. Microparticles were prepared using 
emulsification method with PVA 2.5% as emulsifier. The mean was taken from 
different batches of MPs (n=3). Bars represent SEM. 
 
4.2.3. Effect of PVA concentration 
 The size of particle is not only influenced by polymer type and speed of homogenizer 
during manufacturing process, but is also affected by concentration of surfactant 
used in preparation.  Use of PVA as emulsifier act as a tensio active molecule to 
reduce interfacial tension between organic and aqueous phase [167]. The effect of 
emulsifier concentration on particle size was investigated in preparation of MP from 
40%C18-PGA.  
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Figure 4.4. Effect of PVA concentration on the size of microparticles prepared from 
40%C18-PGA polymer. The mean diameter was taken from three different batches 
of MP except for PVA 2.5% which was taken from seven different batches. Bars 
represent SEM.  
 
Figure 4.4 illustrates the effect of PVA concentration on particle size. The MP 
exhibited a bigger particle size as the concentration of PVA increased from 0.005 % to 
0.025%. However, the higher concentration of PVA used (above 0.05%) led to 
significantly smaller particle size. There is no significant difference on particle size of 
MPs prepared with PVA concentration 0.05 % to 0.5 % (p > 0.05, n=3).  
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(a) (b) 
  
(c) (d) 
  
(e) (f) 
 
 
(g)  
 
Figure 4.5. Particle size distribution of 40% C18-PGA MPs prepared using emulsification 
method with PVA (a) 0%, (b) 0.005%, (c) 0.025%,  (d)0.05%, (e)0.25%, (f)0.5% and (g) 
2.5%. 
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The particle size distributions were also affected by concentration of PVA used in MP 
preparation as seen in Figure 4.5. The poly-dispersed particle distribution with 
negatively skewed distribution was seen with MP without PVA and with PVA 0.005% 
and PVA 0.025%. Negatively skewed distribution indicated coarser particles had been 
produced. Increasing PVA concentration to 0.05% shifted the distribution of MP to a 
more positive skewed distribution, indicating that finer particles had been produced 
above a critical minimum amount of emulsifier. In contrast, with PVA at a 
concentration of 0.25 % and above revealed multimodal size distribution with 
positively skewed distribution except for the MP prepared with PVA 0.5%.  
The effect of PVA as emulsifier on particle size was also investigated on MP prepared 
from 40%C18-PGA-PEG-MIHA. However, due to limited amount of the 40%C18-PGA-
PEG-MIHA polymer, the effect of PVA concentration on particle size was only 
investigated in PVA 0.005% and PVA 2.5% (Figure 4.6).  
 
Figure 4.6. Effect of PVA concentration on the size of microparticles prepared from 
40%C18-PGA-PEG-MIHA. Emulsification method was used to prepare the 
microparticles. The mean diameter was taken from different batches of MP (n=3). 
Bars represent SEM. 
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Figure 4.6 shows the higher concentration of PVA in MP prepared from 40%C18-PGA-
PEG-MIHA produced a smaller diameter of MP. The size of particle prepared with 
PVA 0.005 % was 6 fold bigger than particle prepared with PVA 2.5%. Furthermore, a 
higher PVA concentration used to prepare MP from 40%C18-PGA-PEG-MIHA shifted 
the size distribution from negatively skewed bimodal curve to the normal distribution 
of particle (Figure 4.7).  
 
  
a b 
Figure 4.7. The particle size distributions of 40% C18-PGA-PEG-MIHA MP prepared 
using emulsification method with (a) 0.005%, (b) 2.5% of PVA.  
 
Comparing the effect of PVA concentration to particle size in 40%C18-PGA and 
40%C18-PGA-PEG-MIHA MPs, an increasing PVA concentration generated the fine 
particle size for MP prepared from 40%C18-PGA and 40%C18-PGA-PEG-MIHA (Figure 
4.8). The increasing PVA concentration contributed more impact to reduce particle 
size in 40%C18-PGA MP. By increasing PVA concentration to 2.5%, the 40%C18-PGA 
could generate particles with a diameter almost one tenth of that produced with PVA 
0.005%. However, increasing the PVA concentration from 0.005% to 2.5% in MP 
preparation from 40%C18-PGA-PEG-MIHA resulted in only reduced particle size to one 
sixth. 
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Figure 4.8. Effect of PVA concentration on size of microparticles made from 
modified PGA polymer. The mean diameter was taken from three different batches 
of MP except for MP prepared from 40%C18-PGA with PVA 2.5% (n=7). Bar 
represents SEM. 
 
4.3. Zeta Potential 
Zeta potential of empty microparticles from modified PGA polymer was determined 
in order to investigate the effects of acylation, PEG attachment and ligand 
attachment on MP properties. Empty particles were produced using the method 
described in Chapter 2 section 2.3.2.1 without any drugs encapsulated. Empty MP 
from unsubstituted PGA was produced as a reference to evaluate effect of polymer 
modification on zeta potential. Since the yield of MP produced from unsubstituted 
PGA was not sufficient and physically sticky, the other characterisations such as 
particle size, SEM image and encapsulation efficiency were not applied with 
unsubstituted PGA MP. 
83.0 
9.0 
33.6 
5.0 
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
100.00
0.005 2.5
M
e
an
 P
ar
ti
cl
e
 D
ia
m
e
te
r 
(µ
m
) 
PVA concentration (%) 
40%C18-PGA
40%C18-PGA-PEG-MIHA
 Chapter 4  Microparticle Preparation 
 
134 
 
Table 4.1 shows zeta potentials of modified PGA polymer in 1 mM HEPES buffer pH 7. 
The unsubstituted PGA MP exhibited negative zeta potential, which is related to the 
carboxyl group at the end of polymer chain. The 40% stearoyl substitution on 
pendant hydroxyl group of PGA backbone shifted the zeta potential of 40%C18-PGA 
MP to lower negative value than unsubstituted PGA MP, while 40%C18-PGA-PEG-
MIHA MP revealed a higher negative value of zeta potential compared to zeta 
potential of 40%C18-PGA MP.  
Table 4.1. Zeta potentials of modified PGA microparticles in 0.1 mM HEPES buffer 
pH 7. The measurement was taken from different batches of microparticles (n=3) 
Type of Microparticle Zeta potential (mV)±SD 
Unsubstituted PGA -27.2 ± 3.00 
40%C18-PGA -18.3 ± 1.60 
40%C18-PGA-PEG-MIHA -25.2 ±2.19 
40%C18-PGA-PEG-MIHA + collagen -20.1 ± 1.30 
 
Zeta potential relates to the electrical charge of MP in liquid systems. The zeta 
potential determined the potential difference between the surface of MP and the 
aqueous medium.  Therefore, attachment of collagen as a ligand on the surface of 
40%C18-PGA-PEG-MIHA resulted in a significant reduction in zeta potential of the MP 
compared to the MP without iminothiolane-modified collagen attachment (P < 0.05, 
n=3). 
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a) 40%C18-PGA MP 
 
b) 40%C18-PGA-PEG-MIHA MP 
 
Figure 4.9. Scanning Electron Microscope images of microparticles prepared from 
modified PGA polymer using emulsification method with PVA 2.5% as emulsifier. 
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4.4. Scanning Electron Microscope  Images 
Scanning electron microscope images were obtained to assess the shape of MP 
prepared from modified PGA polymers. The empty MP without drug were prepared 
using emulsification method with PVA 2.5% as surfactant. The MP prepared from 
both 40%C18-PGA and 40%C18-PGA-PEG-MIHA exhibited poly-dispersed particles with 
smooth surfaces and non-spherical shape. However, the 40%C18-PGA-PEG-MIHA MP 
showed a more homogenous and smaller size compared to 40%C18-PGA MP. Figure 
4.9 showed that aggregation had occurred in MP prepared from both polymers.  
4.5. Encapsulation Efficiency 
Dexamethasone phosphate (DXMP) and SIM were used as drug molecules to be 
incorporated within modified PGA MPs. In the initial studies, the double emulsion 
method was used to incorporate DXMP into modified PGA MP, while single emulsion 
method was used to generate modified PGA MP containing SIM. Poly(vinyl alcohol) 
(PVA) was used for emulsification in these processes. Several critical factors relating 
to encapsulation efficiency of drugs within MPs were investigated such as, volume 
ratio of inner phase (O/W) to perform primary emulsion, concentration of PVA as 
emulsifier and concentration of polymer in organic phase.  
The drug loading and encapsulation efficiency was determined using indirect and 
direct methods. The indirect method determined the amount of free drug in 
supernatant and the result was confirmed with a direct method. In the direct 
method, the drugs were extracted with appropriate solvent prior to analysis by HPLC.  
Validation of drug extraction is needed in order to obtain adequate data from direct 
method.  
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The extraction of DXMP from MP was carried out using various combinations of 
dichloromethane (DCM) and water as solvents as stated in Chapter 2, section 2.3.4.2. 
A known amount of DXMP was added to 40%C18-PGA polymer and homogenized. The 
DXMP was then extracted from the polymer using various combinations of DCM and 
water. The amount of DXMP extracted was determined using HPLC to calculate 
efficiency of extraction. The concentration of DXMP was calculated by plotting the 
peak area obtained to DXMP calibration curve in Figure 4.10. The water phase was 
also analysed to determine DXM, a possible degradation product of DXMP. The 
calibration curve of DXM is presented in Figure 4.11.  
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(A) 
 
(B) 
Figure 4.10. HPLC analysis of DXMP using 0.01 M KH2PO4 :MeOH (35:65) as eluent in 
isocratic mode. The Licrosphere 100 RP-18 column (5 µm) was used as stationary 
phase. DXMP was eluted at 3.1 minutes (A). DXMP calibration curve (B) was 
obtained by preparing a series of concentration of DXMP ranging from 0.4-100 
µg/ml in water. All samples are taken triplicate and averages calculated. Bars 
represent SD.  
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(A) 
 
(B) 
 
Figure 4.11. HPLC analysis of DXM using 0.01 M KH2PO4 :MeOH (35:65) as eluent in 
isocratic mode. The Licrosphere 100 RP-18 column (5 µm) was used as stationary 
phase. DXM was eluted at 6.6 minutes (A). DXM calibration curve (B) was obtained 
by preparing a series of concentration of DXM stock solution ranging from 0.4-100 
µg/ml in water. All samples are taken triplicate and averages calculated. Bars 
represent SD.  
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Table 4.2 presents the extraction efficiency of DXMP from modified PGA polymer 
using various combinations of DCM and water. The result showed 97.0± 1.64 % of 
DXMP could be recovered from 40%C18-PGA by extraction using DCM:water (1:4) 
which then became the standard method used.  
Table 4.2. Efficiency of extraction of DXMP from 40%C18-PGA polymer using various 
combination of dichloromethane and water (DCM:water). 
Sample  DXMP added Ratio DXMP recovered Recovery  Average Recovery  
Code  (µg) DCM: water (µg) (%) (%)± SD 
AS62-1 103 1 : 1 62.5 60.7 
 AS62-2 103 1 : 1 63.1 61.2 60.5±  0.83 
AS62-3 103 1 : 1 61.4 59.6 
 AS62-4 103 1 : 2 70.5 68.5 
 AS62-5 103 1 : 2 70.9 68.8 69.7 ± 1.89 
AS62-6 103 1 : 2 74.1 71.9 
 
AS62-7 103 1 : 4 98.3 95.4 
 AS62-8 103 1 : 4 99.9 96.9 97.0 ± 1.64 
AS62-9 103 1 : 4 101.7 98.7 
  
Method validation was also carried out for extraction of SIM from 40% C18-PGA MP. A 
known amount of SIM was mixed with 40%C18-PGA. The SIM was then extracted 
using various combinations of DCM and methanol as solvents. The amount of SIM 
extracted was determined by HPLC analysis and eluted at 4.4 minutes. The 
concentration of SIM obtained was plotted on the SIM calibration curve in Figure 
4.12. 
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(A) 
 
(B) 
 
Figure 4.12. HPLC analysis of SIM using 1 mM ammonium acetate pH 4.4 : MeOH 
(10:90) as eluent in isocratic mode. The Licrosphere 100 RP-18 column (5 µm) was 
used as stationary phase. SIM was eluted at 4.4 minutes (A). SIM calibration curve 
(B) was obtained by prepared series concentration of SIM ranging from 0.2-200 
µg/ml in MeOH. All samples are taken triplicate and averages calculated. Bars 
represent SD.  
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Table 4.3 shows that the highest extraction efficiency of SIM from 40%C18-PGA (96.11 
± 3.34 %) was obtained using a combination of DCM and methanol (DCM:MeOH) 1: 4.  
 
Table 4.3. Efficiency of extraction SIM from 40%C18-PGA polymer using various 
combination of dichloromethane and methanol (DCM:MeOH). 
Sample  SIM added  Ratio SIM  recovered Recovery  Average Recovery  
 Code (µg) DCM: MeOH (µg) (%) (%)± SD 
AS63-1 100.3 1 : 1 68.8 68.6 
 
AS63-2 100.3 1 : 1 64.1 63.9 68.3 ± 4.22 
AS63-3 100.3 1 : 1 72.6 72.4 
 
AS63-4 100.3 1 : 2 78.2 77.9 
 
AS63-5 100.3 1 : 2 80.2 79.9 77.6 ± 2.44 
AS63-6 100.3 1 : 2 75.3 75.1 
 
AS63-7 100.3 1 : 4 98.5 98.2 
 
AS63-8 100.3 1 : 4 98.2 97.9 96.1 ± 3.34 
AS63-9 100.3 1 : 4 92.5 92.3 
  
4.5.1. Effect of volume ratio of inner phase  
The effect of inner phase volume ratio on encapsulation efficiency was investigated 
in DXMP. Incorporation of DXMP into modified PGA polymer was carried out using 
double emulsion method with PVA 2.5% as emulsifier as described in Chapter 2 
section 2.3.2.2 ? /Ŷ ƚŚĞ ĚŽƵďůĞ ĞŵƵůƐŝŽŶ ŵĞƚŚŽĚ  ?t ?K ?t ? ? ƚŚĞ ƚĞƌŵ  “ŝŶŶĞƌ ƉŚĂƐĞ ?
was used to define the primary emulsion. The primary emulsion acts as a dispersed 
phase and undergoes secondary emulsion with the outer phase or continuous phase. 
The 1:200 and 1:20 inner volume ratio of water to organic (W/O) phase was used to 
make the primary emulsion. The result is shown in Figure 4.13 reveals  that the 1:200 
inner volume ratio established a higher encapsulation efficiency of DXMP in 40%C18-
PGA MP and 40%C18-PGA-PEG-MIHA MP with value 2.6 ± 0.40 % and 5.3 ± 0.10 %, 
respectively. However, the encapsulation efficiency of DXMP in 40%C18-PGA MP and 
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40%C18-PGA-PEG-MIHA MP was decreased to 0.9 ± 0.05 % and 3.6 ± 0.14 % when 
inner volume ratio was 1:20. The DXMP had higher encapsulation efficiency in 
40%C18-PGA-PEG-MIHA MP than in 40%C18-PGA MP and seems be related to the 
tethering of MIHA-PEG-NH2 linker on polymer backbone.   
 
Figure 4.13. Effect of inner phase volume ratio (W/O) ratio to encapsulation 
efficiency of dexamethasone phosphate (DXMP) in modified PGA microparticles. 
The initial drug loading is 1 mg per 100 mg polymer. Bars represent SD (n=3). 
 
4.5.2. Effect of drug on encapsulation efficiency 
 
Encapsulation efficiency within modified PGA polymer was also investigated using 
SIM as an encapsulated drug. SIM was incorporated within modified PGA MP using 
the single emulsion method with PVA 2.5% as emulsifier. Incorporation of SIM 
exhibited greater encapsulation than DXMP in 40%C18-PGA MP and 40%C18-PGA-PEG-
MIHA MP in the value 53.5 ± 6.13 % and 54.5 ± 4.83 %, respectively (Figure 4.14).  
The efficiency of encapsulation of SIM reached 25 and 10 times higher than DXMP in 
40%C18PGA and 40%C18-PGA-PEG-MIHA MPs, respectively.  
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Figure 4.14. Encapsulation efficiencies of DXMP and SIM into modified PGA 
microparticles. Incorporation of DXMP into the polymer was carried out in double 
emulsion method, while SIM was incorporated using single emulsion method. The 
1:200 and 1:20 W/O inner phase volume ratio were used to perform primary 
emulsion of DXMP. The initial drug loading is 1 mg per 100 mg polymer. Bars 
represent SD (n=3) 
 
Since establishing good incorporation, the effect of PVA concentration as emulsifier 
on encapsulation efficiency was studied in the MPs containing SIM. Due to limited 
amount of 40%C18-PGA-PEG-MIHA polymer, this study only investigated 40%C18-PGA 
polymer.  
4.5.3. Effect of PVA concentration 
Effect of PVA concentration on encapsulation efficiency was investigated using PVA 
0.25% and 0.5% with the former achieving the highest encapsulation efficiency as 
seen in Figure 4.15. 
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Figure 4.15. Encapsulation efficiency of simvastatin in 40%C18-PGA microparticle 
prepared using single emulsion method with PVA 0.25% and 0.5%. The initial drug 
loading is 1 mg per 100 mg polymer. The encapsulation efficiency was determined 
from different batches of microparticle. Bars represent SEM (n=9).  
 
4.5.4. Effect of polymer concentration in organic phase 
 
Encapsulation efficiency also was influenced by polymer concentration in organic 
phase used in preparation. Microparticle prepared from 0.5% polymer in organic 
phase achieved encapsulation efficiency 20.4± 0.11 %, while 5% polymer exhibited 
70.1 ± 12.81 % of encapsulation efficiency (Figure 4.16).  
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Figure 4.16. Encapsulation efficiency of simvastatin in 40%C18-PGA microparticles 
prepared using single emulsion method with PVA 0.25 %. The initial drug loading is 
1 mg per 100 mg polymer. The encapsulation efficiency was determined from 
different batches of microparticle. Bars represent SEM (n=9).  
 
4.6. Drug Release from Microparticles 
The release of drug from MP is influenced by the formulation. According to physical 
characterisation, the MPs prepared with PVA 2.5% met the size requirement for the 
incorporation into cell aggregates. The release studies were carried out for MP 
containing DXMP and SIM as active drugs. The sample and separate (SS) method was 
used to evaluate amount of drug release from microparticles as described in Chapter 
2 section 2.3.6. Phosphate buffer saline (PBS) was used as a release medium for MP 
containing DXMP, while 0.1% of Tween 20 was added to the release medium for MP 
containing SIM. 
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Polymer concentration in organic phase : 0.5%  
PVA concentration : 2.5%  
Initial drug loading : 10% 
MP yield (%) 
40% C18-PGA 
40% C18-PGA-PEG-MIHA 
 
:          
: 
 
52  
49 
Drug loading (%)±SD 
40% C18-PGA 
40% C18-PGA-PEG-MIHA 
 
: 
: 
 
0.3 ± 0.06  
0.4 ± 0.05 
Particle size (µm)±SD 
40% C18-PGA 
40% C18-PGA-PEG-MIHA 
 
: 
: 
 
7.2 ± 0.10  
5.6 ± 0.29  
Encapsulation Efficiency (%)±SD 
40% C18-PGA 
40% C18-PGA-PEG-MIHA 
 
: 
: 
 
2.9 ± 0.87 
3.6 ± 0.14 
 (A)  
  
Figure 4.17. DXMP release profile from modified PGA microparticles. The release 
study was established at 37°C using PBS as a medium for 21 days. Table (A) showed 
the specification of microparticles used for the study. Bars represent SD (n=3) 
 
The release profile from MP containing DXMP is presented in Figure 4.17. Almost 
10% of drug was released from 40%C18-PGA-PEG-MIHA MP containing DXMP, while 
the 40%C18-PGA MP only released around 8% of DXMP within the first day of study. 
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The release of drug was remained constant after day 1. The 40%C18-PGA-PEG-MIHA 
MP released higher amount of DXMP compared to 40%C18-PGA MP. On the 21st day 
of the release study no further DXMP was found to be released in the medium, 
therefore, the release study was terminated on day 21. Only 9.6± 0.73 % and 13.3± 
1.47 % of DXMP had been released from 40%C18-PGA and 40%C18-PGA-PEG-MIHA 
MPs after 21 days, respectively. 
A further investigation was conducted on the amount of DXMP that remained within 
the MP. The DXMP was extracted from MP and analysed using HPLC.  Around 56% 
and 37% of DXMP remained within 40%C18-PGA and 40%C18-PGA-PEG-MIHA MPs 
(Table 4.4). These data suggested that DXMP has a strong interaction within the 
modified PGA polymer. On the other hand, the lower amount of DXMP remaining in 
40%C18-PGA-PEG-MIHA MP indicated that attachment of MIHA-PEG-NH2 linker to 
40%C18-PGA could enhance the release of drug from modified PGA MP.  
 Table 4.4. DXMP released from and remaining in modified PGA MPs after 21-day 
release study (n=3). 
Type of microparticle 40%C18-PGA 40%C18PGA-PEG-MIHA 
Initial amount of DXMP per 10 mg MPs 
(µg) ± SD 
29.1 ± 0.32 36.3 ± 0.49 
DXMP released from MP 
(µg) ± SD 
2.7 ± 0.21 4.5 ± 0.47 
DXMP released from MP 
(%)± SD 
9.6 ± 0.73 13.3 ± 1.47 
DXMP remaining in MP 
(µg) ± SD 
16.4 ± 2.36 13.5 ± 1.28 
DXMP remaining in MP 
(%)± SD 
56.7 ± 8.56 37.2 ± 3.36 
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Polymer concentration in organic phase : 0.5%  
PVA concentration : 2.5%  
Initial drug loading : 10% 
MP yield (%) 
40% C18-PGA 
40% C18-PGA-PEG-MIHA 
 
: 
: 
 
56.7 
47.9 
Drug loading (%)±SD 
40% C18-PGA 
40% C18-PGA-PEG-MIHA 
 
: 
: 
 
4.8 ± 0.24  
4.7 ± 0.31 
Particle size (µm) ±SD 
40% C18-PGA 
40% C18-PGA-PEG-MIHA 
 
: 
: 
 
12.4 ± 1.54 
10.3 ± 0.24  
Encapsulation Efficiency (%)±SD 
40% C18-PGA 
40% C18-PGA-PEG-MIHA 
 
: 
: 
 
46.4 ± 2.32 
45.8 ± 2.99 
 (A)  
 
Figure 4.18. SIM release profile from modified PGA microparticles. The release 
study was established at 37 C using PBS+0.1% Tween 20 as a medium. Table (A) 
showed the specification of microparticles used for the study. Bars represent SD 
(n=3). 
 
The drug release profile was also investigated with MP containing SIM as active drug. 
The release profile is shown in Figure 4.18. A high amount of SIM was released from 
the MPs on the first day of experiment, around 90% of SIM had been released from 
40%C18-PGA MP, while 95% had been released from 40% C18-PGA-PEG-MIHA MP. The 
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SIM presented more rapid release from 40%C18-PGA-PEG-MIHA MP compare to 
40%C18-PGA MP. The release study was terminated at day 13 for 40%C18-PGA-PEG-
MIHA MP since no more SIM was detected in the medium. Conversely, the release of 
SIM from 40%C18-PGA continued up to 28 days of experiment. The remaining MPs 
were analyzed to determine amount of SIM remaining in MPs after release study. 
The signal of SIM was to low and not be able to detect with HPLC. 
The initial rapid release of drugs from modified PGA MPs would not be useful for 
extended release of bioactive molecule to encourage cell differentiation. The 
differentiation of cells involved several phases over the defined period of time. 
Hence, the MP should be able to retain drug for longer periods and deliver a 
moderately slow release of the drug. In addition, the rapid release of drug at the 
early period may induce toxic effects for the cells due to high concentration drug 
released directly to the cells. Most of initial rapid release, known as burst release, 
caused by diffusion of drug through the preformed water channels on MP [164]. The 
burst release from MP could be related to the nature of polymer itself or 
microparticle formulation. To identify this problem, the solid dispersions of SIM in 
modified PGA polymers were prepared and the release of SIM was investigated.   
4.6.1. Drug release from modified PGA solid dispersion 
The solid dispersions of modified PGA polymer with SIM was prepared using solvent 
evaporation method as stated in Chapter 2 section 2.3.5.2.  Figure 4.19 illustrates the 
release profile of SIM from modified PGA SDs. At the first day, only 24% of SIM had 
been released from 40%C18-PGA solid dispersion, while 36% of SIM had been 
released from 40%C18-PGA-PEG-MIHA solid dispersion. The SIM could be retained 
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within the solid dispersion up to 16 days in 40%C18-PGA solid dispersion and up to 18 
days in 40%C18-PGA-PEG-MIHA solid dispersion. The 40%C18-PGA-PEG-MIHA solid 
dispersion exhibited a higher drug release than 40%C18-PGA solid dispersion. The 
total SIM released from 40%C18-PGA and 40%C18-PGA-PEG-MIHA solid dispersion at 
the end of release studies were around 45% and 56%, respectively.  
 
Figure 4.19. SIM release profile from modified PGA solid dispersions. The solid 
dispersions were prepared using solvent evaporation method containing 1% (w/w) 
of SIM within 100 mg of modified PGA polymers. The release study was established 
at 37°C using PBS+0.1% Tween 20 as a medium (n=3). Bar represents SD. 
 
At the end of release study for the solid dispersions, the SIM was extracted to 
determine amount of drug retained within the polymer. Table 4.5 shows the 
summary of release study of modified PGA solid dispersions. Although the SIM 
released from solid dispersions are around 50%, it was found that the retained SIM 
within solid dispersions were less than 2% of the initial amount. It indicates that SIM 
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could not be completely extracted from the polymers due to strong interaction 
within polymers. It was also noticed that the initial high release of drug from 
modified PGA MPs seems to be mainly caused by its formulation.   
Table 4.5. SIM release from and remaining in modified PGA solid dispersions at the 
end of released study. The release study was carried out for 16 days on 40%C18-PGA 
and 18 days on 40%C18-PGA-PEG-MIHA (n=3) 
Type of solid dispersions 40%C18-PGA 40%C18PGA-PEG-MIHA 
Initial amount of SIM per 5 mg SDs  
(µg) ± SD 
42.7 ± 0.94 51.3 ± 4.45 
SIM released from solid dispersion 
(µg) ± SD 
19.5 ± 1.21 28.6 ± 3.74 
SIM released from solid dispersion 
(%)± SD 
45.4 ± 3.50 55.7 ± 5.23 
SIM remaining in solid dispersion 
(µg) ± SD 
0.7 ± 0.16 0.6 ± 0.11 
SIM remaining in solid dispersion 
(%)± SD 
1.8 ± 0.04 1.2 ± 0.14 
 
Several critical factors relating to MP formulation had previously been identified. 
According to Yeo and Park (2004), the burst release could be controlled by modifying 
polymer concentration and composition of continuous phase during MP preparation 
[164]. Hence, experiments had been established to evaluate effect of polymer 
concentration and PVA concentration in continuous phase on release profile of drug 
from modified PGA MPs. Since SIM showed good incorporation within modified PGA 
MP, further studies were carried out with the MP containing SIM. Due to limited 
amount of 40%C18-PGA-PEG-MIHA polymer, these two critical factors were 
investigated on 40%C18-PGA. 
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4.6.2. Effect of polymer concentration 
Effect of polymer concentration during preparation was studied with 40%C18-PGA 
prepared by emulsification method using PVA 0.25%. Figure 4.20 shows that the 
amount of drug released was affected by polymer concentration in the organic 
phase.   Initial burst released still occurred in both concentrations of polymer. At day 
one, MP prepared from 0.5% and 5% polymer concentration released 86.3 % and 
78.2 % of SIM, respectively. The increasing polymer concentration did not affect the 
initial amount of drug release from MP at the first day of experiment (P >0.05, n=3). 
However, the 5% polymer concentration exhibited lower amount of drug release 
than 0.5% polymer concentration after 14 days of experiment (P<0.05, n=3).  
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Polymer concentration in organic phase  0.5% 5% 
PVA concentration (%) : 0.25 0.25 
Initial drug loading (%) : 1 1 
MP yield (%) : 55.0 60.1 
Drug loading (%)± SD : 0.2 ± 0.01 0.7 ± 0.0 
Particle size (µm)± SD : 10.2 ± 0.49 21.8 ± 0.15 
Encapsulation Efficiency (%)± SD : 20.4 ± 0.11 70.1 ± 1.28 
 (A)   
 
Figure 4.20. The release profiles of SIM from 40%C18-PGA microparticles. 
Microparticles were prepared using emulsification method with PVA 0.25% as 
emulsifier (table A). Two concentration of polymer in organic phase were used in 
formulation, 0.5% and 5%. The release study was established in PBS+0.1% at 37°C. 
Bars represent SD (n=3). 
 
Amount of SIM remaining in MP after 14 days of study was analysed and the result 
are presented in Table 4.6 showing 2.1 ± 0.29 % of SIM remained in 40%C18-PGA MP 
while 5.9 ± 0.16 % was remained in 40%C18-PGA-PEG-MIHA MP. The higher polymer 
concentration seems to provide stronger interaction with SIM as it retained more 
drug inside the MP.  
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Table 4.6. SIM released from and remaining in 40%C18-PGA MPs prepared from 
0.5% and 5% polymer in organic phase after 14-day release study 
Concentration of polymer  0.5% 5% 
Initial amount of SIM per 5 mg MPs  
(µg) ± SD 
16.2 ± 0.37 34.9 ± 0.99 
SIM released from MP 
(µg) ± SD 
15.4 ± 0.61 27.8 ± 0.05 
SIM released from MP 
(%)± SD 
93.8 ± 4.61 79.9 ± 3.03 
SIM remaining in MP 
(µg) ± SD 
0.2 ± 0.16 2.1 ± 0.08 
SIM remaining in MP 
(%)± SD* 
2.1 ± 0.29 5.9 ± 0.16 
 
4.6.3. Effect of PVA concentration 
Effect of PVA concentration on drug release was investigated in MP prepared from 
0.5 % and 5 % polymer. Figure 4.21 describes the release profile of SIM from MP 
prepared with 0.5% polymer concentration. Based on the Figure 4.21, the difference 
in PVA concentration did not affect the total amount of drug released from MPs 
(P>0.05, n=3). Although the MP prepared with PVA 0.25% exhibited lower drug 
release at the beginning, there was no significant difference between the MP 
prepared with PVA 0.25% and PVA 0.5% (P>0.05, n=3). This result also applied to the 
total amount of SIM released from microparticles at the end of the study (Table 4.7).  
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Polymer concentration in organic phase  0.5% 
PVA concentration (%) : 0.25 0.5 
Initial drug loading (%) : 1 1 
MP yield (%) : 54.2 45.0 
Drug Loading (%)±SD : 0.2 ± 0.01 0.3 ± 0.03 
Particle size (µm)±SD : 25.1 ± 0.67 20.1 ± 1.15 
Encapsulation Efficiency (%)±SD : 20.4 ± 0.11 31.3 ± 1.31 
 (A)   
 
Figure 4.21. The release profiles of SIM from 40%C18-PGA microparticles. 
Microparticles were prepared using emulsification method with 0.5 % polymer 
concentration. Two concentrations of PVA, 0.25% and 0.5%, were used in 
formulation (A). The released study was established in PBS+0.1% tween 20 at 37°C. 
Bars represent SD (n=3). 
Table 4.7. SIM released from and remaining in 40%C18-PGA MPs prepared from 
0.5% polymer in organic phase with PVA 0.25 and 0.5% after 21-day release study 
Concentration of PVA 0.25% 0.5% 
Initial amount of SIM per 5 mg MPs 
(µg) ± SD 
11.2 ± 0.25 18.5 ± 0.74 
SIM released from MP 
(µg) ± SD 
10.9 ± 0.33 17.9 ± 0.45 
SIM released from MP 
(%)± SD 
95.8 ± 4.65 96.4 ± 1.50 
SIM remaining in MP 
(µg) ± SD 
0.2± 0.06 0.7 ± 0.06 
SIM remaining in MP 
(%)± SD 
1.9 ± 0.16 3.6 ± 0.19 
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The effect of PVA concentration on drug release from MP was also investigated in MP 
prepared from 5% polymer concentration in organic solvent. Various concentrations 
of PVA were used to prepare MP from 40%C18-PGA. The release profile of MP 
prepared with 5% polymer and various concentration of PVA is shown in Figure 4.22. 
It can be clearly seen that PVA concentration above 0.005% influenced the release of 
SIM from the MPs. There was no significant difference of drug release from MP 
prepared without PVA and with PVA 0.005% (P>0.05, n=3). On the first day of release 
study, the MP prepared with 0.005% released 47.8 ± 5.04% of SIM, while increasing 
PVA to 0.05% could increase release to 57.9 ± 1.68 % of SIM. Further increases in PVA 
concentration to 0.25% increased the drug release up to 78.2 ± 2.79 % at the first day 
of study.   
 
Figure 4.22. The release profiles of SIM from 40%C18-PGA microparticles. 
Microparticles were prepared using emulsification method with 5 % polymer 
concentration with and without PVA. Various concentration of PVA were used in 
the formulation. The release study was established in PBS+0.1% tween 20 at 37°C. 
Bars represent SD (n=3). 
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Table 4.8. SIM released from and remaining in 40%C18-PGA MP prepared with 
various concentration of PVA. Emulsification method was used to prepare MP with 
PVA while solvent displacement method was used to prepare MP without PVA. 
 PVA concentration (%) 
 0 0.005 0.05 0.25 
MP yield (%) 
Initial amount of SIM 
per 5 mg MPs (µg) ± SD 
52.1 
32.5 ± 0.03 
45.1 
30.0 ± 0.66 
57.1 
30.9 ± 1.43 
50.1 
34.9 ± 0.99 
SIM released from MP 
(µg) ± SD 
17.3 ± 0.43 14.6 ± 1.69 17.7 ± 1.27 27.8 ± 0.05 
SIM released from MP 
(%)± SD 
50.7 ± 4.62 48.6 ± 4.49 57.8 ± 1.68 79.9 ± 3.03 
SIM remaining in MP 
(µg) ± SD 
0.6 ± 0.01 0.5 ± 0.14 0.6 ± 0.03 0.7 ± 0.08 
SIM remaining in MP 
(%)± SD 
1.70 ± 0.19 1.7 ± 0.50 1.9± 0.18 2.1 ± 0.29 
 
The remaining MP were then analysed to determine amount of SIM retained inside 
MP after release study.  It is seen from Table 4.8 that only a small amount of SIM 
(<2%) could be extracted from MP. The result was surprising since the amount of SIM 
released was around 50%. It was supposed that around 50% should be retained in 
MPs. Amount of SIM could be extracted is related to the PVA concentration during 
MPs formulation. A higher PVA concentration generated a higher amount of SIM 
could be extracted from MPs, i.e. 1.70, 1.71, 1.97, 2.11 % for MP prepared without 
PVA, with 0.005%, 0.05%, and 0.25% PVA respectively.  
4.7. Ligand Attachment to Microparticles 
Collagen was attached to MP prepared from 40%C18-PGA-PEG-MIHA as a ligand to 
encourage cell attachment. Collagen had been modified with iminothiolane and FITC 
as described in Chapter 2, section 2.3.7. The thiol group on collagen molecule 
attached to maleimide active group on 40%C18-PGA-PEG-MIHA MP via covalent 
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bonding. The amount of collagen attached to the MP was determined by 
fluorescence intensity of collagen.  
 
 
Figure 4.23. Reaction scheme of iminothiolane-modified collagen attached to 
40%C18-PGA-PEG-MIHA MP. 
 
Reaction between 40%C18-PGA-PEG-MIHA MP and iminothiolane-modified collagen is 
illustrated in Figure 4.23. In order to evaluate the specific bond of thiol with 
maleimide group on 40%C18-PGA-PEG-MIHA MP, various amounts of iminothiolane-
modified collagen was added to the MP (5 mg).  
The amount of iminothiolane-modified collagen attached to MP was determined by 
measuring fluorescence intensity of FITC in attached MP. The FITC calibration curve 
as presented in Figure 4.24 was used to determine the amount of FITC attached to 
MP.  Since the ratio of FITC to the iminothiolane-modified collagen was known, the 
amount collagen attached to the MP could be calculated.  
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Figure 4.24. FITC calibration curve in phosphate buffer saline. A range of 
concentrations of FITC from 1.6  ? 100 ng/ml was prepared from FITC 1 mg/ml stock 
solution in acetone. Fluorescence intensity was measured using fluorescence 
ƐƉĞĐƚƌŽƉŚŽƚŽŵĞƚĞƌ Ăƚ ʄexc ŽĨ  ? ? ? Ŷŵ ĂŶĚ ʄemm of 521 nm. All samples are taken 
triplicate and averages are calculated. 
 
 
Figure 4.25. Iminothiolane-modified collagen attached to 40%C18-PGA-PEG-MIHA 
MP. Amount of collagen attached was determined by measuring fluorescence 
intensity of FITC attached to collagen. FITC was attached to the collagen in ratio 1.6 
: 1 (FITC : collagen). All samples are taken triplicate and averages are calculated. 
Bars represent SD (n=3).  
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The amount of iminothiolane-modified collagen attached to the MP is presented in 
Figure 4.25. The amount of iminothiolane-modified collagen attached to the MP was 
increased proportionally with amount of collagen added and reached a plateau at 1.6 
nmol of iminothiolane-modified collagen added. It demonstrated that all active 
maleimide groups on 40%C18-PGA-PEG-MIHA MP had reacted with thiol active group 
on iminothiolane-modified collagen molecule and became saturated. Therefore, it is 
probably related to the specific covalent bond between thiol group and maleimide. 
Further addition of iminothiolane-modified collagen would not be able to attach on 
the surface of 40%C18-PGA-PEG-MIHA MP. The highest efficiency of iminothiolane-
modified collagen attachment was achieved when 0.2 nmol collagen added to 5 mg 
of microparticle (Table 4.9). Although higher amounts of collagen attached to MP 
could be achieved with increasing amount of collagen added, the efficiency of 
attachment became lower.  
Table 4.9. Efficiency of iminothiolane-modified collagen attachment to 40%C18-
PGA-PEG-MIHA microparticle in phosphate buffer saline medium pH 7.2 (n=3). 
Collagen 
added 
(nmol) 
MP 
(mg) 
FITC attached 
to MP 
(ng/ml) )±SD 
FITC attached 
to MP 
(nmol)±SD 
Collagen 
attached to MP  
(nmol)±SD 
Efficiency of 
Attachment 
(%)±SD 
0.1 5 15.7 ±1.41 0.04 ±0.004 0.03 ±0.002 25.0 ± 2.24 
0.2 5 35.8 ±0.68 0.09 ±0.004 0.06 ±0.003 28.5 ± 1.33 
0.4 5 46.9 ±0.40 0.12 ±0.001 0.07 ±0.001 16.4 ± 3.92 
0.8 5 72.4 ±6.99 0.19 ±0.018 0.11 ±0.011 14.4 ± 1.39 
1.6 5 83.4 ±5.54 0.21 ±0.014 0.13 ±0.009 7.7 ± 1.13 
 
Further investigation was conducted to evaluate the possibility of physical absorption 
of iminothiolane-modified collagen attachment to MP. A defined amount of 
iminothiolane-modified collagen was added to 40%C18-PGA MP as well as to 40%C18-
PGA-PEG-MIHA. Figure 4.26 illustrates amount of iminothiolane-modified collagen 
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attached to 40%C18-PGA MP and 40%C18-PGA-PEG-MIHA MP after purification step to 
remove unbound collagen. It showed that there was some iminothiolane-modified 
collagen which could be strongly adsorbed to 40%C18-PGA MP. However, the amount 
of collagen adsorbed was less than half the amount of specifically attached to 
40%C18-PGA-PEG-MIHA MP.  
 
Figure 4.26. Iminothiolane-modified collagen adsorbed and attached to 40%C18-
PGA and 40%C18-PGA-PEG-MIHA microparticles. Amount of collagen adsorbed or 
attached to microparticles was determined by fluorescence intensity of FITC on 
collagen molecule. Bars represent SD (n=3).  
 
4.8. Discussion 
4.8.1. Characterisation of microparticles 
Several critical factors have been investigated relating to physical characteristics of 
MP, encapsulation efficiency and release of drug from MP. According to this study, 
the size of MP was influenced by type of polymer, homogenizer speed and 
concentration of PVA used as emulsifier in continuous phase. The MP prepared from 
40%C18-PGA-PEG-MIHA exhibited a smaller particle size compared to MP prepared 
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from 40%C18-PGA. This phenomenon could be explained by two possibilities. First, 
the attachment of MIHA-PEG-NH2 linker to 40%C18-PGA could reduce the aggregation 
of polymer. It could occur due to formation of steric hindrance around the MP in the 
presencĞ ŽĨ W' ? dŚĞ ƐƚĞƌŝĐ ŚŝŶĚƌĂŶĐĞ ĐŽƵůĚ ĂĐƚ ĂƐ Ă  “ĐŽŶĨŽƌŵĂƚŝŽŶĂů ĐůŽƵĚ ? ƚŽ
prevent MP interactions with each other [133, 173]. Another possibility is that the 
presence of PEG increases the solubility of polymer in aqueous media as mentioned 
in literature [133]. The increasing solubility of 40%C18-PEG-MIHA polymer in aqueous 
phase facilitated the formation of finer emulsion droplets hence reducing the size of 
particle. Moreover, the presence of PEG acts as a surfactant to stabilize emulsion 
droplets [174, 175]. This result seems to be similar with the other studies by Lee et al 
(2005) showing that the presence of PEG in peptide nanoparticles reduced the size of 
particle prepared by emulsification method [174, 176].  
The particle size in both 40%C18-PGA and 40%C18-PGA-PEG-MIHA MPs was affected 
by homogenization speed during emulsification. Increasing the speed of stirrer to 
13,000 rpm gave the size reduction on of particle related to formation of a finer 
emulsion [172]. A relationship between homogenisation speed and particle size had 
been investigated by Sansdrap and Moes (1993) [167]. According to this study, 
increasing stirring speed provides high energy to reduce interfacial tension between 
organic and aqueous solvent during emulsification process.  Therefore, the 
interaction between two phases could be maximised to produce small droplets 
leading to small particle size. In addition, increasing stirrer speed also accelerates 
translational movement of surfactant on the aqueous-organic interface to perform 
particle in emulsion system  [177].  
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As mentioned in the literature, the size of MP could be influenced by variation of 
emulsifier concentration during MP formation. Increasing emulsifier concentration is 
commonly related to the reduction of particle size [167, 172, 174, 177]. Contrary to 
this expectation, the addition of PVA as emulsifier at concentration 0.005% and 
0.025% resulted in the larger particle size than the MP prepared without emulsifier. 
The solvent displacement method was used to prepare the MP without emulsifier. 
According to this finding, it can be seen that solvent displacement method could 
produce a smaller particle size compared to emulsification method even without 
emulsifier.  
The unexpected result was shown with PVA 0.005% and 0.025%.  Increasing PVA 
concentration from 0.005% to 0.025% resulted in the formation of a bigger particle.   
According Lee et al (1999), the size of particles is influenced by amount of PVA per 
specific surface area of particle. However, the increased PVA concentration in 
continuous phase might not change the surface of PVA density, particularly in larger 
particle [178]. Therefore, the 5 fold increasing of PVA concentration in the 
continuous phase might not affect particle size. 
Further increases in PVA concentration during MP preparation, not only reduce 
particle size but also influence the particle size distribution. This may arise due to the 
PVA reducing surface tension between organic and aqueous medium to perform 
emulsion droplet,  resulting in small particle [167]. Although the PVA 0.25% seems to 
produce larger particles compared to PVA 0.05%, there was no overall significant 
difference on particle size (p > 0.05, n=3). The distribution of particles was shifted 
from negatively skewed distribution to positively skewed distribution, indicating that 
 Chapter 4  Microparticle Preparation 
 
165 
 
more fine microparticles were formed with increasing emulsifier concentration. This 
result also applied for MP prepared from 40%C18-PGA-PEG-MIHA.   
The zeta potentials of MPs are affected by the modification of PGA backbone. The 
unsubstituted PGA demonstrated negative zeta potential and is related to carboxyl 
group at the end of polymer [125, 179]. The acylation using stearoyl (C18) on PGA 
backbone shifted the zeta potential to a low negative value. However, this result was 
the opposite of the effect of acylation on PGA polymer made in nanoparticles 
described in previous research by Kallinteri et al (2005) and Puri et al (2008) [125, 
180] where an increase in zeta potential was seen. The difference in the method of 
preparation between nanoparticle and MP might influence the zeta potential value. 
Interfacial deposition method (IDP) was used to perform nanoparticle in Kallinteri et 
al (2005), while the emulsification method was used to prepare MP in this study. The 
method of nano or MP preparation would affect the structural rearrangement within 
the particle, therefore influenced the surface charge of MP.   
The attachment of MIHA-PEG linker shifted the zeta potential to the higher negative 
value. The zeta potential of 40%C18-PGA-PEG-MIHA MP is -25.2± 2.19, while 40%C18-
PGA revealed -18.3 ± 1.60.  According to previous studies, attachment of PEG or PEG 
coating to particle would be able to bring zeta potential to lower negative value [181-
183] since carboxyl group was reacted with PEG molecules resulted in charge 
neutralization and steric effect of PEG.  In contrast with earlier findings, the 
attachment of MIHA-PEG linker in this study increases the negative value of zeta 
potential.  
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The 40%C18-PGA-PEG-MIHA MP decorated with iminothiolane-modified collagen led 
to a lower negative zeta potential value.  Since collagen molecule contains a net 
positive charge, the zeta potential of the MP was shifting to the positive direction 
[179]. This result also indicated that MP is well covered with iminothiolane-modified 
collagen.   
Scanning electron microscope images illustrated that a smooth surface of MP had 
been obtained. It is seen that both types of MP form non-spherical shape. The 
40%C18-PGA-PEG-MIHA MP were small and more homogenous in size of particle. This 
finding supported the result for particle size and size distribution in Figure 4.1 and 
Figure 4.2.  
4.8.2. Encapsulation Efficiency of Microparticles 
The encapsulation efficiency was determined by both indirect methods. The indirect 
method determined amount of free drug in supernatant, but could not determine 
the exact amount of drug incorporated within the microparticle, so the direct 
method was developed for this study.  
The substituted PGA polymer has a good solubility in dichloromethane (DCM) while 
DXMP was soluble in water. Several ratios between DCM and water were applied to 
get optimum extraction of DXMP from modified PGA polymer. The 97 % recovery of 
DXMP could be obtained using solvent combination DCM : water (1:4). One part of 
DCM was used to dissolve the modified PGA polymer then 4 part of water was added 
to dissolve DXMP. The water phase was analysed using HPLC while the organic phase 
was diluted with methanol to obtained dexamethasone (DXM) which is the 
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degradation product of DXMP [184]. The method of DXMP determination using HPLC 
was adopted from Puri. S (2007) [184]. The total concentration of DXMP is the 
concentration of DXMP in water phase and the dexamethasone concentration in 
organic phase. 
A similar method was applied to extract SIM from modified PGA polymer. Due to high 
solubility in methanol, SIM was extracted using methanol. The 96.1 % SIM was 
recovered by extraction using a combination of DCM:methanol (1:4). The method for 
SIM determination using HPLC was adopted from Qutachi (2012) [185]. 
Dexamethasone phosphate (DXMP) was encapsulated within modified PGA polymer 
using double emulsion method. This method was applied to encapsulated hydrophilic 
drugs as described in Tewes et al (2007) [88]. Two variations of inner phase (W/O) 
volume ratio were investigated to obtain the high encapsulation efficiency. The 
highest encapsulation efficiency was obtained in lower inner phase ratio (1:200 of 
water in organic). The strong relationship between ratio inner phase and 
encapsulation efficiency for hydrophilic drug had been reported by Liu (2006) [186]. 
In this research, the small volume of water as inner phase increased the 
encapsulation efficiency of insulin within poly(lactic acid)-poly(lactic glycolic acid) 
(PLA-PLGA) microparticle. The observed increase in DXMP encapsulation within 
modified PGA microparticles could be attributed to lower volume of aqueous inner 
phase. By using small volume of inner phase, the loss of drug during coalescence 
process with outer phase could be prevented [187]. Figure 4.14 also showed the 
encapsulation efficiency of DXMP was influenced by properties of polymer. The 
40%C18-PGA-PEG-MIHA MP exhibited a higher encapsulation efficiency of DXMP due 
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to presence of PEG as a hydrophilic linker.  The presence of hydrophilic linker might 
increase precipitation and solidification rate of MP during preparation, hence 
improving encapsulation efficiency of drug. In addition, the presence of PEG could 
stabilize primary emulsion  increasing encapsulation efficiency of DXMP [164].   
Due to the lower encapsulation efficiency of DXMP into modified PGA MP, the 
encapsulation efficiency of SIM was investigated. SIM as an alternative active drug 
for inducing osteogenic formation was encapsulated within the MPs. A single 
emulsion method was used to prepare MP containing SIM. The interesting finding 
was that SIM had good incorporation within modified PGA polymers. The 
encapsulation efficiency of SIM within MP reached more than 50% in both 40%C18-
PGA and 40%C18-PGA-PEG-MIHA MP. It is suggested that the encapsulation efficiency 
was also influenced by properties of encapsulated drug. Figure 4.27  illustrates that 
both DXMP and SIM had hydrophobic rings which could possibly interact with the 
stearoyl group in 40% stearoyl substituted PGA. As mentioned in several literatures, 
SIM has a higher log P compare to DXMP which is related to its hydrophobicity [188-
192]. Based on this result, it is suggested that the high encapsulation efficiency of 
SIM within PGA microparticles was associated with hydrophobic interaction between 
modified PGA polymers with drug.  
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Figure 4.27. Chemical structure and Log P of DXMP (a) and SIM (b). 
 
Beside the chemical properties of encapsulated drug, the encapsulation efficiency 
was influenced by concentration of emulsifier used during MP preparation. The MP 
preparation using PVA 0.25% exhibited a higher encapsulation efficiency of SIM 
within 40%C18-PGA than PVA 0.5%. The effective PVA concentration has been 
reported by Feczko (2008) for encapsulation of bovine serum albumin (BSA) using 
double emulsion method. This study reported that the optimum PVA concentration 
to obtain the highest encapsulation efficiency of BSA is in the range 1-2%. Further 
increase in PVA concentration will decrease the encapsulation efficiency of BSA 
[193]. Other studies also reported that high emulsifier concentration is needed to 
stabilize the emulsion and obtained high encapsulation efficiency of BSA [164]. In 
contrast with two previous findings, the encapsulation of SIM was decreased with 
increasing PVA as emulsifier. It might be related to hydrophobicity of SIM. Since the  
 Chapter 4  Microparticle Preparation 
 
170 
 
concentration of PVA increased, it would facilitate SIM to diffuse rapidly to the outer 
phase leading to lower encapsulation of SIM inside the microparticle.  
The polymer concentration in organic phase also played an important role in 
encapsulation efficiency. As illustrated in Figure 4.16, the encapsulation efficiency 
increased more than 3 times when the polymer concentration in organic phase 
increased from 0.5 to 5 %. This present finding seems to be consistent with other 
research by Mehta et al (1996) which found that peptide incorporation increased 
from 53% to 71% with increasing polymer concentration from 20% to 32.5% [194].  It 
is related to the high viscosity of polymer in organic solvent leading to a rapid 
solidification of polymer to form MP [164].  
4.8.3. Drug Release from Microparticles 
The release study  from MP  containing DXMP showed less than 14% DXMP had been 
released from 40%C18-PGA and 40%C18-PGA-PEG-MIHA MP. More than 50% of DXMP 
was retained in 40%C18-PGA MP and around 37% of DXMP was retained in 40%C18-
PGA-PEG-MIHA MP after 21 days release experiments. The stearoyl substitution in 
PGA polymer backbone might interact strongly with DXMP and prevent drug 
diffusion from MP. In previous study by Puri et al (2008) it was shown that increasing 
percentage of caprylic (C8) substitution in PGA polymer would reduce burst release of 
DXMP due to strong interaction between DXMP and caprylic group in modified PGA 
polymer [180]. The strong interaction seems to have occurred between DXMP and 
stearoyl in substituted PGA polymer leading to high amount of DXMP retained in 
microparticle. However, MIHA-PEG-NH2 linker attachment to modified PGA polymer 
showed a little enhancement of DXMP diffusion from MP as described in Table 4.4 
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An initial rapid release occurred in MP containing SIM. According to encapsulation 
efficiency, SIM interacts very well with modified PGA polymer and so burst release 
should not happen. This unexpected finding might be related to formulation of MP, 
hence the release study of SIM from solid dispersion was investigated. In solid 
dispersion, some critical factors in MP preparation such as polymer concentration 
and emulsifier were eliminated. Therefore, release of drug from polymer was mainly 
influenced by drug and polymer interaction.  
The SIM was released slowly from solid dispersions and could be maintained up to 16 
and 18 days in 40%C18-PGA and 40%C18-PGA-PEG-MIHA polymer, respectively. There 
was no burst release of SIM released from solid dispersions. However, only a low 
amount of SIM could be extracted from solid dispersions and the mass balance of 
SIM in solid dispersions was incomplete. Around 50% of SIM was released from the 
solid dispersions by the end of release study, but only less than 2% of SIM was 
remained in the polymers. It is hypothesised that SIM interacted strongly with the 
polymer and was not fully extracted from solid dispersions using DCM:MeOH (1:4).  
According to this hypothesis, the burst release of SIM from modified PGA MP was 
related to MP formulation. Yeo et al (2004) described that the reason of initial burst 
release cause by diffusion of drug through preformed water channel and related to 
solidification rate of dispersed phase during particle preparation. These factors 
related to molecular weight of polymer, hydrophilicity of polymer, drug loading, 
polymer concentration and PVA concentration in continuous phase [164].  
The initial rapid release of SIM still occurred in 0.5% and 5% polymer concentration. 
However, MP prepared with 5% polymer concentration had a lower of total amount 
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of SIM released. The higher polymer concentration related to rapid solidification rate 
and high viscosity of polymer that could inhibit the drug diffusion from the matrix 
[164, 195]. The initial rapid release on the MP might be related to PVA as emulsifier 
in microparticle preparation.  
Effect of PVA concentration in continuous phase was investigated in MP prepared 
with 0.5% and 5% polymer concentration. There was no significant difference 
(P>0.05, n=3) in release profile between PVA 0.25% and 0.5% prepared with 0.5% 
polymer concentration. Both of them showed rapid initial release (around 90%) at 
the first day.  
In contrast, PVA concentration had a significant influence on SIM release from MP 
prepared with 5% polymer concentration. As illustrated in Figure 4.22, reducing PVA 
concentration could decrease initial release of SIM from MP prepared from 5% 
polymer concentration. The PVA as emulsifier might be entrapped within the 
microparticles, then, increasing of PVA concentration would enhance drug diffusion 
from MP and drug solubility in medium. This finding is in contrast to a previous 
finding by Mao et al (2007) where increasing PVA concentration is related to a 
reduced burst release in PLGA microparticle prepared with double emulsion 
technique. According to this study, increasing the PVA concentration could stabilize 
emulsion droplets that avoid mass drug transfer to the medium [195]. However, this 
explanation assumed that the PVA is located on the surface of MP, hence the 
diffusion of drug could be restricted by increasing viscosity of medium related to PVA 
concentration. Moreover, the different method of MP preparation investigated in 
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this research (single emulsion) and previous research (double emulsion) might 
influence the result obtained.  
The concentration of PVA also influenced the extraction of SIM from MPs. As seen in 
Table 4.8, the amount of SIM could be extracted from modified PGA MPs prepared 
with various PVA concentrations are under 2%. However, there is a correlation 
between PVA concentration and amount of drug retained in MPs. Since the 
determination process involved SIM extraction from MPs, increasing concentration of 
PVA during MPs preparation would increase the SIM extracted from MPs. It is related 
to the increasing drug solubility in medium during extraction process due to addition 
of PVA in MPs formulation.    
4.8.4. Ligand Attachment to Microparticles 
Iminothiolane-modified collagen showed specific covalent attachment with 40%C18-
PGA-PEG-MIHA MP. The thiol group in modified collagen was attached to MP via 
maleimide group provided on polymer. In this study, the reaction was carried out in 
PBS buffer pH 7.2. According to Hermanson (2008), specific reaction between 
maleimide with sulfhydhryl group proceeds in pH range 6.5-7.5. In this reaction, one 
of the carbons in near the maleimide double bond is attacked with thiolate anion 
leading to the disappearance of maleimide double bond after sulfhydhryl addition  
[150]. As illustrated in Figure 4.25, as the amount of modified collagen increased, the 
amount of collagen attached also increased. However, the amount of collagen 
attached to microparticle reached a maximum suggesting that the maleimide group 
had been saturated with thiol group from modified collagen.  
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However, non-specific attachment of iminothiolane-modified collagen on 40%C18-
PGA MP was found. In 40%C18-PGA MP, iminothiolane-modified collagen was 
attached to MP at around around 40% lower than amount attached to 40%C18-PGA-
PEG-MIHA MP. The non-specific attachment of protein on the surface of the MP was 
also found in maleimide-functionalized-poly(ethylene glycol)-poly(caprolactone) 
nanoparticle decorated with bovine serum albumin (BSA). Gindy et al (2008) 
reported in their study that BSA could be attached to non-functionalized 
poly(caprolactone) nanoparticle at approximately 15% lower than BSA attached to 
functionalized poly(caprolactone) nanoparticle. The research by Gindy et al.,(2008) 
was carried out in sodium chloride (NaCl) containing ethylene diamine tetraacetic 
acid (EDTA) pH 6.2-6.5 with efficiency of BSA attachment around 22% [196].  
According to the result in Table 4.9, the efficiency of collagen attachment to 40%C18-
PGA-PEG-MIHA MP could reach 28% using PBS pH 7.2 as medium for reaction.  
4.9. Conclusion 
 
The MP has been prepared using two types of modified PGA polymers:  40%C18-PGA 
and 40%C18-PGA-PEG-MIHA. Physical characterisations including particle size, 
morphology, zeta potential, encapsulation efficiency as well as the release profile of 
drugs from microparticle have been investigated. In addition, the ability of 40%C18-
PGA-PEG-MIHA microparticle to bear maleimide functional group for ligand 
attachment had been successfully evaluated. However, the success of MP 
preparation is influenced by several critical factors during formulation process. 
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The attachment of MIHA-PEG-NH2 linker to 40%C18-PGA affected the particle size and 
size distribution of particle. Moreover, the speed of homogenisation needs to be 
controlled to achieve desirable size. The concentration of emulsifier such as PVA in 
continuous phase also affected the particle size. A higher of PVA concentration in 
continuous phase gave finer particle and better size of distribution. The increasing of 
PVA concentration in continuous phase had greater effect on size for MP prepared 
from 40%C18-PGA.  
The stearoyl substitution and MIHA-PEG-NH2 linker attachment in PGA polymer 
backbone affected zeta potential value of formed MPs. The 40% stearoyl substitution 
decrease the zeta potential  of MP to the lower negative value, however, further 
attachment with MIHA-PEG-NH2 linker increase the zeta potential of MP to the 
higher negative value. The attachment of iminothiloane-modified collagen to 40%C18-
PGA-PEG-MIHA MP slightly changed the zeta potential of MP to lower negative value 
due to overall charge on the collagen molecule. 
The volume ratio of inner phase for DXMP incorporation influenced the 
encapsulation efficiency. Reducing volume ratio of inner phase (W/O) from 1/20 to 
1/200 increased the DXMP encapsulation efficiency in both 40%C18-PGA and 40%C18-
PGA-PEG-MIHA MP as the small volume of soluble drug in water-inner phase 
prevented the loss of drug during coalescence process with outer phase. However, 
the interaction between polymer and drug also influenced the encapsulation 
efficiency. The modified PGA polymers showed a better interaction with SIM, 
indicated by a higher encapsulation efficiency of SIM within the MP. The 
encapsulation efficiency is also influenced by PVA concentration in continuous phase 
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and polymer concentration. In this study, a high PVA concentration would decrease 
SIM incorporation within MP while increasing polymer concentration in organic 
phase increase the encapsulation efficiency of SIM. 
The release of drug from modified PGA MP strongly influenced by formulation 
process such as polymer concentration and PVA concentration in continuous phase. 
The modified PGA polymers themselves had ability to release drug slowly in 
controlled manner. The MP prepared from 5% polymer concentration had a lower 
diffusion of drug from MP than MP prepared from 0.5% polymer concentration. In 
addition, an increased PVA concentration in continuous phase during microparticle 
preparation encouraged rapid diffusion of drug from microparticle. 
The maleimide functional group in 40%C18-PGA-PEG-MIHA MP showed ability to 
interact specifically with thiol group provided on iminothiolane-modified collagen. 
The iminothiolane modified collagen attached to 40%C18-PGA-PEG-MIHA MP with 
the highest efficiency attachment of 28% in PBS medium pH 7.2.  
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CHAPTER 5 
5. AGGREGATE FORMATION USING MICROPARTICLES 
 
 
5.1. Introduction 
The formation of aggregates as three dimensional (3D) structures of cells is useful to 
mimic in vivo behaviour of the cells and obtain functional substitutes for tissue 
replacement. Cell aggregates can be used as tools to evaluate tissue developments, 
cell interaction, viability and migration, cell differentiation [5, 197, 198] and to test 
drugs. Moreover, the formation of 3D structure of cells could be enhanced by extra 
cellular matrix (ECM) production and metabolic activity rather than in single cells 
[199].  
The development of 3D culture system could be used as an in vitro technique to 
improve accuracy of analysis [5]. The formation of cell aggregates can be achieved 
using several methods such as the aggregation using spinner flasks, hanging drop 
method and manipulation of cell surface chemistry [7, 10, 200, 201]. However, these 
methods have several drawbacks including cell necrosis formation during spinning 
rotation, variable ability to deliver bioactive molecules due to difficulties with 
changing the medium in hanging drop method [202] and possibility of chemical 
toxicity in chemistry surface modification.  
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A possible alternative is to assemble cell aggregates using microparticles (MP). 
Microparticles can be used as micro-carriers to form cell aggregates as described in 
previous study by Rimmer  (2009) and Tan et al (2010) [114, 127]. Microparticles are 
mixed with a suspension of the cells to form a 3D assembly of cell-MP aggregate. In 
this example, MP act as matrices for cells to aggregate, proliferate and differentiate. 
In addition, MP can be used as a reservoir for bioactive molecules and controlled 
release directly within the aggregate [36, 40].   
However, the possibility of forming cell aggregates using MP is influenced by surface 
interaction between MP materials and cells. In this study, PGA polymer has been 
modified with 40% stearoyl (C18) substitution and attachment of MIHA-PEG-NH2 
linker to the polymer backbone. Further modification by attaching collagen as ligand 
was done to encourage specific interaction between MP and cells. The influence of 
MP on cell behaviour is investigated to assess the suitability of these materials for 
cell aggregation, proliferation and differentiation.  
The aim of this chapter is to evaluate interaction between cell and empty modified 
PGA MPs by investigating aggregate formation with mouse embryonic (mES) and 
primary osteoblast cells. The average MP diameters used in this experiment are 
ranging from 5.9 to 7.9 µm, while the cells size ranging from 10-15 µm (for mES) to 
20-30 µm (for osteoblasts). Therefore, tŚĞDWŚǇƉŶŽƚŝǌĞĚĂĐƚĂƐ “ŐůƵĞ ?ƚŽŵĞĚŝĂƚĞĚ
cell-cell interaction. The specific environment was created in order to incorporate 
modified PGA MPs within cell aggregate together with the evaluation of aggregate 
formation. Effect of cells to MP ratios on aggregate formation was also investigated. 
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Finally, the cell growth and proliferation within the cell-MP aggregates was evaluated 
through metabolic activity assay. 
5.2. Interaction of Microparticles with Cells 
5.2.1. Formation of aggregate with mES cells  
The interaction between modified PGA MP and mES cell was investigated using 
empty MPs without active drug. The characteristics of MP used in the experiment are 
described in Table 5.1.  
Table 5.1. Characteristics of microparticles used to interact with mES and 
osteoblast cells. The empty modified PGA microparticles were prepared using 
emulsification method. 
Polymer concentration in organic phase : 0.5%  
PVA concentration 
Particle size (µm)±SD 
40% C18-PGA MP 
40% C18-PGA-PEG-MIHA MP 
40% C18-PGA-PEG-MIHA MP+Collagen 
: 2.5%  
 
: 
: 
: 
 
7.9 ± 0.56 
5.9 ± 0.64 
6.5 ± 0.70 
Zeta potential (mV)±SD 
40% C18-PGA MP 
40% C18-PGA-PEG-MIHA MP 
40% C18-PGA-PEG-MIHA MP+ collagen 
 
: 
: 
: 
 
-18.3 ± 1.60 
-25.2 ±2.19 
-20.1 ± 1.30 
 
The MP were added to non-tissue culture treated 96- well plate at a concentration of 
104 MP per well. The mES cells were then seeded into the wells at ratio of 1:1 MP to 
cells. The total volume of medium in each well was 200 µl. Aggregate formation was 
investigated every 2 hours after the plate was placed on a multifunction rotator at 15 
rpm in 37°C incubator (Chapter 2 section 2.4.6). The formation of aggregates in mES 
cell is shown in Figure 5.1. 
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Figure 5.1. Aggregate formation of mES cell in control (without microparticles) (A), 
with 40%C18-PGA MP (B), with 40%C18-PGA-PEG-MIHA MP (C), and with 40%C18-
PGA-PEG-MIHA MP + collagen. The mES cells were mixed in mass suspension (at 
density 104 cells per well) with modified PGA MPs at ratio 1:1 in non-tissue culture 
treated 96-well plates. The plate was continuously rotated 15 rpm for 6 hours.  
Scale bar represents 200 µm.  
 
Two hours after moving to static condition (8 hours), some cluster formation of cells 
had been found in all conditions. Since the mES have self-aggregating properties, the 
aggregates also formed in condition without MP (Figure 5.1-A). The highest number 
of single cell still appeared with 40%C18-PGA-PEG-MIHA MP at 8 hour (Figure 5.1-C). 
Spheroid aggregates were formed in the control at day 1, whereas with modified PGA 
 Chapter 5  Aggregate Formation 
 
181 
 
MPs, the cells tended to form smaller and loose aggregates. At day 3, the aggregates 
became more compact in all conditions. Some aggregates coalesced to form larger 
irregular aggregates as shown in Figure 5.1-D. The control cell formed few aggregates 
compared to the cell with MPs. However, the aggregate in control group seemed to 
be larger suggesting the presence of more cells involved in individual aggregates. 
The two perpendicular diameters were measured accros the centre of aggregate and 
the average value from each aggregates was taken as described in Chapter 2, section 
2.4.7. The average diameters of mES aggregates over time in culture is shown in 
Figure 5.2 and reveal that the diameter of aggregates increased over the period of 
cell culture. The increase in diameter seems to be related to coalescence  of several 
aggregates after several days of cell cultureand is also supported by data in Figure 5.3 
which showing that the number of aggregates in each well decreased with the longer 
periods of cell culture.  
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Figure 5.2. Diameter of aggregates in mES cell in the presence of modified PGA MP. 
The diameter is an average of two perpendiculars diameter on each aggregate in 
three random selected area of each well at day 3, 5 and 7 (n=15). Bars represent 
SEM.  
 
 
 
Figure 5.3. Number of mES cell aggregates in the presence of modified PGA MP. The 
number of aggregate was counted at three random selected area of each well at 
day 3, 5 and 7 (n=15). Bars represent SEM.  
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The incorporation of MP within cell aggregates was evaluated by dissociating 3-day 
old aggregates using trypsin (Chapter 2 section 2.4.8). The number of MP 
incorporated within cell aggregates was counted relative to the number of cells from 
the dispersed aggregates. This value could be useful to evaluate and estimate the 
interaction between MPs and cells by counting how many particles could be 
incorporated within a certain number of cells. The percentage of MP within mES cell W
MP aggregates is shown at Figure 5.4.  
 
 
Figure 5.4. The percentage of microparticles within 3-day old mES cell-MP 
aggregates. The microparticles and cell were counted from three random selected 
areas in each well (n=15). The number of microparticle was calculated relatively to 
the number of cell which constructs aggregates. Bars represent SEM.  
 
It can be seen from Figure 5.4 that the MP prepared from 40%C18-PGA had the 
highest number of MP with the aggregates. However, the result showed no 
significant difference with MP prepared from 40%C18-PGA-PEG-MIHA MP+ collagen 
(P>0.05, n=5). In contrast, the MP prepared from 40%C18-PGA-PEG-MIHA showed the 
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lowest number with relative number of MP incorporated within aggregates being 
almost half as low as the two other formulations. By attaching the collagen on the 
surface of 40%C18-PGA-PEG-MIHA MP, the percentage of microparticle within 
aggregates was increased.  The increased percentage of 40%C18-PGA-PEG-MIHA MP + 
collagen was almost double compare to the 40%C18-PGA-PEG-MIHA MP without 
collagen attachment.  
5.2.2. Aggregate formation with osteoblast cell 
The empty modified PGA MPs were mixed with osteoblast cells to evaluate their 
interaction and ability of the MPs to encourage cell aggregation.  Similar to studies 
with mES cells, osteoblast cells were seeded with MP in ratio 1: 1 and the plate was 
placed in a multifunctional rotator (15 rpm, 37° C)  for 3 hours and then moved to 
static condition. The aggregate formation with osteoblast cells is shown in Figure 5.5. 
The osteoblast in non-tissue culture treated plates formed a monolayer of cell a few 
hours after mixing with the MPs. The cells started to detach and pulled out from the 
edge of plate as a layer at 8 hours. At day 1, the area of cell detachment became 
wider. The osteoblast cells formed a clump with some of cell monolayer still attached 
to the plate. At day 3, the cells rolled over to form one spherical compact mass and 
fully detached from the plate except for control. Some small aggregates was found 
around the control of osteoblast without MP (Figure 5.5-A). Further evaluation was 
carried out to determine diameter of aggregate in osteoblast cell.  
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Figure 5.5. Aggregate formation with  primary osteoblast cell in control (without 
microparticle) (A), with 40%C18-PGA MP (B), with 40%C18-PGA-PEG-MIHA MP (C), 
and with 40%C18-PGA-PEG-MIHA MP + collagen. The primary osteoblast cells were 
mixed in mass suspension (at density 104 cells per well) with modified PGA MPs at 
ratio 1:1 in non-tissue culture treated 96-well plates. The plate was continuously 
rotated 15 rpm for 3 hours.  Scale bars represent 100 µm.  
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Figure 5.6. Diameter of aggregates from osteoblast cells in the presence of 
modified PGA MPs. The diameter is an average of two perpendiculars diameter on 
osteoblast aggregate at day 3, 5 and 7 (n=5). Bars represent SD.  
 
The diameter of osteoblast aggregates was evaluated at day 3, 5 and 7. The diameter 
of osteoblast aggregate reduced gradually with longer time in culture. The 
aggregates seemed to form more compact mass of the cells. The mixing of MP within 
osteoblast cells generated larger aggregates compared to the control. The largest 
aggregates were formed with  osteoblast cells and 40%C18-PGA-PEG-MIHA MP+ 
collagen attachment,  followed by the osteoblast cell with 40%C18-PGA MP and the 
osteoblast cell with 40%C18-PGA-PEG-MIHA MP.  The numbers of MP incorporated 
within the aggregate also determined at day 3 by dissociating the osteoblast 
aggregate using trypsin. 
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Figure 5.7. The percentage of microparticles within 3-day old osteoblast-MP 
aggregate. The microparticles and cell were counted from three random selected 
areas in each well (n=15). The percentage of microparticle was calculated relatively 
to the number of cell which constructs aggregates. Bars represent SEM.  
 
The percentage of microparticle within osteoblast-MP aggregates was calculated 
relative to the number of osteoblast. As seen in Figure 5.7, the 40%C18-PGA-PEG-
MIHA MP+ collagen had the highest number within osteoblast cell. Without 
iminothiolane-modified collagen attachment on the surface of MP, the 40%C18-PGA-
PEG-MIHA MP exhibited the lowest number of MP within osteoblast aggregates. 
However, the percentage of 40%C18-PGA-PEG-MIHA MP incorporated was similar to 
the percentage of 40%C18-PGA MP incorporated within osteoblast at day 3 (P>0.05, 
n=5).  
5.3. Effect of Microparticles/Cells Ratio on Aggregate Formation 
The ability of modified  PGA microparticle to encourage cell aggregation is difficult to 
evaluate since the mES cell naturally tend to aggregate to form embryoid bodies in 
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the absence of leukemia inhibitory factor (LIF) [202]. This natural aggregation is 
evident from Figure 5.1 but in the presence of MP there seems to be a change in 
aggregate formation with a general reduction in the diameter of aggregates. 
 In order to investigate effect of MP on mES cell aggregate formation, various MP to 
cell ratios were investigated based on diameters of aggregates, the number of 
aggregate formed and the number of single cells not involved in aggregate formation. 
This was done by microscopy analysis of the of mES cell aggregates in various MP: 
cell ratio.  
 
Figure 5.8. Diameter aggregates in mES cell in the presence of modified PGA MP 
with various ratios of microparticles to cells. The diameter is an average of two 
perpendicular diameters on each aggregate in three random selected areas of each 
well at day 3 (n=15) Bar represents SEM.  
 
Figure 5.8 shows the diameter of mES aggregate with several MP to cells ratio. 
Incorporation of MP within mES resulted in aggregates with lower diameters 
compared to the control. This suggested that incorporation of microparticle might 
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disrupt aggregate formation in mES cell.  Figure 5.8 shows that the diameter of mES 
cell aggregates was decreased with the reduction amount of MP mixed with the cells. 
It is suggested that increasing in diameter of aggregate in mES cell related to 
increasing number of particle entrapped in the mES cell aggregate. By reducing the 
amount of seeded MP to the mES cell, the aggregate exhibited lower diameter.  
The number of aggregates and single cells from random selected areas in each well is 
presented in Figure 5.9 and Figure 5.10. 
 
Figure 5.9. Number of mES-MP aggregates in each well. The number of aggregates 
was counted by image analysis in three selected random areas in each well at day 3 
(n=15). Bar represents SEM.  
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Figure 5.10. Number of single cell mES not involved in aggregation. The number of 
single cell was counted by image analysis in three selected random areas in each 
well at day 3 (n=15). Bar represents SEM.  
 
The number of aggregates was reduced relative to lower ratio of microparticles to 
cells. This trend was clearly seen with 40%C18-PGA-PEG-MIHA MP (Figure 5.9). 
However, although a high number of aggregate was found in mES with 40%C18-PGA-
PEG-MIHA MP, a high number of single cells was also found under the same 
conditions (Figure 5.10). The high number of single cells likely occurred due to the 
lack ability of 40%C18-PGA-PEG-MIHA MP to support aggregate formation in mES. 
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0.0
50.0
100.0
150.0
200.0
250.0
1 : 5 1 : 2 1 : 1
N
u
m
b
e
r 
o
f 
m
ES
 s
in
gl
e
 c
e
ll 
Microparticle : Cell ratio 
Control
with 40% C18- PGA MP
with 40% C18-PGA-PEG-MIHA MP
with 40% C18-PGA-PEG-MIHA MP+
Collagen
 Chapter 5  Aggregate Formation 
 
191 
 
with 40%C18-PGA-PEG-MIHA MP+ collagen revealed the number of aggregates and 
single cells was similar to the control. It is suggested that although the presence of 
MP might interrupt aggregate formation in mES cell, the attachment of 
iminothiolane-modified collagen on the surface of MP can help form aggregates 
better than the MP without attachment of collagen. 
The effects of MP: cell seeding ratio was also investigated in aggregate formation 
with osteoblasts. The numbers of osteoblast single cells not involved with aggregates 
could not be determined and counted under microscope because osteoblast cells 
presented as thin monolayers on cell culture well-plates. The diameter of the 
aggregate in each condition was measured and presented in Figure 5.11. 
 
Figure 5.11. Diameter of osteoblast aggregates in the presence of modified PGA 
MPs with various ratios of microparticles to cells. The diameter is an average of two 
perpendiculars diameter on each aggregate in each well at day 3 (n=5). Bars 
represent SD.  
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The diameter of osteoblast aggregates decreased with reducing numbers of MP.  The 
40%C18-PGA-PEG-MIHA MP+ collagen exhibited the largest aggregates in all ratios of 
MP to cells. In contrast, the 40%C18-PGA-PEG-MIHA MP without collagen generated 
the lowest diameter aggregates. This result revealed that iminothiolane-modified 
collagen attachment on the microparticle surface could improve the ability of cell to 
interact with MP. Surprisingly, the good interaction between MP and osteoblast cell 
was also found with 40%C18-PGA MP with 1: 1 microparticle to cell ratio. The cell 
aggregate with 40%C18-PGA MP established the similar diameter with the cell 
aggregate containing 40%C18-PGA-PEG-MIHA MP+ collagen.  
5.4. Effect of Microparticles Incorporation on Cell Metabolic Activity 
The cell metabolic activity was evaluated to investigate the effect of MP 
incorporation within cell aggregates. Metabolic activity is related to cell number as 
well as the viability of cells within aggregates. The Alamar Blue assay was used to 
determine the metabolic activity in mES and osteoblast cells aggregates as described 
in Chapter 2 section 2.4.10. The investigation was carried out in 7-day and 14-day old 
cell aggregates. The principle of Alamar Blue assay is the reduction of Alamar Blue 
(rezasurin solution, blue and non-fluorescent) to resorufin (pink and fluorescent) by 
lack of oxygen in the microenvironment during cellular metabolism [203]. The 
fluorescence intensity measured is related to the level of performed resorufin and 
indicative of the level of cell metabolic activity.  
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Figure 5.12. The metabolic activity of mES cell aggregates evaluated using Alamar 
Blue assay. The fluorescence intensity indicated the proliferation in aggregates. The 
Alamar blue was added to the 7 and 14-day old mES cell aggregates and incubated 
for 15 minutes at 37°C in the dark (n=3). Bars represent SD. 
 
Figure 5.12 shows the fluorescence intensity measurement in mES cell aggregates. 
The increasing fluorescence intensity in this experiment was related to the formation 
of high level of resorufin which indicated more oxygen consumed in cell metabolic 
activity and suggesting cell proliferation.  At day 7, the cell aggregates with MP  had 
higher fluorescence intensity measurements compared with the control suggesting  
that the presence of MP within cell aggregate could support cell  proliferation. 
However, the incorporation of 40%C18-PGA-PEG-MIHA MP revealed the lower value 
of fluorescence intensity compare to the others microparticle at day 7.  
Cell proliferation was also assessed on 14-day old mES aggregates. The effect of MP 
on supporting cell proliferation was seen with 40%C18-PGA-PEG-MIHA MP+ collagen. 
The 40%C18-PGA-PEG-MIHA MP+ collagen exhibited the highest fluorescence 
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intensity in 14-day mES cell aggregates. Conversely, proliferation was reduced in cell 
aggregate at day 14 with 40%C18-PGA and 40%C18-PGA-PEG-MIHA MPs, respectively. 
 
Figure 5.13. The metabolic activity of osteoblast cell aggregates evaluated using 
Alamar Blue assay. The fluorescence intensity indicated the proliferation in 
aggregates. The Alamar blue was added to the 7 and 14-day old osteoblast cell 
aggregates and incubated for 15 minutes at 37°C in the dark (n=3). Bars represent 
SD. 
 
The cell metabolic activity in osteoblast cell aggregates was evaluated and results 
shown in Figure 5.13. At day 7, the metabolic activity of osteoblast aggregates with 
40%C18-PGA or 40%C18-PGA-PEG-MIHA MPs were decreased as indicated by lower 
fluorescent intensity. Conversely, the cell metabolic activity was similar to the control 
with 40%C18-PGA-PEG-MIHA MP+ collagen. Increased metabolic activity was seen 
with osteoblast aggregates with 40%C18-PGA and 40%C18-PGA-PEG-MIHA MPs at day 
14 and for both was similar to the control. A significant increase in metabolic activity 
was seen in cell aggregates with 40%C18-PGA-PEG-MIHA MP+ collagen suggesting 
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proliferation and increased cell numbers with 40%C18-PGA-PEG-MIHA MP+ collagen 
on day 14 of culture. 
Comparing the metabolic activities of mES and osteoblast cells, it is evident that a 
significant increase occurred in mES rather than in osteoblast cell. In mES, the 
fluorescence intensity was related to metabolic activity was increased almost 5 times 
within the 7 days period. At the same time, the metabolic activity of the osteoblasts 
increased only 1.25 times at the highest value. The 40%C18-PGA-PEG-MIHA MP+ 
collagen showed similar effects on metabolic activity and suggested cell proliferation   
with both mES and osteoblast cells. However, 40%C18-PGA and 40%C18-PGA-PEG-
MIHA MPs in mES cell led to the reduction of metabolic activity, while in osteoblasts 
the metabolic activity remained the same as control group. 
5.5. Discussion  
The formation of 3D aggregates is a useful approach to evaluate development of cells 
for tissue regeneration.  The cell aggregates allow the investigation of cell 
interactions in 3D structure and the ability to support cell viability, proliferation and 
differentiation. The differentiation of pluripotent cell ES  cells is often initiated by 
withdrawal of certain cytokines like LIF from cell culture medium to induce the 
spontaneous formation  of cell aggregates, called embryoid bodies [197, 204]. Once 
formed cells within the aggregates proliferate and differentiate to various cell types. 
Although the ES cells can naturally form aggregates and differentiate without the 
addition of exogenous growth factors, the process needs to be controlled to develop 
desired cells.  
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Controlling the process of cell differentiation might be achieved by incorporating MP 
within cell aggregate. The PGA polymer used to make MP has been modified in this 
study to increase the exogenous bioactive molecule encapsulation within the MP.  
Also a collagen ligand for cell attachment has been tethered to the modified PGA 
polymer to increase specific interaction with cells. Here we present the ability of 
modified PGA microparticles to interact with mES cell and osteoblast cell to form 3D 
aggregates. 
5.5.1. Aggregate formation in mES cell 
The MP-cell aggregation was performed using mass suspension which has been 
widely used to perform cell aggregate in various cells type including stem cell [205-
209]. Non-tissue culture treated plates were used to limit adherence to the well and 
to help  promote cell to cell contact and  encourage aggregation processes [202].   In 
order to optimize the aggregate formation, the plate was incubated with gentle 
rotatation at  15 rpm as described by Gothard et al.,(2009) to generate  high numbers 
of  ES aggregates in suspension culture [209]. 
Results from this study showed that the presence of MP with average diameter 
ranging from 5.9 to 7.9 µm seems to interrupt aggregate formation in mES (10-15 µm 
diameter) with 1: 1 MP to cell ratio and results in smaller diameter compared to 
control cell aggregates without MP. The presence of microparticle seems 
Fortunately, the diameter of aggregate in mES cell culture could be maintained below 
300 µm. Previous study by Park et al (2007) presented that maintaining the initial size 
of ES aggregates below 300 µm size could be useful increasing gene expression as 
found in three major germ layers [204].   
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The diameter of MP-cell aggregates increased over time and correlated with a 
reduction in the number of aggregates. This suggested that agglomeration was 
occurring in mES aggregates. Although aggregate formation is important to induce 
cell differentiation, the formation of agglomerates of aggregates might inhibit cell 
growth as well as cell differentiation. Therefore, the balance between cell 
aggregation and agglomeration should be controlled in order to optimize cell growth 
and differentiation [210, 211]. The presence of modified PGA microparticles could be 
useful to prevent agglomeration in mES aggregates. As seen in figure 5.2 and figure 
5.3, the increasing of diameter and decreasing of number of aggregates with MP is 
lower compared to control without MP.  
The most obvious deviation from normal aggregation of control cells was found with 
40%C18-PGA-PEG-MIHA MP as shown by the lowest diameter of aggregates. This 
effect could be related to the effect of sterically stabilizing of MIHA-PEG-NH2 on the 
surface of 40%C18-PGA-PEG-MIHA MP. The hydrophilic layer  of PEG on the surface of 
40%C18-PGA-PEG-MIHA MP provide as steric barrier to prevent interaction between 
cell and the microparticle and generate a low aggregate formation of mES cell. 
The interaction between MP and cell also influenced the numbers of MP 
incorporated within the cell aggregate. The 40%C18-PGA-PEG-MIHA MP exhibited the 
lowest percentage of MP within the aggregates and suggests  lower interaction 
between 40%C18-PGA-PEG-MIHA MP and  mES cell (Figure 5.4). The incorporation of 
MP within cells aggregate mainly influence by surface interaction between MP and 
cells. The result showed that without ligand attachment, 40%C18-PGA and 40%C18-
PGA-PEG-MIHA MP had ability to incorporate within cells aggregate indicate that the 
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surface of 40%C18-PGA and 40%C18-PGA-PEG-MIHA MP have a good interaction with 
mES cells. However, the best MP incorporation within cells was occurred with the 
presence of iminothiolane-modified collagen attached on the surface of 40%C18-PGA-
PEG-MIHA MP by improving the interaction between MP and cells. Collagen could be 
useful to mediate specific attachment between surface of MP and cell via integrin 
interaction since most of cells express integrin at their surface [135, 136]. Therefore, 
the 40%C18-PGA-PEG-MIHA MP+ collagen showed a high proportion of MP within the 
aggregates. Surprisingly, the 40%C18-PGA MP showed the highest proportion of MP 
within cell aggregate although overall there was no significance difference (P>0.05, 
n=5) with the percentage of 40%C18-PGA-PEG-MIHA MP+ collagen within cell 
aggregate.  The percentage of MP within cell aggregates is influenced by two factors. 
First, the percentage of microparticle within the aggregate is influenced by the 
interaction between MP with the cell. The better interaction between MP with cell 
leads to a higher proportion of MP. Secondly, the percentage of MP within cell 
aggregate is influenced by the number of cell involved in forming the aggregate. 
Since data on MP within aggregates was taken at day 3, there is a possibility of cells 
to proliferate. Hence, the increasing number of cells in aggregate would alter the 
ratio with MP. Further investigation is needed to evaluate the ability of MP within 
cell aggregate to encourage cell proliferation. 
5.5.2. Aggregate formation in osteoblast cells 
Unlike mES cells, osteoblasts do not typically spontaneously form aggregates in cell 
culture.  Although this study used non-tissue culture treated plates, the osteoblasts 
did tend to adhere loosely and form a monolayer sheet.  However, PGA MP in 
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osteoblast culture encouraged detachment of osteoblast cell sheet and aggregate 
formation in 15 rpm rotary agitation.  The control group without MP in the same 
rotary agitation with could also form aggregates, but the cells did not fully detach 
from the culture plate. The formation of osteoblast aggregate has also been 
described in a study by Overstreet et al (2004) showing unexpected aggregation of 
osteoblasts after 3 days exposure to bear serum. The bear serum contained a 
molecule that could trigger cell detachment from the plate.  Overstreet et al., (2004) 
explained that with the presence of bear serum in medium, the osteoblast adhered 
to each other and pulled as a layer from the plates. The osteoblast then aggregated 
and remained viable in cell medium [212]. In this study it is suggested that the 
modified PGA DWƐĂĐƚĞĚĂƐ  “ŐůƵĞ ?ƚŽŵĞĚŝĂƚĞ cell adherence and then pulled as a 
layer from the plate. The osteoblast could not fully detach from plate in control 
group since there was no MP to facilitate cell adherence.  
The diameter of aggregates was determined to evaluate effect of MP on aggregate 
formation. The lowest diameter of aggregate was found in control group without 
modified PGA microparticle, while the highest diameter of aggregate was found in 
the presence of 40%C18-PGA-PEG-MIHA MP+ collagen. The low diameter of cell 
aggregate in control group indicated the low number of cell involved in aggregate 
formation. As seen in Figure 5.5-A, some small cell aggregates presented around the 
main aggregate which indicated that some of the osteoblasts were not involved in 
constructing the main aggregate.  
The presence of modified PGA microparticle exhibited larger diameter aggregates as 
shown in Figure 5.6 and might be explained by three reasons. First, the larger 
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aggregate formation related to the higher number of cells involved in aggregate 
formation. More cells involved would lead to the larger diameter of aggregate. 
Secondly, the presence of MP entrapped inside the aggregate would increase the 
bulk volume of aggregate as well as increasing the diameter of aggregate. The size of 
MP (diameter 5.9-7.9 µm) are around one third of the cells (diameter around 20-30 
µm), hence incorporation of MP would increase the volume of cells aggregate.  The 
last reason is the presence of MP could support cell proliferation in the aggregate. 
Since the diameter was determined in day 3, there is a possibility of osteoblast to 
proliferate within 3 days to form bigger aggregate. Although the MP entrapped 
within cell aggregate could increase the diameter of osteoblast aggregate, the 
incorporation of 40%C18-PGA-PEG-MIHA MP with osteoblast exhibited low diameter 
of aggregate related to low incorporation of microparticle as illustrated in Figure 5.7. 
The possible effects and changes to osteoblast proliferation still remain to be 
investigated. 
Looking at the proportion of MP within osteoblast aggregates, the highest 
entrapment within cell aggregate was shown by 40%C18-PGA-PEG-MIHA MP+ 
collagen. The presence of collagen on the surface of MP could enhance interaction 
between MP and osteoblast as explained in section 5.5.1.  The similar percentage of 
MP entrapment within osteoblast was obtained in 40%C18-PGA and 40%C18-PGA-PEG-
MIHA MPs. It is revealed that the steric effect of MIHA-PEG-NH2 linker on the surface 
of 40%C18-PGA-PEG-MIHA MP did not affect the microparticle incorporation within 
osteoblast aggregate. However, since the percentage was calculated based on the 
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number of cell which constructs an aggregate, the proliferation of osteoblast cell 
might influence the result.  
5.5.3. Effect of microparticles/cells ratio to aggregate formation 
Due to disruption in aggregate formation in mES cell with the presence of MP, the 
MPs were added at lower numbers relative to cell numbers. Again analysis was 
performed on the diameter of the aggregates, number of aggregates in each well and 
also the number of single cells not involved in aggregate formation. The results show 
that higher amounts of MP mixed with the cells relates to lower formation of cell 
aggregates based on the high number of single cells not involved in aggregate 
formation. The number of single cell was reduced as the ratio of MP to cell was 
lowered. This result confirms that the efficiency of aggregate formation was 
influenced by the number of MP used as described in previous study by Hayashi and 
Tabata (2011) where aggregate formation by mesenchymal stem cell (MSC) was 
blocked due to excessive number of microparticle mixed with the cells. The excessive 
number of particle physically inhibiting contact and interaction between cells [199].  
An interesting observation was noted with 40%C18-PGA-PEG-MIHA MP+ collagen 
(Figure 5.10) where the number of single cell involved in aggregate was seemingly 
not affected by the number of MP. As the number of MP increase, the number of 
single cell not involved in aggregate formation remained constant and similar to the 
control. This finding supported statement in section 5.5.1 that the presence of 
collagen on the surface of microparticle could encourage specific interaction 
between microparticle and cell [135, 136].  
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Unfortunately, the effect of MP to cell ratio did not clearly influence osteoblast 
aggregate formation. The osteoblast still formed aggregates with the lower amount 
of MP. The decrease in diameter of osteoblast aggregates was related to the 
reduction in number of MP incorporated. However, the osteoblast with 40%C18-PGA-
PEG-MIHA MP+ collagen revealed the biggest diameter of aggregate even with the 
low amount of MP.  It is suggested that 40%C18-PGA-PEG-MIHA MP+ collagen had a 
good interaction and incorporation within osteoblast cell as described in Figure 5.7. 
This finding also supported the role of collagen to support interaction between 
microparticle and cell. 
5.5.4. Effect of microparticle incorporation to cell metabolic activity 
Since the percentage of MP within cell aggregates and diameter of aggregate in both 
mES and osteoblast cells were influenced by the number of cells involved in the 
aggregate construct, the ability of MP to support cell growth and proliferation was 
evaluated. The metabolic activity was related to the cell viability, cell proliferation 
and compatibility with biomaterial cells was assessed using the Alamar Blue assay. 
This method has been used widely in several studies to assess metabolic activity of 
cell [213-215], cell viability [215, 216] as well as cell proliferation [203, 217]. The use 
of Alamar Blue offers the advantage of being non-toxic to the cells with the exposure 
of reagent [203]. However, the accuracy of method is influenced by efficiency of 
reagent diffusion into the sample. Ng et al (2005) noted the importance of doing 
trials to optimize reagent concentration and incubation time to avoid saturation of 
signal [213]. Optimisation for incubation time had been done to avoid high 
fluorescent intensity produced in reduced sample (data for mES aggregate is shown 
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in appendix). In order to optimize the reagent diffusion to reach a whole sample, the 
sample was exposed to the reagent for 15 minutes in 37°C incubator.  
The evaluation for cell metabolic activity was assessed at day 7 and 14 of cell culture. 
The fluorescence intensity related to cell metabolic activity was significantly 
increased at day 14 in all condition of mES cell aggregates. It is suggested that 
proliferation of mES was increased during 14 days of culture. Comparing the cell 
metabolic activity data at day 14, the highest activity was seen with 40%C18-PGA-
PEG-MIHA MP+ collagen. The presence of collagen on the surface of MP likely 
encouraged the interaction between microparticle and cell due to presence of 
integrin receptor on the surface of the cell which interact with collagen. As presented 
in previous study by Woo et al (2003), the presence of proteins from the material or 
cell itself could be useful to mediate cell growth [218].  
The similar cell metabolic profile also was found in osteoblast cells culture. Although 
the increasing metabolic activity from day 7 to day 14 was lower than mES cells, the 
incorporation of modified PGA MPs increased metabolic activity of osteoblast cells. 
The highest metabolic activity was found with the 40%C18-PGA-PEG-MIHA MP+ 
collagen within osteoblasts aggregate.  
This result revealed the biocompatibility of modified PGA MP, particularly with 
iminothiolane-modified collagen attachment, could act as matrices to support the 
growth of cells in 3D constructs. Increasing the osteoblasts metabolic activity with 
the presence of MP is consistent with earlier finding by Hayashi and Tabata (2011). 
Hayashi and Tabata reported that the presence of particle within the cells aggregate 
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may increase the oxygen diffusion inside the aggregate. Hence, the number of live 
cells in aggregate with incorporation of microparticles is higher [199].    
The other factor that influenced cell metabolic activity in both mES and osteoblast is 
the presence of collagen on the surface of microparticle. Collagen plays an important 
role to promote interactions between MP and cells. Collagen as component of ECM 
has the ability to interact with the cell through specific glycoprotein on the cells and 
influence the behaviour of cell including cell proliferation [151, 219]. The specific 
interaction between cell and collagen depends on the type of cell and collagen. 
Hence, certain types of cell can adhere to specific collagen [151]. Collagen type IV as 
a component of basement membrane [145, 219-221] was used in this study and it 
exhibited interesting effective interaction with mES as well as osteoblast cells. As the 
major component of basement membrane, the interaction between collagen and cell 
lead to promote cellular proliferaƚŝŽŶ ďǇ ĨŽƌŵĂƚŝŽŶ  “ƐƉŝĚĞƌ ƐŚĂƉĞ ? ƐƚƌƵĐƚƵƌĞ[145, 
221].  The ability of collagen type IV to support cells adhesion was reported in 
previous study conducted by Olivero and Furcht (1993). Olivero and Furcht conveyed 
that surface coating with collagen type IV endorses maximal adhesion with rabbit 
epithelial cells in vitro [222].  In addition, the role of collagen type IV for cell 
proliferation had been reported by Anbalagan and Rao (2004). Anbalagan and Rao 
informed that the presence of collagen type IV could stimulate the progenitor Leydig 
cells (PLC) proliferation in vitro by mediated intracellular signalling [223]  
5.6. Conclusion 
To summarize, the incorporation of modified MP at ratio of 1:1 with cells did not 
encourage aggregate formation in mES cells and seemed to disrupt the normal 
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aggregation process. In contrast, the addition of modified PGA MP at ratio 1: 1 with 
cell could enhance the formation of 3D structure in osteoblast cells indicated by fully 
detachment of osteoblast aggregate from cell culture plate.  
However, the formation of aggregates with cells was determined by properties of MP 
and the ratio of MP to cells. The attachment of collagen on the surface of 40%C18-
PGA-PEG-MIHA MP could improve the aggregate formation in mES and osteoblast 
cells as well as increase the percentage of microparticle incorporated within cells 
aggregate. Surprisingly, the 40%C18-PGA microparticle also exhibited a good 
incorporation within mES cells aggregate.  In order to optimize the aggregate 
formation in mES and osteoblast cells, the number of microparticle should be 
adjusted to allow sufficient contact between microparticles and cells.  
Although the presence of MP did not markedly change the aggregate formation in 
mES cells, the metabolism activity using Alamar Blue assay showed that the presence 
of 40%C18-PGA-PEG-MIHA MP+ collagen increased metabolic activity of mES in 14 
days culture of aggregates. The same finding also presented in osteoblast cells. The 
highest metabolic activity which might be related to cell proliferation was presented 
in osteoblasts aggregates with 40%C18-PGA-PEG-MIHA MP+ collagen.  In addition, the 
osteoblasts metabolic activity remained similar to the control group with 40%C18-PGA 
MP and 40%C18-PGA-PEG-MIHA MP. Those findings indicated that MP prepared from 
modified PGA polymer had ability to support cell growth in 3D constructs of cells 
aggregate.  
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CHAPTER 6 
6. MICROPARTICLE INCORPORATION FOR 
OSTEOGENIC DIFFERENTIATION 
 
 
6.1. Introduction 
The control of cell differentiation and engineering of tissue formation using three 
dimensional (3D) cells aggregate is one approach to help obtain functional 
substitutes for tissue regeneration. Potentially, 3D cell aggregates formed in vitro can 
be injected at the later stage to fill a defect and restore function to the damaged 
tissue. This technique is a promising system for tissue regeneration particularly for 
bone replacement due to reducing of patient discomfort and low risk of infection [40, 
41]. In order to enhance natural regeneration, the combination between cell sources, 
signals and extracellular matrix (ECM) should be provided. As a potential source of 
cell for bone replacement, the differentiation of stem cells could be induced by 
providing bioactive signals from growth factors or active drugs while ECM formation 
could be induced by formation of 3D constructs using material such as metals, 
ceramics, synthetic or natural polymers. The formation of 3D structure is a way for 
the cell to develop well-organized structure to imitate the functional characteristics 
of specific tissue.  
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Microparticle (MP) could be used as matrices for cell in 3D construct to produce 
ECM. Several studies had been conducted on formation of 3D cell constructs using 
MP for tissue replacement as described by Mercier et al (2005), Bible et al (2009) and  
Tan et al (2010) [114, 115, 224]. Most of those studies used MP as a micro-carrier to 
perform 3D cell aggregate for tissue transplantation. Besides acting as a matrix for 
cell attachment, MP could be used as a reservoir for bioactive molecules. By 
incorporating MP within cell aggregate, the amount of bioactive molecule 
incorporated could be easy to customize.  
Simvastatin (SIM), a cholesterol lowering drug, is one of active molecule widely used 
to induce osteogenic differentiation in vitro. Simvastatin is a statin derivative which 
has ability to increase anabolic effect and gene expression for osteogenic 
differentiation. In addition, simvastatin involves Bone Morphogenetic Protein-2 
(BMP-2) up regulation and induces production of bone matrix mineralisation [55, 74-
76]. However, the effective dose and the mechanism of simvastatin for osteogenic 
differentiation still under investigation [75]. Active molecules or drugs usually 
interact with the cell through specific receptor on the surface membrane. In 3D 
aggregate, the delivery of molecule should be able reach not only on the surface of 
the aggregate but also inside the aggregate. The conventional route such as adding 
active molecules to the culture media is not effective way for delivery, as it is not be 
able to easily penetrate and reach all cells within the aggregate. Incorporating of 
active molecules within the polymeric microparticle is one way to facilitate the 
release of drug within an aggregate and could facilitate the release of drug over 
defined periods of time.  
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In this study poly(glycerol) adipate (PGA) has been modified with 40% stearoyl (C18) 
to increase the encapsulation of drug within the polymer and attached with MIHA-
PEG-NH2 linker for specific ligand attachment on the surface of the MP.  Based on 
studies in previous chapters, SIM had a high incorporation within the 40%C18-PGA as 
well as 40%C18-PGA-PEG-MIHA microparticles (MP). The 40%C18-PGA-PEG-MIHA MP 
also showed ability to attach with collagen as ligand for specific interaction with cell. 
The release of drug from modified PGA polymer could be tailored by optimising 
formulation process.  MP prepared from modified PGA polymers also exhibited the 
ability to form aggregates with mES and osteoblast cells and also seemed to enhance 
cell metabolic activity particularly with collagen attachment on the surface of 
microparticle. The aim of this chapter was to investigate delivery of simvastatin from 
modified PGA MPs and its effect for osteogenic differentiation in mouse embryonic 
stem (mES) and osteoblast cells. The osteogenic activity was assessed through 
alkaline phosphatase (ALP) assay, osteocalcin immunostaining and von Kossa staining 
for mineralisation.  
6.2. Simvastatin and Osteogenic Differentiation 
In order to evaluate the effect of simvastatin for osteogenic differentiation, the cells 
were cultured in osteogenic media containing simvastatin. The correlation between 
simvastatin concentration and alkaline phosphatase level was assessed on mES 
aggregates. The aggregate was formed by placed the mES cell in multifunctional 
rotator (15 rpm) for 6 hours. The alkaline phosphatase level was determined at day 7, 
14 and 21 of culture. The effect of simvastatin addition to alkaline phosphatase level 
in mES cells is illustrated in Figure 6.1.   
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Figure 6.1. Alkaline phosphatase (ALP) level in mES cell culture treated with 
simvastatin ranging from 0.1 to 200 nM. The ALP was determined in 7, 14 and 21-
day old cell culture using pNPP substrate. Bars represent SD (n=3). 
 
The ALP was produced in the mES culture without simvastatin (control) at day 7 and 
the level is similar with the mES culture with 100 nM of simvastatin (P>0.05, n=3). 
The addition of simvastatin in the range concentration 0.1 to 10 nM to the medium 
reduced the level of ALP in mES below the alkaline phosphatase in control. Figure 6.1 
showed that the level of alkaline phosphase at day 7 increased related to increasing 
of simvastatin concentration in medium.  
The ALP level in mES cells culture reached the peak at day 14 of cell culture. There is 
positive correlation between simvastatin concentration and alkaline phosphatase 
level. However, there is no significant difference in mES cultured in 0.1 nM 
simvastatin and control (P>0.05, n=3). It is indicated that addition of 0.1 nM 
simvastatin on medium did not promote the osteogenic differentiation in mES cells. 
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In addition, there is also no significant difference on ALP level in mES cells at day 14 
with addition of simvastatin 1 and 10 nM to the medium. Yet, the increasing 
concentration of simvastatin from 10 nM to 100 nM could increase alkaline 
phosphatase from 34.23 to 47.64 ng/ml. The level of ALP dropped to lower levels 
after 14 days of cell culture. This trend occurred in all level of concentration of 
simvastatin as well as in the control.  
6.3. Simvastatin Release Profile from Modified PGA Microparticles 
The optimum formulation was applied to prepare the MPs from modified PGA 
polymers. The release of drug for extended period was considered to be an 
important factor when deciding on the best formulation for MP preparation. The 
specification of modified PGA MP used to incorporate within cell aggregate is 
described in Table 6.1 and the particle size distribution illustrated in Figure 6.2.  
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Table 6.1. The specification of modified PGA MP used for mES and osteoblast 
differentiation. The microparticles were prepared using single emulsion method 
containing SIM as a drug. 
Polymer concentration in organic phase (%) : 5%  
PVA concentration (%) : 0.005%  
Initial drug loading (%) : 1% 
MP yield (%) 
40% C18-PGA MP 
40% C18-PGA-PEG-MIHA MP 
 
: 
: 
 
51.5 
43.0 
SIM loading (%)±SD 
40% C18-PGA MP 
40% C18-PGA-PEG-MIHA MP 
40% C18-PGA-PEG-MIHA MP+Collagen 
 
: 
: 
: 
 
0.6±0.04 
0.6±0.01 
0.5±0.01 
Particle size (µm)±SD 
40% C18-PGA MP 
40% C18-PGA-PEG-MIHA MP 
40% C18-PGA-PEG-MIHA MP+Collagen 
 
: 
: 
: 
 
49.6± 2.97 
24.9± 0.43 
27.6± 2.13 
Zeta potential (mV)±SD 
40% C18-PGA MP 
40% C18-PGA-PEG-MIHA MP 
40% C18-PGA-PEG-MIHA MP+Collagen 
 
: 
: 
: 
 
-18.3 ± 1.60 
-25.2 ±2.19 
-20.1 ± 1.30 
 
 
Figure 6.2. Particle size distribution of modified PGA MP. The 40%C18-PGA MP and 
40%C18-PGA-PEG-MIHA MP were prepared using emulsification method with PVA 
0.005% as emulsifier, while 40%C18-PGA-PEG-MIHA MP+ collagen was prepared by 
attach collagen to 40%C18-PGA-PEG-MIHA MP. Particle size was determined using 
Beckman Coulter LS 230. 
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The release profile of simvastatin from modified PGA MPs had been evaluated in 
phosphate buffer saline (PBS) containing 0.1% Tween 20. The effect of polymer 
modification and collagen attachment to MP on its release was determined. As 
illustrated in Figure 6.3, more than 50% of SIM was released from 40%C18-PGA and 
40%C18-PGA-PEG-MIHA MPs within 6 hours of released study. The attachment of 
MIHA-PEG-NH2 linker to 40%C18-PGA increased the speed of simvastatin release from 
the MP. Surprisingly, the initial release was slower with attachment of collagen on 
the 40%C18-PGA-PEG-MIHA MP.  It is seen from the graph that the release of SIM 
from 40%C18-PGA-PEG-MIHA MP+ collagen was 36% within the 6 hours of released 
study.  
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Figure 6.3. The release profiles of SIM from modified PGA MP. The MP was 
prepared using emulsification method with 5 % polymer concentration and 0.005% 
PVA. The release study was established in PBS+0.1% tween 20 at 37°C. Bar 
represents SD (n=3). 
 
The release study ended at 16 days for 40%C18-PGA-PEG-MIHA MP and 21 days for 
the others as there was no drug released from MP at those particular days.  Around 
90% of SIM had been released from 40% C18-PGA-PEG-MIHA MP, while only 80% had 
been released from 40%C18-PGA MP and 40%C18-PGA-PEG-MIHA MP+ collagen at the 
end of study. The remaining microparticles were then analysed to determine the 
amount of SIM retained inside MP. Table 6.2 shows that a small amount of SIM is still 
retained MP and confirm that SIM was not completely released from MP.  
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Table 6.2. Percentage of SIM released from and remaining in modified PGA MP 
prepared using emulsification method with 0.05%PVA.  
 Type of Microparticle 
 40%C18-PGA 40%C18-PGA-PEG-MIHA 40%C18-PGA-PEG-MIHA 
+ Collagen 
Initial amount of SIM  
(µg) ± SD 
29.6 ± 0.01 30.2 ± 1.08 26.2 ± 1.15 
SIM released from MPs 
(µg) ± SD 
24.4 ± 0.95 27.6 ± 1.75 21.1 ± 0.38 
SIM released from MPs 
(%)± SD 
82.3 ± 3.22 91.2 ± 6.46 80.8 ± 7.97 
Release period 
(day) 
21 16 21 
SIM remaining in MPs 
(µg) ± SD 
1.3 ± 0.26 0.7 ± 0.06 0.4 ± 0.02 
SIM remaining in MPs 
(%)± SD 
4.5 ± 1.90 2.5 ± 0.39 1.6 ± 0.36 
 
The percentage of remaining drug in MP was determined by extraction of SIM from 
remained MP after release study ended. The MP prepared from 40%C18-PGA showed 
the highest amount of SIM remained within the MP followed by 40%C18-PGA-PEG-
MIHA MP and 40%C18-PGA-PEG-MIHA MP+ collagen. The attachment of MIHA-PEG-
NH2 linker to the 40%C18-PGA polymer increased the amount of SIM released from 
MP, thus, SIM remaining in 40%C18-PGA-PEG-MIHA MP was lower compared to 
40%C18-PGA. An interesting result is that 40%C18-PGA-PEG-MIHA MP+ collagen had 
released 80% of SIM in 21 days, but the amount of SIM remaining in MP was only 
1.6%. This amount was lower compared to the SIM remained in 40%C18-PGA-PEG-
MIHA MP and suggests  that collagen attachment on the surface of MP also 
influenced the extraction of SIM from 40%C18-PGA-PEG-MIHA MP+ collagen.  
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6.4. Interaction of microparticles with cells 
The modified PGA MP containing simvastatin were mixed with cells in ratio 1:10 MP 
to cell. The low ratio of MP to the cells was applied as the MP has tendency to 
interrupt aggregate formation in mES cell. In addition, the low amount of MP was 
used to avoid SIM toxicity in cells as around 50% of SIM had released from MP at the 
first day. Based on the cell metabolic assay in Chapter 5, section 5.4, the 40%C18-PGA 
MP and 40%C18-PEG-PEG-MIHA MP+ collagen showed the ability to support cells 
proliferation in 3D aggregate culture. Therefore, these two types of MP containing 
SIM were used with the cells. The low ratio of MP was used in order to minimize 
possible cell toxicity which might initiated by release of SIM from MP. The aggregate 
formation in mES and osteoblast cells was carried out using the method as described 
in Chapter 2 Section 2.5.2. The incorporation of MP within cells was evaluated on day 
3 of cell culture under the bright field and fluorescence microscope.  
Figure 6.4 shows the incorporation of modified PGA MPs containing SIM within mES 
cell aggregate. The aggregation occurred in mES in the presence of modified PGA MP 
and without MP. Some of MP adhered on the surface of cells aggregate as shown in 
Figure 6.4-B and C. The 40%C18-PGA-PEG-MIHA MP+ collagen showed better 
distribution within mES aggregate than 40%C18-PGA MP.  
The incorporation of modified PGA MP containing SIM was also evaluated in 
osteoblasts (Figure 6.5).  Figure 6.5-B shows poor distribution of 40%C18-PGA MP 
within MP-osteoblasts aggregate and some 40%C18-PGA MP appeared to be 
aggregated each other and did not locate homogenously within the aggregate. The 
40%C18-PGA-PEG-MIHA MP+ collagen showed a better distribution within osteoblasts 
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aggregate (Figure 6.5-C) and  a higher number of MP  within osteoblasts aggregate 
compare to the 40%C18-PGA MP (see also Table 6.3). However, some aggregation also 
occurred in 40%C18-PGA-PEG-MIHA MP+ collagen.  
 Non Fluorescence Fluorescence 
A 
 
B 
 
C 
 
Figure 6.4. The mES cell aggregate without MPs (A), with 40%C18-PGA MPs (B) and 
with 40%C18-PGA-PEG-MIHA MP + collagen. MP were loaded with SIM and labelled 
with rhodamine. MP was mixed with the cells in ratio 1: 10 MPs to cells. Images 
were taken at 3 days of cell culture.  Scale bars represent 100 µm. 
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Figure 6.5. Osteoblast cell aggregate without MPs (A), with 40%C18-PGA MP (B) 
and with 40%C18-PGA-PEG-MIHA MP + collagen. MP was loaded with SIM and 
labelled with rhodamine. MP was mixed with the cells in ratio 1: 10 MP to cells. 
Images were taken at 3 days of cell culture.  Scale bars represent 100 µm. 
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Table 6.3. Number of MP relative to the number of cells in aggregates (n=9) 
Type of microparticle (MP) 
Initial ratio 
MP : Cell 
MP inside cell aggregates 
(%)± SEM 
  
 
mES  osteoblast  
40%C18-PGA MP 1 : 10 3.1 ± 0.09 3.1± 0.03 
40%C18-PGA-PEG-MIHA MP+ collagen 1 : 10 7.7 ± 0.28 3.6± 0.14 
 
In order to determine the effectiveness of MP incorporation within aggregates, the 
number of MP inside cells aggregate was evaluated by dissociating the aggregates at 
day 3 using trypsin. The number of fluorescence particles inside aggregates and the 
number of cells within the aggregates were counted and presented as percentage of 
MP within aggregates. It can be seen in Table 6.3 that 40%C18-PGA-PEG-MIHA MP+ 
collagen exhibited high incorporation within mES and osteoblast aggregates. The 
percentage of 40%C18-PGA-PEG-MIHA MP+ collagen incorporation in mES was two 
times higher compared to incorporation of 40%C18-PGA MP, while the incorporation 
in osteoblast cell was only  0.44% higher than 40%C18-PGA MP.  
6.5. Alkaline Phosphatase activity 
The release of SIM to cells for inducing osteogenic differentiation was evaluated 
using ALP assay (Chapter 2 section 2.5.3). ALP enzyme is a useful marker of 
osteogenic differentiation and was determined based on reaction of alkaline 
phosphatase with pNPP as substrate at 7, 14 and 21 days of cells culture. Based on 
the result of incorporation into cell aggregates and the ability to encourage cell 
proliferation, the 40%C18-PGA MP and 40%C18-PGA-PEG-MIHA MP+ collagen was 
used to deliver simvastatin (SIM) to mES and osteoblast cells. The MP was seeded 
with the cells to construct aggregates in ratio 1: 10 MP to cells.  
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Figure 6.6. Alkaline phosphatase (ALP) level in mES cell at 7, 14 and 21 days of cell 
culture. The microparticles were mixed in ratio 1:10 microparticle to cell. Bars 
represent SD (n=3). 
 
Figure 6.6 shows the alkaline phosphatase levels in mES cells aggregate at day 7, 14 
and 21 of cell culture. The level of ALP is almost similar in all conditions at day 7. A 
significant increase in ALP level was seen at day 14 for mES aggregate with MPs.  At 
day 14, the mES aggregate with 40%C18-PGA MP showed an ALP activity of  38.17± 
6.56 ng/ml while the mES aggregate with 40%C18-PGA-PEG-MIHA MP+ collagen 
showed activity of 120.3 ± 13.30 ng/ml. ALP activity in control group at day 14 
remained similar to day 7. The level of ALP activity was markedly lower at decreasing 
to 22.3 ±1.02 ng/ml and 8.9 ±0.01 ng/ml for mES cells aggregate with 40%C18-PGA 
MP and 40%C18-PGA-PEG-MIHA MP+ collagen, respectively.  
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Figure 6.7. Alkaline phosphatase (ALP) level in osteoblast cell at 7, 14 and 21 days 
of cell culture. The microparticles were mixed in ratio 1:10 microparticle to cell. The 
alkaline phosphatase was determined based on the reaction of ALP with pNPP as 
substrate. Bars represent SD (n=3). 
 
The ALP level was also evaluated in osteoblasts aggregates with modified PGA MPs. 
As shown in Figure 6.7, the highest ALP level at day 7 was found in osteoblasts 
aggregate with 40%C18-PGA-PEG-MIHA MP+ collagen followed by ALP in control 
group and the osteoblasts aggregate with 40%C18-PGA MP. The level of ALP activity 
increased significantly at day 14 with around 11 ng/ml ALP activity in osteoblast cells 
with 40%C18-PGA MP and 40%C18-PGA-PEG-MIHA MP+ collagen and 7.3 ±0.25 ng/ml 
for control (osteoblasts aggregate without MP).  Again, as occurred in mES cells, the 
level of ALP decreased in day 21 in all conditions including control.  
Comparing the ALP activity in mES and osteoblast cells, the mES had markedly higher 
levels of enzyme/activity than osteoblast cells. It was noted that the trend of 
increasing of alkaline phosphatase level from day 7 up to day 14 occurred in both 
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mES and osteoblast cells. The 40%C18-PGA-PEG-MIHA MP+ collagen in mES revealed 
the higher ALP level than 40%C18-PGA MP in mES while in osteoblast cells the levels 
of ALP activity were similar with both types of MP 
6.6.  Osteocalcin Immunostaining 
The presence of osteocalcin as a marker for maturation osteoblast was evaluated in 
28-day old of mES aggregates. The osteocalcin immunostaining was not evaluated in 
28-day old osteoblasts aggregate as the aggregate could not be longer maintained 
and spreading to form monolayer cells on cell culture after 28 days of incubation. 
Osteocalcin was detected using antibodies and location revealed using secondary 
antibody conjugated to horseradish peroxide-streptavidin (HRP-streptavidin) and 
using diamino-benzidine (DAB) as substrate for HRP. The method for osteocalcin 
immunostaining on cell aggregates is described in Chapter 2 section 2.5.4. In order to 
determine specificity of reaction, controls were provided for primary antibody, 
secondary antibody and HRP as label. The list of treatment for the controls and 
samples is listed in Table 6.4. 
The presence of osteocalcin as a non-collagenous bone matrix in mES aggregate is 
shown in Figure 6.8 and it can be seen that under all conditions osteocalcin protein 
was detected, as indicated by dark brown staining within cells aggregate. The 
osteocalcin was seen in cells aggregate with and without microparticle containing 
simvastatin. The intense brown staining in samples indicated abundant production of 
osteocalcin in mES aggregate at 28-day old cell aggregate. 
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Table 6.4. Treatment applied on controls and sample for osteocalcin imunostaining 
Treatment Control Sample 
 Primary 
antibody 
Secondary 
antibody 
HRP  
Blocking for endogenous peroxidase using 
H2O2 
я я я я 
Blocking with secondary serum я я я я 
Incubated with primary antibody я - - я 
Incubated with secondary antibody - я - я 
Incubated with HRP conjugate - - я я 
Incubated with DAB я я я я 
Keys:  ?A? ? PƚƌĞĂƚĞĚ ? ?-): not treated 
 
 
  
 
 
 
2
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Condition Control Primary Antibody Control Secondary Antibody Control HRP Sample 
A 
   
 
 
B 
    
C 
    
 
Figure 6.8. Osteocalcin imunostaining of mES cell aggregate using horseradish peroxide (HRP)-diamino-benzidine (DAB) detection. Sample is 28-day old 
mES cell without MP(A), with 40%C18-PGA-PEG-MIHA MP (B) and with 40%C18-PGA-PEG-MIHA-MP+ Collagen (C). The MP was loaded with SIM. Images 
were taken under brightfield microscope. Scale bars represent 100 µm. 
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Figure 6.9. Von kossa staining on 28-day old mES cell. Samples are mES aggregate 
without microparticle (A), with 40%C18-PGA-PEG-MIHA MP (B) and with 40%C18-
PGA-PEG-MIHA-MP+ Collagen (C). The MPs was loaded with SIM. Images were 
taken under light microscope. Scale bars represent 100 µm. 
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6.7. Mineralisation in Cells 
Von Kossa staining for calcium salts was used to evaluate the mineralisation in 28-day 
old cells aggregate. The staining was carried out by incubating the aggregates with a 
1% silver nitrate solution under strong light as described in Chapter 2 section 2.5.5. 
The staining in 28-day old mES aggregate is shown in Figure 6.9 and is seen as dark 
brown to black staining. Figure 6.9 shows that osteoclacin staining was seen in mES 
aggregate with 40%C18-PGA-PEG-MIHA MP+ collagen but no staining was seen  in 
control nor in mES aggregate with 40%C18-PGA MP.  
6.8. Discussion 
Microparticles can be used as matrices to deliver active molecule for inducing cell 
differentiation in 3D constructs. Good interaction between cells and MP is needed to 
encourage cells differentiation. In this study, the PGA polymer had been modified by 
40% stearoyl substitution and attachment of MIHA-PEG-NH2 as ligand-bearing linker. 
The modified polymer showed high encapsulation efficiency of SIM and the 
attachment of MIHA-PEG-NH2 linker showed the ability to hold collagen attachment 
on the surface of MP prepared from modified PGA polymer. Here we present the 
ability of MP prepared from modified PGA polymer to deliver SIM for inducing 
osteogenic differentiation in mES.   
6.8.1. Simvastatin and osteogenic differentiation 
sĂƌŝŽƵƐ ‘ĞĨĨĞĐƚŝǀĞ ?concentrations of SIM for inducing osteogenic have been reported. 
Kupcsik et al (2009) reported that the maximum concentration of SIM to induce 
calcification in mesenchymal stem cells is 1 µM, while Pagkalos et al (2010) reported 
the concentration for inducing osteogenic differentiatio
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0.1 to 100 nM [76, 225].  The variation in SIM concentration might be influenced by 
several factors such as the type of cells, the density of cells and the condition of cell 
culture whether 2D or 3D.  In order to evaluate osteogenic induction by SIM in cells 
aggregates, a range concentration of SIM were applied to aggregates.  
The ability of SIM added directly to the culture medium to induce osteogenic 
differentiation in mES cells was assessed over a range of concentrations from 0.1 to 
200 nM. The level of ALP activity for osteogenic differentiation was detected by 
reaction with the substrate of ALP enzyme, p-nitrophenyl phosphate (pNPP). The 
principle of this reaction is the development p-nitrophenol, by hydrolysis of pNPP 
using ALP enzyme and can be assessed by colorimetric change [226, 227]. It was 
found that untreated  mES aggregate exhibited ALP activity and is linked to high 
intrinsic ALP activity in pluripotent cells [228]. By day 7, there was a reduction in level 
of ALP with SIM treatment in the range concentration of 0.1-10 nM. Hwang et al 
(2004) and Lee et al (2007) suggested  that SIM treatments  could reduce cell 
proliferation and disrupt cell self-renewal ability [229, 230] and consequently reduce 
ALP expression in embryonic stem cell [230]. On the other hand, treatment of SIM on 
murine osteoprecursor (MC3T3-E1) and bone marrow stromal (BMS) cells enhanced 
the ALP activity in dose dependent manner [75, 229, 231] by enhance bone 
morphogenetic protein-2 (BMP-2) expression and induction in estrogen receptor-
alpha (ER-ɲ ?ǁŚŝĐŚŝŶǀŽůǀĞĚŝŶďŽŶĞĨŽƌŵĂƚŝŽŶ[75, 76, 231]. Based on the ALP assay 
at day 7, it can be seen that there is possibly some disruption on cells proliferation 
caused by SIM treatment. 
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The ALP activity in mES cells peaked at day 14 of cell culture and was related to the 
dose of SIM. This finding was consistent with the previous studies that describe 
increasing ALP activity related with the increasing dose of SIM in medium [75, 229, 
231]. The level of ALP decreased at day 21 in all conditions including control. The 
decrease in ALP level is probably related to next stages of cells differentiation and 
also found in ALP expression of human embryonic stem (hES) cell and mesenchymal 
stem cell studied by  Arpornmaeklong et al (2009) and Shafiee et al (2010) [232, 233]. 
6.8.2. Simvastatin release profile from modified PGA microparticles 
The MP incorporated with cells aggregates should have ability to release the active 
molecule in controlled manner and if required over an extended period. Several 
studies on osteogenic differentiation using SIM showed the minimum period of 14 
days for  osteogenesis process in stem cell [75, 225, 233-235]. This period includes 
proliferation phase, matrix maturation and mineralization phases and is related to 
the mature differentiation of the osteoblast [56, 235]. Therefore, the MP should be 
able to extend the drug release minimum for 14 days to ensure sufficient amount of 
drug is delivered.  
According to the studies in Chapter 4 section 4.6.3, the release of SIM from modified 
PGA MPs could be extended by reducing the concentration of PVA as emulsifier 
during the formulation process. The minimum concentration of PVA, 0.005%, was 
used to prepare MP from modified PGA polymer. Consequently, the preparation 
using emulsification method with PVA 0.005% generated the poly-disperse MP with a 
range of mean diameter depending of characteristics of the MP as shown in Table 
6.1. The MP prepared from 40%C18-PGA-PEG-MIHA polymer produced smaller 
diameter MP than those prepared from 40%C18-PGA and is related to the MIHA-PEG-
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NH2 linker attachment at the end of carboxyl group of polymer backbone. 
Attachment of collagen on the surface of 40%C18-PGA-PEG-MIHA MP resulted in 
larger size of MP. The presence of collagen on the surface increased the particle size 
by approximately 2.7 µm possibly related to small aggregation due to the presence of 
protein layer (Figure 6.2). The increasing of particle size after attachment with 
protein seems to be consistent with previous study by Gindy et al (2008) which found 
that attachment of bovine serum albumin (BSA) on the functionalized 
poly(caprolactone) nanoparticle increased the particle size [196]. The difference in 
zeta potential was also influenced by attachment of PEG-MIHA linker on the PGA 
polymer backbone and attachment of collagen as explained in Chapter 4, section 4.3. 
The in vitro release study showed that the SIM release from 40%C18-PGA MP and 
40%C18-PGA-PEG-MIHA MP+ collagen could be maintained for up to 21 days. It can 
be seen from Figure 6.3 that the presence of collagen on the surface of 40%C18-PGA-
PEG-MIHA MP extend the period of drug release from MP until day 21 compared to 
the MP without collagen attachment. Attachment of collagen on the surface of MP 
might reduce the diffusivity of drug from MP to medium and help to extend the time-
course of release of drug from MP.  It was noted that there was incomplete release 
of SIM from MP with only around 82.3 % and 80.8 % of SIM released from 40%C18-
PGA MP and 40%C18-PGA-PEG-MIHA MP+ collagen, respectively. The extraction of 
SIM from remaining MPs after release study indicated 4.5 % of SIM remained within 
40%C18-PGA MP while 1.6 % remained within 40%C18-PGA-PEG-MIHA MP+ collagen. 
The incomplete mass balance on SIM released might relate to the strong interaction 
between SIM and modified PGA polymer and the extraction of SIM from MP. The 
presence of collagen on the surface of the MP probably reduced the extraction 
Chapter 6  Microparticle for Osteogenesis 
 
229 
 
efficiency of SIM from the MP. Although the modified PGA polymer presented 
incomplete release of SIM in vitro, the drug is expected to completely release when 
applied to the cells. The research by Meng et al (2006) reported that the nanoparticle 
prepared from PGA polymer degraded when applied to the cells by the esther bonds 
breaking of polymer backbone [143].  
6.8.3. Incorporation of microparticles with cells  
The fluorescence images of modified PGA MPs in mES cells aggregate showed MP 
had distributed within the aggregate with some MP attached on the surface of 
aggregates. In mES cells aggregate, the 40%C18-PGA-PEG-MIHA MP+ collagen showed 
more MP within cell aggregate (Table 6.3). The presence of collagen on the surface of 
40%C18-PGA-PEG-MIHA MP+ collagen likely encouraged the MP interaction with the 
cells. Although the percentage of MP within aggregates is also influenced by the 
number of cells which constructs the aggregate, cell metabolic activity assay data 
(Chapter 5, section 5.4) suggested that the presence of collagen on the surface of 
might also encourage increased cells proliferation. In addition, the 40%C18-PGA-PEG-
MIHA MP+ collagen had better distribution of particle within cells aggregate as 
shown in Figure 6.5. Some aggregation had appeared in 40%C18-PGA-PEG-MIHA MP+ 
collagen in osteoblasts aggregate and but it was lower than had occurred in 40%C18-
PGA MP. The presence of MIHA-PEG-NH2 linker on the molecule of PGA polymer 
provided a PEG layer to prevent interaction between particles [133, 173]. The 
research by Mishra et al (2004) also reported that the particle with PEG grafting 
exhibited non-aggregating particle when incorporated with cell aggregates and it 
remained on the surface of cells [236].  
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6.8.4. Osteogenesis Differentiation  
The ALP activity, as marker for osteogenic differentiation, reached a peak at day 14 in 
mES. ALP is widely known as an important component expressed in mineralized cell 
and it is observed on the cell surface and matrix vesicle [237].  ALP 
expression/activity usually   peaks   near to the end of proliferation stage and during 
the matrix deposition stage [234]. In mES cells culture, the highest ALP activity was 
seen with 40%C18-PGA-PEG-MIHA MP+ collagen. The ALP enzyme is expressed during 
the maturation stage of osteoblasts differentiation [56]. In this study, the maturation 
of cell is not only influenced by SIM as an active drug, but also influenced by MP as 
supporting matrix within aggregate. As described in Chapter 5, section 5.4, the 
40%C18-PGA-PEG-MIHA MP+ collagen revealed increases in cells metabolic activity, 
possibly related to cells proliferation. Since the 40%C18-PGA-PEG-MIHA MP+ collagen 
gave a better support for cell proliferation, the incorporation of the MP containing 
SIM within mES cell with this MP achieved the higher ALP enzyme compare with mES 
aggregate with 40%C18-PGA MP. Although the maturation stages reduces cell 
proliferation capacity [238], the proliferation stage at initial phase correlated with 
the further stage of cell differentiation.  Turning into the ALP level in osteoblast cells, 
the ALP also reached the peak at 14 days as occurred in mES. The ALP level in 
osteoblast cells with 40%C18-PGA MP and 40%C18-PGA-PEG-MIHA MP+ collagen is 
produced at similar level and the ALP level peaked lower compare to mES aggregates. 
The presence of osteocalcin was evaluated in 28-day old mES.  In order to prevent 
non-specific binding between HRP and endogenous peroxide from the cells, sample 
was pre-treated with hydrogen peroxide (H2O2)  [239].  Blocking the samples with the 
serum from the host of secondary antibody was applied in order prevent non-specific 
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binding of secondary antibody [240, 241]. The negative control also provided for 
primary antibody, secondary antibody and HRP label to show the specificity of 
reaction in each antibody and label as recommended by Burry (2011) [242]. The 
osteocalcin staining was detected using HRP enzyme. The HRP reacted specifically 
with the diamino-benzidine (DAB) substrate to produce brown colour on the sample 
[240].  
The osteocalcin imunostaining and von Kossa staining for mineralization were not 
performed in osteoblast aggregate since the osteoblast aggregate failed to maintain 
its integrity and spread as monolayer on culture plate after longer period of 
incubation. Therefore, the maintenance condition and formation of aggregate in 
osteoblast should be optimized.  
Positive osteocalcin staining was produced in mES cells at day 28 without and with 
MP containing SIM and was similar in all examples. Zur Nieden et al (2003) described 
the presence of osteocalcin in embryonic stem cell to represent the late stage of 
osteogenic differentiation and could be identified in the fourth week of ES cell 
culture [234]. The osteocalcin staining in mES cell aggregate showed the abundant 
level of osteocalcin in the condition without and with MP containing SIM. Thus, effect 
of PGA polymer modification on SIM delivery to the cell could not be distinguished by 
osteocalcin staining. 
The von Kossa staining showed there was deposition of calcium salts and possibly 
indicating mineralization in mES cells aggregate with 40%C18-PGA-PEG-MIHA MP+ 
collagen. The result revealed that the 40%C18-PGA-PEG-MIHA MP+ collagen was able 
to effectively deliver SIM for osteogenic differentiation. There is no positive von 
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Kossa staining in mES without MP and with 40%C18-PGA-MP.  This result was contrary 
with the expectation about mineralization in mES cells. The osteocalcin 
immunostaining showed the abundant presence of osteocalcin particularly in mES 
with and without modified PGA MPs but the von Kossa staining only detect the 
mineralisation in mES cell aggregate with 40%C18-PGA-PEG-MIHA MP+ collagen. 
Schroder et al (1999) mentioned that the mineralization phase was indicated with 
the expression of osteocalcin [56], thus the presence of osteocalcin in sample would 
correlate with the positive result using von Kossa staining. The previous studies by 
zur Nieden et al (2003) showed that the positive result of osteocalcin staining in 
differentiated ES cells also related with the positive result in von Kossa staining [234].  
The result for mineralisation using von Kossa staining is unexpected and could be 
explained by two reasons. The first reason is the SIM could be delivered to the cells 
but the amount of SIM released is not sufficient enough to support mineralisation in 
mES cells. The release study of modified PGA MP in vitro showed that around 50% 
SIM was released at day 1 and then become slower after day 7. The release of SIM 
from the MP was ended in the period of 21 days. Since the mineralization phase was 
evaluated at fourth week, there is possibility that the amount of SIM not sufficient 
enough to support mineralisation phase in osteogenesis. Secondly, the amount of 
calcium phosphate in differentiated cells is not sufficient enough to be detected 
using von Kossa staining. Therefore, Bonewald et al (2003) suggested to confirm the 
result from osteocalcin staining using Alizarin red staining and mineralisation analysis 
using electron microscope analysis, X-ray diffraction and Fourier transform infrared 
spectroscopy [243].  
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6.9. Conclusion 
In conclusion, the MP prepared from modified PGA polymer showed the ability to 
incorporate drug and deliver it for the 21-day period. The attachment of collagen on 
the surface of MP affected the initial release of drug from MP to become lower than 
the MP without collagen attachment. However, the incomplete release of drug from 
modified PGA microparticles had shown in 40%C18-PGA MP and 40%C18-PGA-PEG-
MIHA MP+ collagen. 
Although the formulation of MP using PVA 0.005% generated larger particles, the 
modified PGA MP could be incorporated within cell aggregate in ratio 1: 10 of MP to 
cells. The attachment of collagen on the surface of MP exhibited higher incorporation 
within cells aggregates and more homogeneous distribution within cells aggregate. 
The attachment of MIHA-PEG-NH2 linker showed the ability to prevent aggregation of 
microparticle within cells aggregate. 
The delivery of SIM from modified PGA polymer showed the ability to induce 
osteogenesis process in mES cells, particularly for maturation stage. The 
incorporation of 40%C18-PGA-PEG-MIHA MP+ collagen within cells aggregate 
exhibited the higher ALP level on the cells than the cell aggregate with 40%C18-PGA 
MP. However, the ability of modified PGA polymer to induce osteogenesis for 
mineralization stage needs to be reviewed using the others assay to support the 
result. In addition, the condition for aggregate formation in osteoblasts should be 
optimized.  
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CHAPTER 7 
7. CONCLUSION AND FUTURE WORK 
 
 
7.1. Conclusion 
To summarize, poly glycerol adipate (PGA) polymer had been modified by 40% 
stearoyl (C18) substitution on the pendant hydroxyl group of PGA polymer (40%C18-
PGA) to increase drug incorporation within the polymer. The acyl substitution 
increase the hydrophobicity of polymer, thus increases the interaction between 
hydrophobic drug and the polymer. This modification would be useful to generate 
microparticles containing active molecule for cells development process. The 
polymer also modified with a MIHA-PEG-NH2 linker to bear a ligand for optimising the 
interaction between microparticles and cells.    
The substitution of 40% hydroxyl group in poly(glycerol adipate) (PGA) with stearoyl 
(C18) is effectively catalysed by pyridine. The percentage of substitution could be 
identified using 1H-NMR spectrum by comparing the peak intensity of methyl group 
near carboxyl in PGA backbone with the methyl at the end of C18 molecule.  Further 
attachment MIHA-PEG-NH2 linker to the terminal carboxyl group of polymer 
backbone (40%C18-PGA-PEG-MIHA) also identified using 
1H-NMR spectrum to assure 
that the attachment generated 1 to 1 ratio of PGA polymer to MIHA-PEG-NH2 linker. 
All of these synthesis also confirmed by FTIR analysis to identify important functional 
 Chapter 7  Conclusion and Future Work 
 
235 
 
group related to substitution and attachment on modified PGA polymer.  Together 
with these synthetic reaction steps, collagen as a proposed ligand was also modified 
by attaching iminothiolane group and FITC. The modification of collagen molecule 
using iminothiolane is necessary to provide thiol group on collagen molecule for 
attachment with maleimide group on the molecule of 40%C18-PGA-PEG-MIHA 
polymer. In addition, FITC attachment on collagen would be useful for further 
analysis such as determination of collagen attachment as well as for cell work. The 
modified collagen with iminothiolane and FITC did not alter the ability of collagen to 
interact with the cells although the interaction of collagen and the cells is influenced 
by collagen concentration and density of the cells. 
The modified PGA polymers, 40%C18-PGA and 40%C18-PGA-PEG-MIHA, were 
formulated into microparticle (MP) for tissue engineering purpose. The 
emulsification method was used to prepare the MP from modified PGA. Some critical 
factors in formulation process related to physical characteristics and release of drug 
from modified PGA MP had been identified. The attachment of MIHA-PEG-NH2 linker 
to 40%C18-PGA polymer generated a smaller particle size. In addition, the size of 
particle was also influenced by the speed of homogenizer and concentration of PVA 
as emulsifier. The attachment of MIHA-PEG-NH2 linker on the 40%C18-PGA polymer 
also affected the zeta potential value of microparticle as well as the attachment of 
iminothiolane-modified collagen on the surface of microparticle. The 40%C18-PGA-
PEG-MIHA MP exhibited a higher negative value of zeta potential than 40%C18-PGA 
MP while the attachment of iminothiolane modified collagen on the surface of the 
40%C18-PGA-PEG-MIHA MP reduced the zeta potential to the lower negative value 
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due to the presence the amino group on the collagen molecule. The modification of 
PGA polymer by 40% stearoyl substitution on PGA polymer backbone (40%C18-PGA) 
exhibited the good interaction with SIM indicated by more than 50% encapsulation 
efficiency of SIM as well as in 40%C18-PGA-PEG-MIHA polymer. However, the 
encapsulation efficiency is also influenced by polymer concentration during 
preparation and concentration of PVA as emulsifier. The modified PGA polymers had 
ability to extend the release of drug from polymer as demonstrated in release of SIM 
from solid dispersions prepared from modified PGA polymer. The formulation of MP 
played important role for the release of drug from microparticle. As demonstrated in 
the result, the release of drug was influenced by polymer concentration in organic 
phase and the concentration of PVA as emulsifier. The attachment of MIHA-PEG-NH2 
linker on 40%C18-PGA polymer resulted in a high release of drug at initial phase. 
Moreover, the MP prepared from 40%C18-PGA-PEG-MIHA had the ability to attach 
with iminothiolane-modified collagen through maleimide functional group on the 
modified PGA polymer.  
The modified PGA microparticle showed the ability to incorporate within mES and 
osteoblast cells. Although the presence of the MP did not encourage aggregate 
formation in mES cells, but it was be able to support aggregate formation in 
osteoblast cells. The formation of aggregate is determined by ratio of MP to cell as 
well as the properties of microparticle. The formation of aggregate using MP could be 
improved by using a low ratio of MP to the cells. In addition, the attachment of 
iminothiolane-modified collagen on the surface of MP improve the interaction 
between the microparticle and cells, therefore it could exhibited better aggregate 
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formation. The cells metabolism assay showed that the 40%C18-PGA-PEG-MIHA MP+ 
collagen could act as a matrix for cell to grow and proliferate.  
The release of SIM from modified PGA microparticles could be extended up to 21 
days by using minimum amount of PVA involved in MP preparation. In addition, 
iminothiolane-modified collagen attachment on the surface of 40%C18-PGA-PEG-
MIHA MP could reduce initial high release caused by the presence of MIHA-PEG-NH2 
linker on the polymer backbone. The SIM was effectively delivered from modified 
PGA MP indicated by increasing of ALP level as a marker for ostegenesis process. The 
mineralisation of cells showed by positive staining on osteocalcin but presented 
unsatisfactory result using von Kossa staining. 
In conclusion, the modification of PGA polymer by providing stearic moiety in PGA 
polymer backbone exhibited high encapsulation efficiency of SIM. However, the 
encapsulation efficiency of drug within the polymer not only influenced by 
interaction polymer with the drug but also influenced by formulation of MP. The 
formulation process could be tailored by adjusting the critical factors related to 
particle size, encapsulation efficiency and release of drug to achieve the desired 
physical properties and drug release. In addition, attachment of MIHA-PEG-NH2 linker 
to the end of carboxyl group of PGA polymer showed the ability for ligand 
attachment on MP prepared from 40%C18-PGA WPEG-MIHA polymer. The attachment 
of collagen as a ligand on the surface of MP improved the ability of microparticles to 
act as matrix for cells proliferation in 3D structures. Moreover, the attachment of 
collagen on the surface of modified PGA MP showed the better support for inducing 
osteogenesis in mES cells.  
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7.2. Future Work 
Although the 40% stearoyl (C18) substitution on pendant hydroxyl group of 
poly(glycerol adipate polymer ) (PGA) successfully exhibited the high encapsulation 
efficiency of simvastatin (SIM),  interaction between  the polymer and other drugs 
and proteins particularly for tissue development need to be explored. According to 
Puri et al (2008), the acyl substitution containing more than 8 atoms carbon (C8) with 
the high percentage of acyl group is effective in enhancing drug incorporation for 
hydrophobic drug due to increasing of hydrophobic interaction between drug and 
polymer [180]. Therefore, the different acyl substitution with alteration in degree of 
substitution could be useful to improve interaction between other drugs with the 
PGA polymer. Since most of growth factors for inducing cell differentiation consist of 
proteins that bind specifically to receptor in cell membrane, the further exploration is 
needed for protein encapsulation within substituted PGA polymer. Previous work by 
Rimmer (2009) presented unsatisfactory result for lysozyme incorporation within 
40%C18-PGA microparticle with the encapsulation efficiency less than 10% [127]. 
However, the encapsulation efficiency of protein within the polymer is not only 
influenced by interaction between drug and polymer but also affected by formulation 
parameters such as concentration of polymer in organic phase, ratio inner phase to 
outer phase, the rate of solvent removal and emulsifier concentration [164, 194]. For 
that reason, the formulation parameters should be precisely controlled to achieve 
the desired drug loading as well as release profile.  
The attachment of MIHA-PEG-NH2 linker with 1 to 1 ratio to PGA polymer showed the 
ability to attach specifically with iminothiolane-modified collagen, reduce the particle 
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size and minimize aggregation of MP when applied to the cell. In addition, the 
collagen attachment on the surface of 40%C18-PGA-PEG-MIHA MP is also promising 
to use as a matrix for cell growth in 3D structure by increasing cells proliferation and 
generated better effect for cells differentiation. However, the identification of MIHA-
PEG-NH2 attachment on 40%C18-PGA at 1 to 1 ratio using 
1H-NMR and FTIR spectrum 
was not easy due to small intensities of important peaks on the spectrum. In order to 
overcome this problem, gel permeation chromatography (GPC) analysis to estimate 
the ratio of attachment by identification polymer molecular weight is needed.  
The properties of microparticle such as particle size, encapsulation efficiency and 
release of drug could be controlled by adjusting formulation parameters. Among 
those factors, controlling of MP size into monodispersed particle is the most 
important property related to drug loading, drug distribution within microparticle 
and release profile of drug as explained in Tran et al (2011) that the hydrophilic drugs 
tend to distributed near the surface of microparticle while the hydrophobic drugs 
distributed around the core of the microparticle larger than 40 µm. The homogenous 
distribution of drug in microparticle was found in small size microparticle (10-20 µm) 
[244]. Looking at the release profile, the smaller particle related to the larger surface 
area, thus the release of drug tend to be faster compare to larger particle. Therefore, 
the others methods for MP preparation and scale up production should be explored. 
Several novel methods are need to be explored to produce monodispersed MP such 
as using microfluidic systems [244-246] and electro spraying [244, 247].  
The aggregate formation using suspension cell in non-treated plate was successfully 
to incorporate the modified PGA microparticle within mES and osteoblast cell 
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aggregate. However, the number of microparticle incorporated in each aggregate 
may vary as the number of cell and microparticle used to form aggregate depend on 
the probability of cells and microparticle to interact each other. As a result, the broad 
variation of size and shape in cells aggregate had been found. According Park et al 
(2007), the initial size of aggregate influence the extent of cell differentiation where 
the expression of ectodermal marker increased in the smaller aggregate (100 µm) 
while the mesodermal and endodermal marker expression increased in 500 µm 
aggregates [204]. Consequently, the size of aggregate should be controlled to achieve 
desired differentiation in reproducible manner. In addition, the agglomeration 
between aggregate should be noticed as the agglomeration might inhibit cell growth 
and differentiation [210] due to difficulties of oxygen transfer to cell aggregate. 
Controlling aggregate size and formation could be achieved using stirred-suspension 
culture in spinner flask as reviewed by Kurosawa (2007) and Sasitorn et al (2009). 
This system offers benefits related to simple design and easiness to monitor culture 
environment such as dissolved oxygen, pH and homogeneity of nutrient in medium.  
Moreover, the agglomeration could be prevented by a spinner flask equipped with an 
impeller [202, 248]. The spinner flask technique has been successfully used to 
differentiate human amniotic fluid stem cell (hAFSC) for cellular cardiomyoplasty 
[249] and re-differentiate chondrocytes [250].  The other benefit using spinner-flask 
method is the ability to scale up to meet the demand for therapeutic application. 
Spinner-flask method as part of bioreactor expected to generate a robust and well 
defined expansion of cell aggregate formation and differentiation [202, 248, 250].  
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APPENDIX 
Appendix 1.  
Metabolic activity of mES cell aggregate evaluated using Alamar Blue Assay 
Fluorescence ŝŶƚĞŶƐŝƚǇǁĂƐŵĞĂƐƵƌĞĚĂƚʄexcitation  ? ? ?ŶŵĂŶĚʄemission 590 nm. 
Day 7 
Day 7 5 minutes 
 
Fluorescence Intensity 
  Blank Control 40%C18-PGA MP 40%C18-PGA-PEG-MIHA MP 
40%C18-PGA-PEG-MIHA 
MP+ collagen 
  70 54 85 67 89 
  80 68 75 76 104 
  73 69 89 73 103 
Mean 74.3 63.7 83.0 72.0 98.7 
SD 3.6 5.9 3.2 5.1 5.9 
 
 Day 7 10 minutes 
  
 
Fluorescence Intensity 
  Blank Control 40%C18-PGA MP 40%C18-PGA-PEG-MIHA MP 
40%C18-PGA-PEG-MIHA 
MP+ collagen 
  72 130 202 168 223 
  81 170 198 187 260 
  76 173 232 183 258 
Mean 76.3 157.7 210.7 179.3 247.0 
SD 3.2 17.0 7.1 13.1 14.7 
 
Day 7 15 minutes 
 
 
Fluorescence Intensity 
  Blank Control 40%C18-PGA MP 40%C18-PGA-PEG-MIHA MP 
40%C18-PGA-PEG-MIHA 
MP+ collagen 
  95 187 390 337 411 
  102 209 383 357 382 
  90 237 399 318 383 
Mean 95.7 211.0 390.7 337.3 397.0 
SD 4.3 17.7 8.0 19.5 14.0 
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Day 7 30 minutes 
  Fluorescence Intensity 
  Blank Control 40%C18-PGA MP 40%C18-PGA-PEG-MIHA MP 
40%C18-PGA-PEG-MIHA 
MP+ collagen 
  98 18632 38220 32350 42130 
  105 21150 38060 35890 38458 
  92 22748 39890 31976 38560 
Mean 98.3 20843.3 38723.3 33405.3 39716.0 
SD 4.6 1467.3 716.7 1527.3 1478.7 
 
Day 7 60 minutes 
  Fluorescence Intensity 
  Blank Control 40%C18-PGA MP 40%C18-PGA-PEG-MIHA MP 
40%C18-PGA-PEG-MIHA 
MP+ collagen 
  105 34372 32959 37881 41960 
  115 34538 39779 36770 42015 
  98 29147 37893 33164 39150 
Mean 106.0 32685.7 36877.0 35938.3 41041.7 
SD 6.0 2167.8 2490.2 1743.7 1158.6 
 
Day 14 
Day 14 5 minutes 
 
Fluorescence Intensity 
  Blank Control 40%C18-PGA MP 40%C18-PGA-PEG-MIHA MP 
40%C18-PGA-PEG-MIHA 
MP+ collagen 
  68 398 338 376 485 
  70 413 411 346 510 
  68 390 339 366 463 
Mean 68.7 400.3 375.0 356.0 474.0 
SD 0.8 8.3 36.0 10.0 11.0 
 
Day 14 10 minutes 
 
Fluorescence Intensity 
  Blank Control 40%C18-PGA MP 40%C18-PGA-PEG-MIHA MP 
40%C18-PGA-PEG-MIHA 
MP+ collagen 
  72 955 845 940 1212 
  70 1032.5 927 865 1270 
  71 975 846 915 1197 
Mean 71.0 987.5 886.5 890.0 1204.5 
SD 0.7 28.4 40.5 25.0 7.5 
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Day 14 15 minutes 
  Fluorescence Intensity 
  Blank Control 40%C18-PGA MP 40%C18-PGA-PEG-MIHA MP 
40%C18-PGA-PEG-MIHA 
MP+ collagen 
  74 1999 1690 1867 2409 
  80 2074 1564 1730 2572 
  69 1975 1701 1844 2317 
Mean 74.3 2024.5 1695.5 1798.5 2444.5 
SD 3.9 49.5 5.5 68.5 127.5 
 
Day 14 30 minutes 
  Fluorescence Intensity 
  Blank Control 40%C18-PGA MP 40%C18-PGA-PEG-MIHA MP 
40%C18-PGA-PEG-MIHA 
MP+ collagen 
  102 37158 OVER 41567 71503 
  115 32450 63315 43262 76096 
  98 33540 65509 51650 OVER 
Mean 105.0 34382.7 64412.0 45493.0 76096.0 
SD 6.3 1742.7 1097.0 3817.7 2296.5 
 
Day 14 60 minutes 
  Fluorescence Intensity 
  Blank Control 40%C18-PGA MP 40%C18-PGA-PEG-MIHA MP 
40%C18-PGA-PEG-MIHA 
MP+ collagen 
  110 OVER OVER OVER OVER 
  128 OVER OVER OVER OVER 
  104 OVER OVER OVER OVER 
Mean 114.0         
SD 8.8     
 
*) Over indicated the high fluorescence intensity and not be able to detect using 
plate reader.  
 
